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ABSTRACT 
The human immune system has evolved to successfully eradicate most pathogens, 
however organisms such as hepatitis C virus (HCV) can circumvent the immune re ponse 
and establish persistent infection in the majority of exposed individuals. While it is clear 
that broadly directed anti-HCV CD4+ and CD8+ T cell responses are important in 
spontaneous viral clearance, the immunologic correlates of persistent infection and 
treatment-associated vi ral clearance are markedly less well defined. There is conflicting 
data on how HCV modulates the immune system in monoinfection, and the data 
surrounding immunologic issues is even more limited in HIV coinfection. 
The type of immune cells that permit or facilitate persistent infection, as well as 
the character of the anti-HCV T cell response in the context of immunodeficiency and 
differential infectious outcomes, is unclear. The objective of thi study was to assess 
potential mechanisms of immune modulation by HCV, ·delineate the types of cells that 
may be involved, and define anti-HCV T cell responses in the context of coinfection. 
In this work, we investigated whether HCV gene products induce interleukin-1 0 
(IL-l 0), an immunomodulatory cytokine that facilitates chronic infection. We identified 
and phenotyped a novel cell population producing IL-1 0, not just in those infected with 
HCV, but in all healthy controls tested. IL-l 0 production by this new cell type may have 
a role in immune system homeostasis through immune regulation, but may also 
contribute to viral persistence. More of these previously undescribed cells produce IL-l 0 
when exposed to HCV proteins, an effect that is accentuated when HCV-na·ive cells from 
HIV-infected individuals are exposed to HCV proteins. We demonstrated more robu t 
Ill 
anti-HCV T cell responses with viral clearance, and distinguished features of anti-HCV T 
cell responses associated with spontaneous versus treatment-induced clearance. We also 
described distinct HCV -specific T cell responses in HIV coinfection. Together, these 
findings emphasize the role of the immune system in HCV clearance, as well as in 
control of chronic infection, and illustrate the complex interactions between chronic 
pathogens in terms of their effects on the immune system. 
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CHAPTER 1 
RATIONALE AND OVERVIEW 
The human immune system has evolved to successfully combat viral, bacterial, 
fungal, and parasitic pathogens. Elements of innate and adaptive immunity come 
together to clear the invader in a vast majority of infections, however, there are a number 
of organisms that circumvent the immune response and establish persistent infection. 
Listeria monocytogenes, Mycobactetium tuberculosis, and Helicobacter pylori are all 
capable of chronic infection, and many viruses in the herpes family (Epstein-BatT virus, 
Herpes zoster, Herpes simplex) are more likely than not to persist in the human host. 
Changes to the host immune system (e.g. manipulation of antigen presenting cells, 
alteration ofT cell maturity, and production of immunosuppressive cytokines), as well as 
the pathogen itself (e.g. rapid generation time, infection of immunologically privileged 
sites, antigenic shift and drift), are all ways of establishing and maintaining chronic 
infection. The exact mechanisms of persistence at play in each infection are often not 
fully elucidated, indicative of complex host-pathogen interactions. Human 
immunodeficiency vtrus (HIV) and hepatitis C vtrus (HCV) both establish persistent 
infection, and in the case ofHCV, little is known of how the virus manipulates the host 
immune system to establish and maintain infection. 
HCV maintains chronic infection in the majority of exposed individuals, and 
while it is clear that strong and broadly directed CD4+ and CD8+ T cell responses are 
important in spontaneous viral clearance, the immunologic correlates of persistent 
infection and treatment-associated viral clearance are markedly less well defined. There 
2 
is conflicting data on how viral gene products modulate the immune system, and little 
information on the role of immune cells other than antigen presenting cells and T cells. 
The data surrounding these HCV -related immunologic issues is even more limited in HIV 
coinfection. From the clinical perspective, HCV -related disease is more aggressive and 
associated with higher mortality in HIV coinfection. There also exists an apparent 
dichotomy between the accelerated hepatic immunopathology of HCV-related liver 
disease despite increasing HIV -associated immunodeficiency. 
The type of immune cells that permit or facilitate persistent infection, as well as the 
character of the anti-HCV T cell response in the context of immunodeficiency and 
differential infectious outcomes, is unclear. In this context, there were several objectives 
for this work: 
1. Review the clinical spectrum of HCV and HIV related disease, as well as 
literature on the anti-HCV immune response in viral clearance and persistence; 
2. Define cell types in circulation that secrete cytokines relevant to viral persistence; 
3. Assess potential mechanisms of immune modulation by HCV; 
4. Define the character of anti-HCV T cell responses in the context of HIV 
coinfection in general, as well as in subgroups with immunologically distinct 
outcomes; and 
5. Compare the character of anti-HCV T cell responses in spontaneous and 
treatment-associated HCV resolution with responses in persistent HCV infection. 
Chapter two reviews the current literature on HIV and HCV from the clinical and 
immunologic perspectives. Chapter three describes a nove] type of circulating 
3 
mononuclear cell that produces an immunomodulatory cytokine known to be 
instrumental in the establishment and maintenance of other bacterial infections. Chapter 
four describes how this novel cell type responds to HCV-derived proteins in uninfected 
individuals, as well as those with HIV infection and chronic HCV infection. Chapter five 
describes the character of T cell responses in the context of HIV coinfection and the 
contribution ofT cell responses to the natural history of disease. Chapter six delineates 
the components of the anti-HCV T cell response associated with HCV clearance, and 
differentiates between responses observed in spontaneous and treatment-induced HCY 
clearance that suggest more than one avenue to sterilizing responses. The impact and 
synthesis of these units, as well as the limitations and future research directions, is 
outlined in chapter seven. 
CHAPTER2 
BROTHERS IN HARM: 
4 
IMMUNOLOGICAL AND CLINICAL IMPLICATIONS OF COINFECTION 
WITH HEPATITIS C VIRUS AND HUMA.N IMMUNODEFICIENCY VIRUS 1 
Lisa Barrett and Michael Grant 
Immunology Program, Division of Basic Medical Sciences, Faculty of Medicine, 
Memorial University ofNewfoundland, St. John's, NL, Canada. 
1This is an updated and revised version of the manuscript published in Clinical and 
Applied Immunology Reviews, 2002. 
Tel: 709-777-8290 
Fax: 709-777-8294 
email: I is a. barrett@dal.ca 
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2.1. Abstract 
Hepatitis C v1rus (HCV) infection has emerged as a huge global epidemic. 
Because HCV and the human immunodeficiency virus (HIV) share several routes of 
transmission, a significant proportion of HIV-infected individuals are coinfected with 
HCV. Coinfection with these viruses complicates an already complex set of is ues 
related to diagnosis, clinical disease progression, monitoring disease activity, treatment 
options and basic immunology. Compared to HIV infection, our understanding of the 
natural history and epidemiology of HCV infection remains preliminary, leaving many 
clinical and treatment issues surrounding HCV/HIV coinfection unclear. The potential 
impact of coinfection with HCV has become an important issue in HIV research and 
clinical care. This review addresses the virology and natural history of HIV and HCV 
infections, together with some of the relevant clinical and immunological aspects of HCV 
infection and how these may be modified in HIV coinfected individuals. 
6 
2.2. HIV epidemiology and natural history 
HIV infection is a pandemic with over 30 million persons infected worldwide. 
HIV spreads through parenteral, sexual and vertical transmission, therefore, risk factors 
for infection include high risk sexual encounters, needle sharing, intravenous drug use, 
exposure to unscreened blood and blood products, and breastfeeding from infected 
women. Before the advent of highly active antiretroviral therapy (HAART), the mean 
life expectancy for an HIV -infected individual was 9 years. Although the data from the 
HAART era is relatively new and followup is not yet sufficient to provide reliable 
estimates, it is clear that life expectancy in HIV infection has increased dramatically 
enough to justify reclassification of the disease as chronic rather than fatal. 
HIV is an enveloped RNA virus belonging to the lentivirus family of retroviruses. 
The primary targets of HIV infection are CD4+ T cells, although the virus also infects 
macrophages and dendritic cells. The glycoproteins gp 120 and gp41 in the viral envelope 
allow cell binding, fusion of the cell and viral lipid bilayers, and entry of the viral 
nucleocapsid into host cells. The CD4 molecule is the primary receptor for HIV on host 
ce1ls, while C-C motif receptor 5 (CCR5), CXC motif receptor 4 (CXCR4) and other 
related chemokine receptors act as coreceptors ( 1, 2), as reviewed by Berger et al. (3). 
Individuals homozygous for deletion mutations in the CCR5 gene resist HIV infection, 
even after multiple high-risk exposures (4, 5). · 
Once HIV enters the host cell , an error-prone viral reverse transcriptase creates a 
DNA copy of the genome that tran locates to the nucleus, splices into the host cell 
7 
genome and becomes an integrated provirus. Upon activation of the host cell, integrated 
proviral DNA is transcribed, viral proteins are synthesized, and new virions assembled 
and released. The antiretroviral drugs used to treat HIV infection interfere with viral 
replication at several stages of the viral life cycle. Protease inhibitors prevent the 
proteolytic maturation of precursor polypeptides into functional proteins, while 
nucleoside, nucleotide, and non-nucleoside analogue reverse transcriptase inhibitors 
decrease production of proviral DNA by inhibiting the viral reverse transcriptase. 
Combination therapy employing 2 or more drug classes is usually recommended due to 
the high rate of viral mutation and the associated rapid development of drug resistance. 
Several new groups of antivirals are now in use, including inhibitors of viral entry, 
integration and maturation. Entry inhibitors include maraviroc, a CCR5 antagonist (6, 7) 
with Federal Drug Administration approval, and CXCR4 antagonists (8). Other agents, 
such as enfuvirtide, limit viral entry through interaction with gp41 (9, 1 0). lntegrase 
inhibitors of various types have been tested ( 11 ), and raltegravir is cuJTently approved for 
use in heavily pretreated individuals (12, 13). Maturation inhibitors that act on the viral 
protease substrate are also in development. One compound, PA-457, prevents maturation 
ofthe capsid protein and is currently undergoing Phase 2 clinical trials (14). 
Acute HIY infection is characterized by high viremia, transient loss of CD4+ T 
cells, and often a flu-like illness. This acute stage may last 2-6 weeks, throughout the 
early part of which the infected individual usually remains seronegative. HIV -specific 
CD4+ and CD8+ T cells effect the initial decline of viremia and maintain the dimini hed 
levels of virus throughout the prolonged clinically asymptomatic pha e. The immune 
8 
response is insufficient to clear the virus, and eventually viremia rebounds, CD4+ T cell 
counts fall to dangerously low levels and oppOiiunistic infections symptomatic of AIDS 
develop. Common opportunistic infections in late stage HIV disease, which often 
demand long-term prophylaxis, include Toxoplasma, Mycobacterium avmm 
intracellulare, Pneumocystis jiroveci. Cytomegalovirus infection or reactivation may 
occur, however only those who are chronically immunosuppressed require secondary 
treatment. In addition to the many opportunistic infections, various virus-associated 
malignancies such as Kaposi 's sarcoma (human herpes virus 8), non_-Hodgkins 
lymphoma (Epstein-Barr virus), cervical cancer and anal cancer (human papilloma virus) 
increase in prevalence with the immunodeficiency of advanced HIV infection. 
2.3. Hepatitis C virus 
Since initial identification of the HCV genome in I989 (IS), an intense research 
effort has characterized HCV. HCV is a positive strand RNA flavivirus with a 9.6 
kilobase (kb) genome translated as a single polyprotein and cleaved into ten products, 
four structural (core, E I , E2, p7) and six non-structural proteins (NS2, NS3, NS4A and B 
and NS5A and B (16) (Figure 2.1 ). Several alternate reading frame proteins (F protein, 
double frameshift protein, and short fonn of core + I) have also been described (17) and 
although they may not function in the HCV lifecycle directly, they are immunogenic (18, 
19) and perhaps immunomodulatory (20). 
The HCV lifecycle begins with viral entry into the host cell. A number of cellular 
receptors have been proposed, including CD8I (21 ), heparin sulphate (22), low density 
lipoprotein receptor (LDL-R) (23), scavenger receptor class B type I (SR-BI) (24), 
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liver/lymph node-specific ICAM-3 grabbing nonintegrin (L-SIGN) and dendritic cell-
specific ICAM-3 grabbing nonintegrin (DC-SIGN) (25-27). These receptors are found 
on many cell types and suggest that HCV interacts with cells other than hepatocytes. 
Although thought primarily to be hepatotropic, HCV can also replicate in lymphoid tissue 
(28-33), and brain (34) and gut epithelial cells (35) are other possible viral reservoirs in 
chronic infection. However, conflicting reports suggest that the techniques used to 
demonstrate lymphotropism through detection of negative strand HCV RNA, purely a 
replicative intermediate, are unreliable (36-38). More recent studies using a modified 
poly-A tail technique (28) to reduce the impact of positive strand contamination detected 
negative strand intermediates in lymph nodes (33). It is generally accepted that lymphoid 
cells support HCV replication, while other tissues remain contentious. 
One of the non-structural proteins, an error-prone RNA-dependent RNA 
polymerase (NS5B), dtives the rapid development of viral quasispecies within a single 
infected individual during times of high viral replication (39). Quasispecies are viruses 
that are similar, but not identical, and do not have enough sequence diversity to be 
classified as distinct genotypes. There is compartmentalization of HCV quasispecies 
populations with clear hypervariable region 1 (HVRl) sequence differences between the 
liver, peripheral blood ce11s, and general circulation (40-42). Between individuals, HCV 
speciation is sufficient for delineation of multiple genotypes that differ by about 30% 
from each other at the amino acid level (43), with six major genotypes and up to three 
subtypes within each of these major types ( 44). There is differential distribution of these 
genotypes between countries, and subpopulations of HCV-infected individuals infected 
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through similar transmission routes often share predominant genotypes (Figure 2.2). 
Studying the HCV life cycle and pathogenesis of HCV disease has been hindered 
both by lack of a cell culture system supporting significant viral replication and lack of 
suitable animal model other than the endangered and expensive chimpanzee. 
Development of infectious HCV eDNA clones (45-47) was key to demonstrating that 
HCV infection could cause liver disease. However, high levels of RNA replication are 
still only seen with one isolate (JFH-1), and in vitro replication is restricted to only 2 cell 
lines (Huh-7, HuH6) (reviewed by Bartenschlager (48)). Work with the genotype 1 a 
RNA H77-S is promising (49), however this clone is only about 100-fold as infectious as 
the JFH-1 clone, limiting its use as a reliable in vitro model. A recentl y developed 
chimeric mouse model with a humanized liver (50) will hopefully facilitate elucidation of 
the mechanisms of HCV infection, replication and disease pathogenesis. This mouse 
model, as well another (51), are produced in immunodeficient mice and limit the ability 
to study HCV in the context of a competent immune system, an important restriction 
given that part of disease pathogenesis is immune mediated. In vivo infection of a tree 
shrew subspecies, Tupaia belangeri chinensis, has been described, but only after 
significant immunosuppression (52). Overall, the small animal models provide important 
but limited information on natural infection of immunocompetent hosts. Further 
information from chimpanzees and humans is needed to elucidate the mechanisms of 
pathogenesis related specifically to immune function. 
1 I 
2.3.1. HCV epidemiology and natural history 
An estimated 170 million people are infected with HCV. Parenteral risk factors for 
infection include injection drug use, blood and blood product transfusions in the pre-
HCV screening era, and HCV-infected liver transplants. Intravenous (IV) drug users, 
persons with inherited and acquired coagulopathies, and fetuses of infected mothers are at 
particularly high risk for infection. There are still a significant number of HCV 
infections without known risk factors, suggesting that other important routes of 
transmission remain to be identified. The risk of sexual (53) and vertical (54) 
transmission of HCV is considerably greater in HIV coinfected individuals, probably 
reflecting the higher HCV loads in this group. 
The mean incubation period of HCV is estimated between 7 and 20 weeks (55). 
Acute infection is generally characterized by moderate increases in serum transaminases 
and production of anti-HCV antibodies. Eighty percent of acutely infected individuals 
experience no clinical symptoms and, thus, are generally not investigated. The remaining 
20% develop acute symptomatic hepatitis. Between 50% (56) and 85% (55) of acute 
infections become chronic, accompanied by an insipid disease course with approximately 
two thirds of those with chronic infection· having elevated aminotransferases (55). 
Estimates of the proportion with chronic HCV infection that progress to cirrhosis vary 
between 20% and 30%. Approximately 25% of those with cirrhosis develop 
complications such as hepatocellular carcinoma (HCC) and decompensated liver disease 
requiring liver transplant (Figure 2.3). 
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The impact of HCV infection on HIV-related disease progression is not entirely 
clear. Certainly, survival analysis in populations with different HCV risk factors indicate 
an increased rate of mortality in HJY/HCV coinfected individuals compared to HIV only 
patients, and this increased death rate cannot be attributed entirely to the increased 
incidence of liver disease (57, 58). However, not all HIY-infected individuals with HCV 
coinfection exhibit lower CD4+ T cell counts or higher HIV viremia than those with HJV 
infection alone (59, 60). Although there are conflicting reports, at least one study showed 
accelerated clinical progression of HIV disease in coinfected individuals (58). This study 
included 119 HIV -infected subjects and 119 HIV /HCV -infected subjects followed for up 
to 108 months. It demonstrated an adjusted hazard ratio of 1.64 for clinical HIV disease 
progression in individuals with HCV coinfection versus those without HCV. The Swiss 
HIV Cohort Study also indicates a relative hazard of 1.7 for a new AIDS defining illne s 
or death for HCV-seropositive compared to HCY-negative, HIV-infected individuals 
(57). A prospective Danish study of HIV individuals starting HAART therapy between 
1995 and 2004 demonstrated increased overall mortality and mortality attributable to 
acquired immunodeficiency syndrome-related disease in the coinfected population (61). 
One study of CD8+ T cell responses in coinfected haemophiliacs found that HCV 
coinfection altered the phenotype of HIV-specific CD8+ T cells to a relatively low 
perforin state (62) that was associated with HJY disease progression. Conversely, an 
American longitudinal study followed 10,481 HIV infected individuals with 19% HCV 
coinfection for 1.9 years, and there was not an increased progression to an AIDS-defining 
illness or death (63). However, the followup was short considering the insidious disease 
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course ofHCV infection. Thjs study also followed individuals within one year of starting 
HAART therapy and found that HCV coinfection did not negatively impact HIV viral 
load reduction or CD4+ T cell count recovery. Clearly, there is till a lack of consensus 
on the effects ofHCV on HIV related disease and response to treatment. 
Earlier reports of little difference between HIV alone and HJV /HCV -infected 
groups could reflect a failure to identify all HCV coinfected individuals. Second 
generation anti-HCV tests used by many group to identify coinfected individuals do not 
detect up to 20% of HCV-infected individuals coinfected with HIV (64, 65). 
Consequently, a significant number of coinfected individual were probably not 
identified in early studies that did not use RNA based testing to determine HCV 
infection. These seronegative, HCV RNA-positive patients would mistakenly be grouped 
with the HIV group, perhaps falsely increa ing the rate of clinical progression of the HJV 
group. Studies reporting no effect of HCV on HlV progre sion should be viewed with 
some scepticism if only HCV antibodies were used to diagnose H V infection. Infection 
with different HCV genotypes also produces distinct clinical outcomes and early studies 
that did not stratify HCV infection by genotype may also be misleading when studying 
clinical progre sion. HCV genotype I b is associated with a poor re ponse to treatment, 
and with a poor prognosis once liver disease develops (66, 67). It may be that this is a 
more pathogenic HCV genotype not only on its own, but also in HIV coinfection. 
HlV infection does impact clinical parameters of HCV infection. Coinfected 
individuals have higher virus loads than those of individuals with only HCV (68-70). A 
study of 19 drug users showed that the mean number of HCV RNA copie per ml of 
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plasma was significantly higher in HIV co infected individuals (1 07 copies per ml) than in 
HCV only infected subjects (<106 copies per ml) (71). HCV-infected individuals 
infected with HIV during the study had significant increases in HCV RNA levels that 
were sustained throughout the followup time of up to 110 months. HIV infection also 
changes the rate of hepatic fibrosis progression (72, 73). An indirect measure of the 
fibrosis rate can be obtained by estimating the time from infection to cirrhosis. In one 
study, HIV/HCV coinfected individuals had a median time of 26 years to cirrhosis while 
patients infected only with HCV had a median time of 38 years (74). Although some 
studies suggest otherwise, it appears that lower CD4+ T cell counts are generally 
associated with accelerated progression to liver disease in HIV /HCV coinfected patients 
(75). Not only does fibrosis occur more frequently and at earlier time points in 
coinfection, but the time between HCV exposure and development of hepatocellular 
carcinoma is shorter in coinfected individuals than in subjects infected with HCV alone 
(76). The incidence of HCC in the coinfected group may also be higher (77), in part 
because there is more rapid progression to all end-stage liver disease manifestations. 
2.3.2. Diagnosis ofHCV infection 
Serological diagnosis of HCV infection utilizes both enzyme immunoassays 
(EIAs) and recombinant immunoblot assays (RIBAs). First generation assays only detect 
antibodies against an antigenic sequence primarily within the HCV NS4 region, the 
recombinant c1 00-3 antigen. The restricted scope of antigens in these tests resulted in 
many false negatives in some populations (78). It was also found that antibody 
production to antigens of cl 00-3 can be delayed for up to 6 months producing false 
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negative tests m early infection (79). Second generation tests include recombinant 
antigens from other regions of the hepatitis C genome, such as core (c22) and NS3 
(c33c), in addition to cl00-3. Antibodies to these antigens can be detected up to 8 weeks 
earlier than cl00-3 reactive antibodies, resulting in earlier diagnosis of HCV infection, 
particularly in high risk populations (80). In addition to the core, c33c and cl 00-3 
antigens, third generation tests include NSS antigens. With their comprehensive array of 
HCY antigens, the third generation tests are the most sensitive for detecting acute HCV 
infection when seroconversion is still ongoing (81 ). 
Detection of anti-HCV antibodies by third generation EIA is currently the primary 
screening test for HCV infection. Anti-HCV antibodies are found in most individuals 
that are chronically infected, and in many individuals with resolved HCV infection (82), 
however antibodies may decline to undetectable levels in the small minority of HCY 
infections that spontaneously resolve (83). Antibodies are not found early in acute 
infection and may not arise against a background of severe immunosuppression or 
immunodeficiency (84, 85). Therefore, antibody-based diagnosis of HCV infection is not 
always reliable. When clinical findings suggest possible HCV infection (high risk 
activity, elevated levels of liver enzymes in serum or HCY associated clinical phenomena 
in unusual populations, such as porphyria cutanea tarda in a very young individual), RNA 
based testing is necessary to accurately determine HCV infection status. Once diagnosed 
as HCV infected, genotyping is recommended in all viremic patients as it affects the 
likelihood of sustained virological response to treatment (86). 
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There are several groups of HCV-exposed individuals based on antibody and 
RNA testing: HCV antibody positive individuals with detectable RNA are considered to 
be chronically infected, and those with antibodies but undetectable RNA are said to have 
resolved infection. Another group, HCV antibody negative but detectable HCV RNA in 
serum, are referred to as seronegative chronic infections. Some individuals are HCV 
antibody and HCV RNA negative via serum testing but have elevated liver enzymes. 
Liver biopsy has demonstrated HCV RNA, as well as the negative strand replicative 
intermediate, in greater than 50% of those tested (87). In these cases, peripheral blood 
mononuclear cells (PBMC) have also been infected. Recent work has also demonstrated 
HCV RNA in the liver of individuals who are HCV exposed (antibody positive) but 
serum HCV RNA negative in the face of normal liver enzymes (88). This 'occult' 
infection has been described by other groups in both the liver and PBMC (89, 90). There 
is association of occult infection with milder but present liver disease and a weak 
association with HCC (91, 92), therefore in individuals with high clinical suspicion, 
excluding HCV infection by more invasive means may be an option worth considering. 
Diagnosis of HCV infection in the coinfected individual illustrates well the 
possible deficiencies of antibody-based testing for HCV infection. Antibody production 
in HIV infection may be impaired by a Jack of CD4+ T cell help to B cells or by other 
types of immune dysregulation. Consequently, early generation ELISA testing in the 
HIV -infected population often reports HCV -infected individuals as either HCV antibody 
non-reactive or indetenninate (84). The percentage of false negatives for second 
generation EIAs in the general population has been estimated at approximately 5-l 0% 
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(93, 94). Our group and others found that upwards of 20% of coinfected individuals may 
be HCV RNA positive, but seronegative using the second generation test (64, 65). While 
third generation assays have improved this situation during seroconversion by up to 25% 
(81) and reduced the number of indeterminate tests, it is still difficult to rely on 
seroreactivity in HIV -infected persons for HCV diagnosis. The situation may be 
compounded if an individual contracts HCV after becoming immunodeficient due to HJV 
infection. Even in individuals infected with HCV before HIV, there is some evidence 
that antibody titers fall and may become undetectable (95, 96), therefore, HCV RNA-
based testing is definitely recommended for HIV-infected individuals if there is any 
underlying reason to suspect HCV infection. 
ln some situations, economics and infrastructure limit the use of PCR-based 
diagnosis. A recent trategy to increase early diagnosis in the context of blood donation 
and immunosuppression in HCV RNA positive, anti-HCV negative samples has been 
developed where a combination of HCV core antigen and antibody are detected (97). 
Another study looked specifically at HIV positive individuals and found the individuals 
are deemed HCY positive in 65% of cases earlier than by third generation anti-HCV 
assay alone (98). While not a replacement for RNA-based diagnosis, it may provide a 
useful adjunct in specific situations. 
2.3.3. HCV monitoring 
Defining reliable markers that allow comprehensive evaluation of HCY disease 
progression is challenging. Markers such as low serum albumin and increased 
International Normalized Ratio (INR), indicating . reduced production of important 
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proteins made by the liver, can both be signs of serious liver damage or end-stage liver 
disease. Serum alanine transaminase (AL T) levels are commonly used to monitor liver 
damage in HCV-infected individuals that are otherwise asymptomatic. However, 
increases in serum ALT indicate hepatocellular damage that may have many causes other 
than HCV related disease, such as drug hepatotoxicity or acute alcohol ingestion. ALT 
levels may also be elevated late in liver disease, but do not allow sensitive detection of 
slow, progressive deterioration in the liver. While generally used as a marker of 
cholestatic disease, increases in serum gamma-glutaryl transpeptidase (GGT) may be a 
more sensitive marker for liver disease, especially in hemodialysed populations where the 
normal range for ALT levels are lower and relatively elevated ALT levels may be missed 
(99). Definitive estimation of the stage of liver disease relies on investigation of biopsy 
material. Pathologists examine liver biopsy specimens for evidence of lymphocytic 
infiltration, liver fibrosis and cirrhosis. Several scoring systems have been designed to 
quantitate the degree and extent of pathological changes occurring in the liver. 
Various studies have addressed the need for non-invasive tests correlating with 
liver disease. Five biochemical markers (a2-macroglobulin, apolipoprotein Al , 
haptoglobin, GGT and total bilirubin) have been combined to fonn the Fibrotest which 
can differentiate between non-clinically significant and clinically significant fibrosis, and 
may be useful in initial evaluation and follow-up of individuals undergoing therapy (1 00, 
101 ). Other scoring indices include the AST to platelet ratio index ( 1 02), serum 
hyaluronic acid level (1 03), and the Foms index (age, GGT, cholesterol, platelet count, 
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and prothrombin time) (1 04). Although none have replaced liver biopsy, they are 
increasingly valued in clinical practice. 
Monit01ing disease activity and progression is difficult enough in HCV infection 
alone, but this challenge is compounded in the HIV coinfected individual. Potent 
antiretroviral drugs used effectively to treat many HIV patients have a positive effect on 
both HIV viral load and CD4+ T cell counts (1 05, 1 06). Treatment is, however, a double 
edged sword as some of these drugs, in particular protease inhibitors and nonnucleoside 
reverse transcriptase inhibitors (NNRTis) such as nevirapine, are highly hepatotoxic. 
Therefore, in individuals receiving HAART, ALT levels may rise more due to drug 
induced damage than to HCV-associated liver damage (107, 108). Moreover, 
maintenance of normal serum AL T levels in these individuals does not mean that 
insidious hepatic changes are not occurring. HIV/HCV coinfected patients progress more 
quickly to liver-related morbidity, and have higher levels of HCV viremia than HCV-
infected individuals (70, 72), but this is not always associated with abnonnal ALT level . 
In the face of accelerated liver deterioration in these patients, diligent monitoring of ALT 
levels and also periodic liver biopsies may be necessary. 
2.3.4. HCV treatment 
The ultimate goals of HCV treatment are eradication of HCV and regression of 
liver fibrosis. The current standard of treatment for HCV infection is pegylated 
interferon-alpha (PEG-IFN-a) injection ·weekly and oral ribavirin daily (66, 1 09). A 
sustained virologic response (SVR) is defined as undetectable serum HCV RNA 24 
weeks after finishing therapy. Treatment regimes range from 6 months in non-genotype 
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1 b infections to 12 months in genotype I b infections. Most clinical trial results to date 
indicate low rates of SVR in genotype 1 (40%) compared with genotypes 2 and 3 (70-
80%) (11 0, Ill). Genotypes 4, 5, and 6 have intermediate levels of SVR (86). Sustained 
virologic response is associated with reduced fibrosis ( 112) however, treatment-
associated improvement in individuals without significant change in HCV RNA viremia 
has also been reported ( 113). Response rates are affected by HCV RNA levels, sex, 
cirrhosis, age, weight, stage of fibrosis, steatosis and racial differences (67, Ill, 114-
117). A study of 475 patients showed a decreased response rate in African-Americans 
compared to White, Hispanic and Asian-Americans (118). These factors should be 
weighed, particularly if considering treatment in the HCV viremic individual with no 
clear evidence of liver disease. 
Current guidelines recommend treatment in all HCV genotypes 2 and 3 without 
absolute conh·aindications, as the rates of SVR are relatively high ( 119, 120). For 
individuals who are genotype 1, 4, 5,or 6 with serum HCV RNA viremia, elevated ALT 
levels, and biopsy evidence of hepatitis, treatment should be considered (119, 121). 
Individuals with normal liver enzymes but HCV viremia may be treated but the decision 
is individualized based on level of patient concern, comorbidities, age, weight and 
genotype (86). There is some data that treatment of these patients is indicated from both 
a SVR (122) and cost effectiveness (123) perspective. 
It is rare to identify acute (< 3 month) HCV infection as jt does not often cause 
fulminant disease. Individuals with an exposure risk should be monitored for 12 weeks 
from the estimated or known time of infection. If they do not spontaneously clear the 
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virus, one report supports treatment with IFN-a. It demonstrated much higher response 
rates to IFN-a monotherapy when individuals were treated in the acute phase of HCV 
infection (124) compared with chronic infection. Forty-two of the 44 patients in this trial 
had undetectable serum HCV RNA up to 24 weeks after completing a 24 week course of 
IFN-a monotherapy. The majority of these individuals were genotype 1 and there was no 
significant difference in the response rate between genotypes. 
As described above, a positive response in terms of HCV eradication is defined on 
the basis of serum HCV RNA. It is uncommon to look for HCV RNA in the liver in 
monitoring for these trials, but HCV RNA can sometimes be found in mononuclear cells 
and the liver, even in the absence of serum HCV RNA (125-128). Hence, undetectable 
serum HCV RNA does not confirm viral eradication. It is important in individuals who 
may undergo immunosuppressive regimens after anti-HCV treatment to consider that the 
virus is unlikely to be completely eradicated. 
Toxic side effects of treatment are multiple and significant. They include malaise, 
depression, IFN-associated thyroiditis, bone mmrow suppression, and hemolysis. Better 
treatments that would eradicate HCV more frequently or reduce replication in 
asymptomatic individuals are urgently needed. There has been a great deal of research 
into the basis of 'IFN-resistance' and the mechanisms by which IFN and ribavirin work 
in treatment of HCV (reviewed by Wohnsland (1 29)). Treatment at present is only a 
symptomatic therapy, with the goal of reversing or limiting damage mediated by a virus 
replicating unchecked. Other treatments have been directed at reducing symptoms in 
individuals failing IFN/ribavirin therapy. For example, treatment with interleukin-1 0 (lL-
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I 0) reversed and reduced rates of fibrosis in a group of HCV -infected individuals (130). 
Ursodeoxycholic acid, nonsteroidal anti-inflammatory drugs and thymosi"h-a have been 
used as adjuncts to IFN-a with no clear benefit demonstrated (131). Newer studies of 
immunomodulators such as thymosin-a have suggested there may be a role in chronic 
hepatitis C patients who have previously failed interferon/ribavirin treatment (132). 
As more information regarding the HCV lifecycle becomes available with the 
advent of in vitro infectious replication systems, specifically directed antivirals are being 
tested. Two NS3/4A protease inhibitors have reached Phase 2 trials. VX-950 and 
SCH503034, both peptidomimetic inhibitors, have been tested as monotherapy and in 
combination with IFN treatment and results are currently in press. Viremia recurs after 
cessation of therapy with these drugs and drug resistance accumulates rapidly ( 129). 
Early data in Phase 1 trials of polymerase inhibitors indicate a similar propensity for the 
development of resistance mutations, but less efficacy in te1ms of reducing HCV RNA 
viral load (129). 
Making appropriate treatment decisions concemmg HCV in HIV coinfected 
patients requires consideration of more than just the response rate and side effect profile 
of treatment. Treatments for HIV are very effective in many individuals, restoring CD4+ 
T cell counts and delaying the development of AIDS-defining illnesses for increasingly 
long periods of time. When there are no contraindications, treatment of HlV infection is 
the first priority, unless there is evidence of decompensating liver disease ( 133). Many 
classes of antiretrovirals, including NRTis, NNRTls and Pis, can be hepatotoxic, with 
nevirapine and full dose ritonavir being some of the worst (1 08). Therefore, care should 
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be taken in coinfected patients to optimise HIV treatment while minimizing use of the 
most toxic drugs ( 134, 135). With respect to HCV treatment, another potential drug 
interaction looms between ribavirin and zidovudine, a nucleoside analogue reverse 
transcriptase inhibitor (NRTI). In vitro studies have shown that ribavirin inhibits the 
phosphorylation of zidovudine and stavudine (d4T) by competing for thymidine kinases 
(136, 137). Although no adverse effects have been shown in vivo, close monitoring 
while individuals are receiving both drugs is essential. 
While treatment of HIV is obviously necessary in patients meeting established 
criteria, the increase in CD4+ T cell counts and general increase in immune function can 
actually cause HCV -related liver disease to develop more rapidly. Such immune 
reconstitution has been related to increased rates of liver fibrosis (138, 139), suggesting 
that at least some of the hepatic damage in HCV infection is related to the host immune 
response and not a direct effect of the virus. Although there are conflicting report (140-
142), several studies found increases in HCV virus load in HIV -infected individuals 
given protease inhibitors (135, 143). These repmis led to speculation that protease 
inhibitors could either induce HCV replication somehow or that competitive interference 
between HIV and HCV kept HCV levels lower in HIV -infected individuals with higher 
HIV loads. These hypotheses have not been confirmed and other studies reported no 
consistent effect ofHIV treatment on HCV levels (140, 144). 
Combination HCV treatment is recommended in stable, immunocompetent 
HIV/HCV coinfected individuals without other absolute contraindications to either 
ribavirin or IFN-a (86, 145). Response rates to combination pegylated HCV treatments 
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in immunocompetent HCV/HIV coinfected populations have been lower than those in the 
general population (146-152). As in HCV monoinfected individuals, baseline HCV RNA 
levels, and HCV genotype are involved in predicting response to treatment in the 
coinfected patient, and the baseline CD4+ T cell count has also been associated with 
outcome in one study (153) as well as a recent meta-analysis (146), although the odds 
ratio confidence interval does cross unity in this pooled analysis. It may be that 
individuals on more effective HAART therapy with higher CD4+ T cell counts are more 
likely to clear the HCV virus, but this is still not clear. The abundance of data at this 
point suggests only treating individuals with HCV/HIV coinfection after control of HIV 
related disease. 
2.3.5. Extrahepatic manifestations o.fHCV infection 
Various extrahepatic manifestations occur in chronic HCV infection (reviewed by 
Zignego (154)), and some groups propose it be considered a systemic disease. Current 
classification divides the associated disease into 4 groups: association by high prevalence 
and pathogenesis (mixed cryoglobulinemia), association with higher prevalence than 
controls (B cell non-Hodgkins lymphoma, monoclonal gammopathies, porphyria cutanea 
tarda, and lichen planus), association to be confirmed (autoimmune thyroiditis, thyroid 
cancer, sicca syndrome, alveolitis-lung fibrosis, diabetes mellitus, non-cryoblobulinemic 
nephropathies, aortic atherosclerosis), and anecdotal observations (psoriasis, peripheral 
neuropathies, rheumatoid arthritis, polyarteritis nodosa, fibromyalgia, chronic urticaria, 
and cardiomyopathies). 
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Cryoglobulinemia, the most common of these clinical issues (155, 156), was 
actually treated with interferon-a prior to identification of HCV infection as the primary 
cause (157). Approximately 35-55% of people with chronic HCY infection have 
cryoglobulins (158) and 90% of patients with essential mixed cryoglobulinemia (EMC) 
are HCV -infected (159). HCV RNA, antigens and anti-HCV antibodies can be found in 
cryoprecipitates, suggesting a direct role for HCV in formation of these complexes (159). 
Up to 25% ofHCV-infected individuals have clinical symptoms that occur independently 
of any overt liver disease ( 160), however a meta analysis of 19 studies between 1994 and 
2001 has shown an increased odds ratio of 4.87 for cirrhosis in HCV patients positive for 
cryoglobulins (161). The most common clinical manifestations of EMC depend on the 
particular 'population studied, but include neuropathies (162), glomerulonephritis, and 
cutaneous vasculitis (163). Other syndromes and diseases suspected to be associated 
with HCV infection include porphyria cutanea tarda (164, 165), aplastic anaemia ( 166), 
non-Hodgkin ' s lymphoma (167), multiple myeloma (168), diabetes me11itus (169), 
arthritis (170, 171 ), idiopathic pulmonary fibrosis (172), and fibromyalgia syndrome 
(173). 
The exact link between HCV and these diseases has not been finnly identified, 
but B cell dysfunction and other regulatory problems within the immune system are 
suspected. Studies have associated chromosomal translocation, t(14; 18) with HCV 
infection ( 174) and mixed cryoglobulinemia (175), supporting a role for HCV in the 
development of clinical entities characterized by immunoglobulin dysregulation. Some 
of the diseases and syndromes associated with HCV are also associated with other 
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chronic viral infections such as HIV and hepatitis D vtrus (HDV) (176), raising the 
question ofwhether these symptoms are truly HCV-specific or epiphenomena related to 
the long-term immune stimulation accompanying chronic infection. 
Whether HIV coinfection impacts the type and incidence of HCV-associated 
extrahepatic manifestations is not clear. Many of the syndromes have features of 
autoimmune disease and whether immunocompromised HIV -infected hosts are as likely 
to develop some of these symptoms remains unknown. Conversely, if these syndromes 
are not truly autoimmune and are more symptomatic of immune dysregulation, they may 
occur more frequently in severely immunocompromised individuals. Evidence strongly 
favoring or discounting either of these possibilities is lacking. A prospective cross 
sectional study of HCV/HIV coinfected, HIV monoinfected and HCV infected 
individuals found similar rates of cryoglobulinemia in HCV monoinfected and HIV /HCV 
coinfected individuals, however the prevalence of anti-thyroglobulin and anti-cardiolipin 
antibodies was increased in coinfected individuals compared with HCV monoinfected 
individuals (177). This increased prevalence of autoantibodies was not associated with 
an increase in clinical autoimmune disease. While this study suggests that there is an 
interaction between HIV and HCV on immune regulation, the issue is far from resolved. 
Treatment approaches to extrahepatic HCV manifestations vary, depending on 
other comorbid illness and the sensitivity of the individual to current HCV therapies. In 
general, specific antiviral treatment is useful in treating mixed cryoglobulinemia, 
glomerulonephritis, porphyria cutanea tarda, and panarteritis nodosa (160). Studies of 
combination PEG-IFN-a and ribavirin in mixed cryoglobulinemia have demonstrated 
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reasonable response rates in terms of HCV RNA clearance and improvement of 
cryoglobulinemia-related disease (178-180). Symptomatic therapy, in addition to 
specific anti-viral treatment, is indicated for autoimmune thyroid disease, lymphoma, 
aplastic anaemia, autoimmune thrombocytopenia, lichen planus, neuropathy, sicca 
syndrome, and diabetes mellitus ( 160). Autoimmune disorders such as thyroiditis, lichen 
planus, and sialadenitis are worsened by the immune activation instigated by interferon-
a. Thus, treatment of patients whose disease is characterized by these symptoms should 
exclude interferon-a. 
2.3. 6. Pathogenesis of HCV disease 
Controversy remains regarding the cytopathicity of HCV. Some evidence suggests 
that the virus itself is non-cytopathic ( 181 ), and that hepatic pathogenesis is directly 
linked to the pro-inflammatory immune response of chronic viral infection (182, 183 ). 
The pathologic picture of chronic HCV infection is typified by infiltration of CD4+ and 
CD8+ lymphocytes, B cells, NK cells and NK T cells. Similar to the case with hepatitis B 
vinis (HBV) infection, there is an expansive hepatic lymphocytic infiltrate that consists 
largely of non-HCV -specific cells that produce IFN-y (184), leading to hepatic fibrosis 
and portal inflammation (182). Other evidence indicates that HCV is cytopathic to host 
cells, causing changes similar to those seen in Dengue virus infection (1 85). HCV-
infected individuals with cyclosporine-induced immunosuppression following 
transplantation (186) or with HIV -associated immune deficiency (75) may still have 
progressive liver disease, arguing against a purely inflammatory pathogenesis. In 
· addition, there have been reports that HCV may preferentially infect B cells m the 
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peripheral blood (29, 187). Lower B cell counts have been reported in HCV-infected 
individuals (1 88), which may indicate destruction of infected B cells by the host immune 
response or a direct cytopathic effect of the virus. The true pathogenic origin of HCV-
related disease both in the liver and extrahepatic compartment probably involves 
components of both virus cytopathicity and damage mediated by the host immune 
response. 
2.4. Immunology of HCV Infection 
2.4. I. Introduction 
The immune response that arises against HCV during acute infection eliminates 
the virus only in about one quarter of cases. If viral clearance does not occur in the 
period directly following acute infection, it likely will not happen without antiviral 
treatment. Since the available treatments are effective in only a minority of cases, most 
HCV -infected individuals currently face lifelong chronic infection, irrespective of the 
anti-HCV immune response they ultimately develop. As in HIV infection, this 
immunological inadequacy remains a poorly understood aspect of the natural history of 
HCV infection. However, the roughly 25% of acutely infected individuals that do clear 
HCV infection provide examples of successful immune responses from which to discern 
the effective components of anti-HCV immunity. Even in cases of chronic HCV 
infection, the immune response is stil l meaningful, as illustrated by the higher plasma 
HCV virus loads and more rapid disease progression in settings of immunodeficiency 
mediated by anti-rejection drugs or HIV (69, 70). 
- --------------------- ---------------------
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The natural history of chronic HCV infection reflects the highly variable outcome 
of complex interactions between adaptive immunity and effective viral strategies for 
evading immunity. Since coinfection with HIV worsens the predilection towards 
inadequate immunity, it is not surprising that chronic HCV infection is a more frequent 
outcome in the HIV -infected population (189, 190). Even though it is uncommon for the 
immune system to eradicate HCV, some components of immunity provide long-tenn 
protection against symptomatic disease in most immunocompetent cases (55). Thu , 
there is a continuum of effective immunity against HCV ranging from sterilizing 
immunity and lifelong protection against disease to ever diminishing disease protection 
over the duration of infection. Evidence of what constitutes an effective immune 
response against HCV lies within qualitative and quantitative differences in anti-HCV 
immunity over this natural continuum. Aspects of anti-HCV immunity peculiar to 
individuals clearing the virus or suppressing replication to inconsequential levels offer 
rational targets to guide the design of prophylactic and therapeutic vaccines. 
For the most part, people fully recovered from HCV infection have anti-HCV 
antibodies, but very little or no HCV RNA in their blood (126, 189-191 ). Viral clearance 
can also occur without development of anti-HCV antibodies, but this is difficult to 
document and probably quite rare. It is important to determine during acute infection 
how anti-HCV immunity differs between those who clear the virus and those who 
progress to chronic infection, as this is the key period for natural viral eradication. 
Immunological differences that persist between fully recovered individuals, healthy 
individuals with chronic infection and those with active liver disease can also be 
---·-----------------------------------
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informative, but to some extent will reflect the long term effects of chronic infection or 
clearance subsequent to the pivotal conditions that determined the outcome of acute 
infection. 
The following sections review the evidence for anti-HCV immune responses in 
groups with HCV exposure but no infection, spontaneous clearance, persistent infection, 
successful treatment with sustained virologic response, and unsuccessful treatment with 
persistent viremia. We focus primarily on the anti-HCV CD4+ and CD8+ T cell response 
in monoinfected and HIV coinfected groups, but also comment on relevant aspects of 
innate immunity. 
2. 4. 2. Exposure to HCV without infection 
HCV seronegative spouses and other family members of HCV-infected 
individuals exhibit a much higher incidence of anti-HCV helper and cytolytic T cell 
(CTL) responses than do unexposed controls (192-194). The T cell responses are broadly 
directed against different HCV proteins and there is speculation these responses may 
indicate previous HCV infection that was cleared as a result of these responses. Past 
infection in these cases was not confirmed by detection of HCV RNA in retrospective 
samples, however these results were obtained using a relatively insensitive HCV viral 
load test (approximately 1000 copies/mL). Clearance in these cases may be associated 
with exposure to levels of HCV too low to induce either anti-HCV antibodies or acute 
hepatitis. Lack of viremia was detennined prospectively in a more recent study that 
looked at acutely infected HCV individuals and their sexual partners ( 195). Cellular 
immune responses, measured by IFN-y production in enzyme-linked immunsorbant spot 
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(ELISPOT) assays, were detectable in eight of sixteen aviremic seronegative contacts. A 
relationship between lower HCV levels and lack of anti-HCV antibody induction is also 
suggested by descriptions of individuals with low level HCV infection who either lost or 
never developed anti-HCV antibodies (196). Conversely, antibody responses sometimes 
do become apparent as HCV levels rise in chronic HCV infection. 
It would seem that exposure to low levels of HCV may induce antibodies and 
cellular immune responses in the absence of persistent infection. Whether these 
responses are protective in the context of challenge with higher viral loads remains to be 
detennined, but these findings have important implications for prophylactic and 
therapeutic HCV vaccine development. 
2.4.3. Acute self-limiting HCV infection 
The presence of HCV -specific T cell responses without anti-HCV antibodies in 
some individuals who may have cleared HCV infection indicates a central protective role 
for cellular immunity (192, 193, 195), at least under some challenge conditions. This is 
true of most viral infections, however, the potential effector role of CTL in killing HCV-
infected cells and the role of helper T cells, beyond that ofhelping CTL to proliferate and 
differentiate, has been studied by many groups without a clear consensus being reached. 
Many studies have demonstrated multispecific vigorous anti-HCV CD4+ and CD8+ T 
cells in acute infection (197-201). Not all individuals with strong CD4+ T cell responses 
cleared the virus (200) suggesting that CD4+ T cell responses alone are not sufficient for 
persistent control of virus. Despite expansion of CD4+ T cell responses, a dysfunctional 
phenotype in those who initially control the virus followed by relapse has been described 
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(202, 203). Other studies have underscored the importance of CD4+ T cell responses in 
individuals with acute infection. In 16 individuals with acute HCV infection, all had 
CD8+ T cell responses but only those with concurrent CD4+ T cell responses cleared the 
virus (204). These ' successful ' CD4+ T cell responses were typically Th 1 in nature (i.e. 
T cells produce IL-2, IFN-y and TNF-a (205, 206)). No one particular antigenic region 
of the genome has been associated with particularly 'effective' CD4+ T cell responses, 
and major histocompatibility complex (MHC) class II epitopes have been defined from 
most non-structural regions (184). A recent study of 22 individuals with spontaneous 
HCV clearance identified several promiscuous human leukocyte antigen (HLA) class 11 
epitopes from nonstructural regions that were found more frequently in spontaneous 
clearers than those with chronic infection (207). Estimates of the number of HCV-
specific CD4+ T cells in acute infection differ widely based on the technique (MHC 
tetramer, IFN-y production, or surface flow cytometry) used (20 1, 208). 
Generally, CD8+ T cell responses in viral infection are essential for clearance 
(209). In the case of I-ICY, CD8+ T cell expansion in acute infection is associated with 
control of viremia (200, 21 0), and a lack of CD8+ T cell response resulted in persistent 
infection. While these cells expand reasonably well during acute infection, development 
of cytotoxic and IFN-y effector function is delayed (199, 200, 211 , 212), which may 
allow the establislunent of persistent infection. Broad specificity, functional CD8+ T cell 
responses are associated with HCV clearance and HLA class I restricted epitopes have 
been described in all regions of the genome (21 0, 213-216), although there have been no 
clearly defined immunodominant regions. The exact breadth of the response, and 
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whether there is a threshold for clearance versus persistence, remains to be detem1ined. 
CD8+ T cells have been classified in various ways. In other persistent infections 
such as HlV and EBV, the differentiation of effector T cells in acute infection has been 
divided into early, intermediate, and late, based on expression of costimulatory molecules 
CD27 and CD28 (213, 217). Like HlV and EBV infections, HCV-specific CD8+ T cells 
during acute infection are CD28+ and CD27+ with low levels of effector molecules such 
as perforin, suggesting an early stage of differentiation (213) that does not include HCV-
specific cytolytic 'late' effectors. Another model uses the lymph node homing receptor 
C-C motif chemokine receptor 7 (CCR 7) to differentiate memory and central effectors 
(218). The large population of CCR T CD8+ T cells in acute infection were consistent 
with memory effector cells, but they did not proliferate ex vivo indicating a functional 
impairment beyond the differentiation explanation (219). Because interleukin 7 is 
involved in memory T cell differentiation, lL-7-R (CD127) distribution on T cells has 
been investigated. The memory T cell phenotype that develops in acute resolving HCV 
infection is characteristic of the phenotype found in other resolving infections such a 
respiratory syncytial virus (RSV) and influenza (220). CD127+ T cells secrete IL-2, are 
long lived, and are associated with the development of a central memory phenotype 
common in viral clearance. High levels of CD127 (206) expression are associated with 
HCV clearance, although this phenotype is also found in persistent HCV infection (221) 
in association with low killer cell lectin-like receptor G 1 (KLRG 1 ), questioning their 
functional role in clearance. Programmed death- I (PO-l), a negative regulator ofT cell 
activation and function, is increased in persistent infections such as HlV (222). In acute 
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HCV infection, PD-1 +CD8+ T cells were present but decreased with resolving infection 
and remained at high levels in unresolving infection (223). These studies suggest further 
functiona l stunting ofHCV -specific T cells, although the mechanism is unclear. 
Since some chronically-infected individuals retain anti-HCV CTL and helper T 
cell responses (83, 224), or at least manifest these responses temporarily, there must be 
qualitative or quantitative differences within the response that differentiate those that 
clear the virus or remain healthy from those developing chronic hepatitis. Another 
indication of the central role of cellular immunity comes from the associations reported 
between expression of particular HLA alleles and viral clearance. These antigens present 
viral peptides to T cells and presumably, the alleles associated with viral clearance 
present a range of HCV peptides that allow for a more effective immune response. 
Several studies concluded that the HLA class II alleles DR~ 1 * 110 I and DQ~ 1 *0301 
(which are strongly linked) are more common in persons who clear HCV infection 
compared to persons with chronic HCV infection (225, 226) and an Irish study associated 
DR~ 1 *OJ with viral clearance as well (227). These findings have been supported by a 
recent meta-analysis, however it should be noted that the 1 1 study populations were 
European with the exception two (one from Thailand and another from North America) 
(226, 228). Since these HLA class II alleles present peptides to CD4+ helper T cells, this 
provides circumstantial evidence that strong helper T cell responses against HCV 
promote viral clearance. More multiethnic studies where the HLA diversity is increased 
would be informative. 
Viral clearance is associated with higher frequencies of HCV-reactive CD8+ T 
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cells in the 6 month period following acute infection (229), indicating that these cells 
may be the ultimate effector arm of the immune response against HCV. As such, it is 
reasonable that there would be associations between HLA class I genotypes and viral 
persistence or clearance. However, there have been few reports as ociating alleles of the 
classical HLA class I molecules presenting viral peptides to CD8+ CTL with the outcome 
of acute HCV infection. One Egyptian study of genotype 4 infected individuals 
associated HLA B50 with viral clearance but this was in only 2 individuals (230), and 
similar findings in other genotypes have not been found. The lack of trong association 
may mean there are factors other than CD8+ T cell mediated immunity involved in 
clearance. 
T cell, B cell and hepatocyte cell lines are permissive to HCV infection (185). 
However, the host cell receptor for HCV is not known with certainty and there are only 
recently developed in vitro culture systems. There is also a high degree of virus 
variability within the putative principal neutralizing determinant or hypervariable region 
1 (HVR1) of the HCV envelope protein, making reliable measurement of HCV 
neutralizing antibody titers possible only in chimpanzee challenge expe1iments (231). 
These animal experiments have shown that pre-existing or co-administered antibodies 
specific for the challenge virus can prevent infection. Antibodie may also play a role in 
viral clearance in human infections, most likely through preventing new cycles of 
infection by viruses released from infected hepatocytes into the circulation. · Surrogate 
measures of neutralizing antibodies have been derived in vitro from inhibition of 
recombinant HCV envelope protein binding to human cells (232) and from measurement 
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of serum antibody binding to HVR 1-derived synthetic peptides from the HCV envelope 2 
(E2) protein (233). These assays have shown associations between the development of 
high titers of antibodies against either HCV E2 HVR 1, HCV itself or recombinant E2 and 
resolution of HCV infection (234). Several reports also suggest that anti-HCV antibodies 
from chronically infected individuals may lack the diversity nonnally associated with 
polyclonal B cell responses (235). Anti-HCV antibodies from chronically infected 
individuals often express a common idiotype, and show evidence of K or 'A 
immunoglobulin light chain dominance characteristic of oligoclonal 8 cell responses 
(236). In HIV infection, such responses led to speculation that 8 cell clonal dominance 
established early in infection inhibits adaptation of the humoral immune response to 
emerging viral mutants (237). A similar hypothesis for the effect of oligoclonal 
responses in HCV infection may explain the ineffectiveness of the anti-HCV response in 
adapting to HCV variants in vivo (236). 
Innate immunity is a cornerstone of anti-viral immunity, and recent studies have 
increased our knowledge of the role of non-specific immunity to pathogens in general. 
Receptors for pathogen-associated molecular patterns, or PAMPs, have been identified 
for RNA (particularly toll-like receptor (TLR)-3), and these instigate the immune 
response mediated by type I interferons (238, 239). Indirect evidence for the importance 
of innate immune responses in controlling HCV infection stem from observations oflFN-
signalling obstruction by various HCV proteins (240-242). Given the central role for NK 
cells in early antiviral immunity (243, 244), a model ofHCV persistence with NK cells at 
the center has been proposed (245) although there are few studies in acute in vivo or in 
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vitro infection (246) as of yet to substantiate the hypothesis. NK cells interact with class 
I ligands on host cells through killer immunoblobulin-like receptors (KIRs) that either 
activate or inhibit natural killer activity (247). The Bw4 motif (common to multiple 
HLA-A and B alleles) and the dimorphic HLA-C motifs Cl and C2 are inhibitory. The 
natural ligands for HLA-Cl and C2 are the NK cell KIR2D receptors, while the KIR3D 
receptor family binds Bw4. One group found that the genotype KIR 2DL3/HLA C I Cl 
was associated with clearance of acute HCV infection in those who did not acquire the 
virus by transfusion (248), while another study of HIV /HCV co infected individuals did 
not support this finding (249). Overall, the role for NK cells and genotype in clearance of 
acute HCV infection remains unclear, however the innate immune system likely has the 
most impact in infections with limited viral load. 
HCV is relatively hepatotropic, and it is interesting to wonder whether circulating 
anti-HCV T cell responses are the same as intrahepatic lymphocyte populations in 
frequency, specificity and function. Acute infection in humans is generally a benign 
disease, and as such, liver biopsy is not often performed, and information on intrahepatic 
lymphocyte populations comes from chimpanzee studies that have demonstrated 
multispecific CD4+ T cell responses in the liver of resolving acute infection occur more 
frequently than in persistent infection (200). Further human based data is lacking. 
Cellular immune responses in seronegative HCV -exposed individuals, combined 
with the associations between HLA class II molecules and HCV clearance, highlight the 
role of helper T cells in protection from HCV infection. However, natural history studies 
suggest that humoral immunity and CTL can also play important roles in resolution of 
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HCV infection. Coinfection with HIV lowers the natural rate ofl-ICV clearance to below 
15% (189, 190) and increases the likelihood of recurrent infection after initial HCV 
control ( 190, 250). This effect could also largely be attributed to primary helper T cell 
dysfunction and depletion associated with HIV infection, supported by improved viral 
clearance rates in coinfected individuals treated with HAART, CD4+ T cell counts greater 
than 250 cells/mm3, and HIV viral loads <5000 copies/mL (251). At least one study has 
found that the magnitude and breadth of the circulating anti-HCV CD8+ T cell response is 
related to the CD4+ T cell count in HIV coinfection (252). Seronegative HCV infection 
is clearly more common in the HIV coinfected population than the general population 
and may reflect a reduced capacity to make new antibody response (64, 95). This could 
also favor establishment of chronic infection. Cytotoxic T cell responses against other 
viruses tend to be preserved through advanced HIV infection (253, 254), but reduced 
HCV-specific CD8+ T cell activation secondary to helper T cell dysfuncti~n could also 
contribute to the establishment of chronic HCV infection in HIV coinfected individuals. 
There have been few studies of HCV -specific CTL activity in HIV co infected individuals 
addressing this possibility. The key variable in the coinfected population, in tenns of the 
nature of HCV -specific immune responses, is probably the time of exposure to HCV in 
relation to progression ofHIY-related immunodeficiency. 
2.4.4. Chronic HCV infection 
Except in clear cases of pre-existing immunodeficiency, establishment of chronic 
HCV infection reflects both the failure to generate sterilizing immunity and the success 
of viral strategies to evade the resultant immune response. A key component of the 
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immune evasion strategies of both HIV and HCV is the infidelity of genomic replication 
mediated by error prone RNA-dependent polymerases that lack proof-reading ability. 
Both viruses evolve into a swarm of quasispecies during acute infection and variability 
within sequences targeted by humoral and cellular immunity favors persistence of poorly 
recognized variants. A study of 12 individuals with acute HCV infection indicated that 
variation within the HVR1 of HCV E2 protein was greater in those who developed 
chronic infection than in those who resolved infection (255). The appearance of new 
variants was also associated with HCV seroconversion, indicating an important role for 
potentially neutralizing antibodies in mediating immune selective pressure on HCV. 
Although these results appear to stress the role of humoral immunity in viral clearance, it 
is possible that the selective pressure of the antibodies only impacts HCV once it has 
already escaped the cellular immune response. If the cellular immune response is 
mediating the pnmary selective pressure, there would be no immediate selective 
advantage for HCV HVR 1 variants. Whether escaping the cellular or humoral response, 
generation of diversity by HCV plays a critical role in persistence. 
In chronically infected individuals, T cell-mediated recognition of endogenous 
HCV sequences is compromised relative to recognition of the index peptide sequences 
identified as CTL epitopes (256), although some studies have not found evidence of 
particularly strong CTL escape variants (257). Similar evolution takes place within 
helper T cell epitopes indicatiog that the virus evolves away from T cell recognition in 
chronic infection (258). In acute HCV infection, CTL escape variants also emerge in 
chimpanzees that progress to chronic HCV infection (259). These studies indicate that 
40 
mutational escape from T cell recognition is an important aspect of HCV's ability to 
evade the immune system during acute infection and to persist in chronic infection. 
HCV-reactive CD8+ and CD4+ T cells expand in peripheral blood during acute HCV 
infection (224, 260) and the strength and breadth of this anti-HCV T cell response 
correlates with resolution of infection ( 198, 210, 229, 261 ). The high virus loads 
associated with acute infection may produce what has been referred to as the "stunned" 
phenotype of HCV -reactive cells in which the expanded HCV -specific cells fail to release 
interferon-y in response to stimulation ( 199). This phenotype disappeared as virus load 
fell, and although HCV -specific T cell frequencies also decreased compared to levels 
during acute infection, they remained higher in individuals resolving infection than in 
those developing chronic infection. Thus, just as in HIV infection, it appears that viral 
persistence reflects the ability of HCV to diversify and expand at a greater rate than the 
responding immune effector cells. 
As in most chronic infections, HCV-specific peripheral blood T cell responses in 
chronically infected individuals are skewed towards Th2 type cytokine production (262). 
T cells isolated from the liver of chronically-infected individuals, however, continue to 
produce pro-inflammatory cytokines when stimulated (263, 264), which may be linked to 
the immunopathogenesis ofHCV disease. PBMC from HCV-infected individuals appear 
to produce immunologically significant amounts of transforming growth factor-~ (TGF-
~' as antibody neutralization ofTGF-~ increased levels of anti-HCV CTL generated by in 
vitro stimulation (265). Certain peptides from HCV non-structural proteins also 
selectively stimulate T cells to produce IL-1 0 (266, 267), an immunosuppressive cytokine 
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with anti-inflammatory properties. We found that HCV proteins stimulate IL-1 0 
production by CD36+ mononuclear cells and depletion ofT cells does not potentiate this 
effect (268). Thus, a propensity for HCV proteins to stimulate production of 
immunosuppressive cytokines and inhibit production of pro-inflammatory cytokines may 
help tilt the balance against immune system mediated clearance of HCV. 
Regulatory T cells with a CD4+CD25+ phenotype have been found in relative 
abundance in chronic HCV infection (269), and were associated with high levels ofTGF-
~ production (270) in HCV infected individuals with normal ALT levels (271 ). Those 
with elevated ALT levels had lower TGF-~ levels, supporting a role for the ongoing 
immune response in the development of hepatitis, as well as a potential mechanism of 
immune evasion. Depletion of CD25+FoxP3+ regulatory T cells increased JFN-y 
production from CD8+ T cells in vitro (272, 273), and in persistently infected or cleared 
chimpanzees, CD8+ T cells have an altered phenotype in comparison to uninfected 
animals that suggests ongoing regulatory roles in chronic and cleared infection (274). 
The immunophenotype of peripheral (223, 275) and hepatic (276) T cells m 
chronic HCV infection is similar to that of other persistent infections, with high PD-1 and 
low CD127 levels. Loss of CD127 has been associated with progression to viral 
persistence in acute infection (277), presumably by promoting a ' dysfunctional ' CD8+ T 
cell phenotype that is unable to respond to the IL-7 signals necessary for memory cell 
survival and proliferation. Other studies have found intrahepatic CD8+ T cells in HCV 
infected persons are not as responsive to TCR stimulation as those from uninfected 
individuals, despite a terminally differentiated effector phenotype (278). Of note, the loss 
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of mature phenotype in chronically infected individuals extended to cytomegalovirus 
(CMV)-specific CD8+ T cells in one study and may suggest more generalized 
immunomodulation by HCV than previously thought (279). 
In terms of innate immunity, various studies have indicated dysfunction at the 
level of NK cell receptor expression as well as cytotoxic function. Reduced expression 
of NKp46 and NKp30 and natural cytotoxicity receptors (NCR) were found in chronic 
HCV patients compared to healthy donors, and were associated with a decrease in target 
cell killing (280). Other groups have found that NK cells have conserved cytotoxic 
activity against most targets in vitro but expressed significant IL-l 0 when triggered 
(281 ). 
There are few studies on the breadth and frequency of anti-HCV CTL responses 
in HIV coinfected individuals with either chronic or resolved HCV infection. In a study 
of 26 coinfected and 47 HCV monoinfected individuals, the frequency of CD8+ T cell 
responses measured by IFN-y ELISPOT was similar between the groups but the breadth 
was reduced in coinfected individuals (282). However, another group reported decreased 
frequency and breadth ofCD4+ and CD8+ T cell responses in coinfected individuals (283, 
284). The frequency of peripheral anti-HCV CD8+ T cell responses was associated with 
the CD4+ T cell count in HIV coinfected individuals (252), however, this is not consistent 
between studies. Intrahepatic CD8+ and CD4+ responses based on expanded T cells 
derived from ·liver biopsies of 10 coinfected and 8 HCV mono infected individuals found 
comparable CD8+ and CD4+ T cell frequencies in both groups, and CD4+ T cell responses 
correlated with the presence of CD8+ T cell responses (285). Another study of liver 
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biopsies based on pathology and not in vitro expanded cells found a depletion of 
intrahepatic CD4+ T cells in coinfected individuals compared with HCV monoinfected 
that was not affected by peripheral CD4+ T cell count (286). 
The propensity to stimulate immunosuppressive cytokines may be exacerbated by 
HIV coinfection, as HIV infection is also associated with a skewing ofT cell responses 
towards production of Th2 type anti-inflammatory cytokines and peripheral blood T cell 
counts are often lower in HIV infection. Compared to monocytes from uninfected 
individuals, more monocytes from HTV-infected individuals appear primed to produce 
IL-l 0 when exposed to recombinant HCV proteins (268). CD8+ T cells from coinfected 
individuals were reported to secrete TGF-~ and attenuate T cell responses (287). 
Surprisingly, against this backdrop ofTh2 skewed cytokine production, the results of one 
study indicated that HIV coinfection increased production of Thl type cytokines by T 
cells stimulated with HCV proteins, relative to the cytokine production profile ofT cells 
from individuals chronically infected with HCV alone (288). Although this result seems 
contradictory in terms of the higher HCV plasma virus loads and increased incidence of 
chronic HCV infection in HIV coinfected individuals, it would fit with the accelerated 
rate of immune-mediated liver disease. 
In summary, anti-HCV T cell responses are present but weaker in peripheral 
circulation compared with liver in those with chronic HCV infection. These responses 
ate further attenuated by HIV coinfection. A stunned or exhausted CD8+ T cell profile, 
in the context of diminished CD4+ T cell responses over time, may partially explain the 
failure of both peripheral and intrahepatic T cell responses. No particularly 
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immunodominant epitopes have been consistently described, and augmentation of 
existing T cell responses may be important to viral clearance. 
2.4.5. IFN/Ribavirin treatment with or without viral response 
The innate immune system plays a role in priming adaptive responses, and 
therefore, it might be expected that treatment of HCV infection with interferon-a would 
result in the augmentation of detectable T cell responses. A study ofT helper CD4+ T 
cell responses in 30 individuals treated with IFN-a monotherapy demonstrated enhanced 
NS3 and NS4 responses in patients with viral clearance, but increased CD4+ responses to 
NS5 and core in those with viral persistence (289). This group also described the 
association of viral clearance with increased frequency CTL, although the association is 
compl icated by differing pre-treatment precursor frequencies and HCV viral load (290). 
Wl1ile CD4+ and CD8+ T cell responses are important, there is also evidence that 
decreased dendritic cell frequency and function (by measurement of allogeneic CD4+ T 
cell stimulation) is associated with reduced response to PEG-IFN/ribavirin treatment 
(291 ). Few studies have compared T cell responses in the same individuals before and 
after treatment. One group who studied early therapy in acute HCV infection did not find 
a correlation between more frequent CD4+ or CD8+ T cell responses and viral response to 
combination therapy (216), suggesting that while T cell responses may contribute to viral 
clearance, they are not sufficient without other factors. There have been no studies of the 
effects of treatment on cell mediated or innate immunity in coinfected populations to 
date. 
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Thus, although it seems intuitive that IFN-based therapy would improve cell 
mediated responses, the lack of agreement among a small number of studies suggests the 
mechanism of action of treatment is not just related to cell mediated immunity and may 
play a larger role at the level of innate immunity induction and regulation. This has 
implications for the development of more efficacious treatments and vaccine 
development. 
2.4.6. fmmurie evasion strategies 
Several strategies directed towards potentiating the immune response may 
contribute to HCV persistence. Both structural and non-structural HCV proteins have 
potentially immunoregulatory functions. Recombinant HCV core protein mediates 
several activities that can subvert an effective immune response, including in vitro 
inhibition of lymphocyte proliferation to core peptides (292), modulation of dendritic cell 
function (293-295), induction of tumor necrosis factor (TNF)-mediated apoptosis in T 
cell lines (296), enhancement ofFas-mediated death domain (FADD)-mediated apoptosis 
(297) and suppression of CTL responses, IFN-y and IL-2 production in mice (298). Core 
protein can also regulate transcription of the interleukin-12 (IL-12) p70 subunit, which 
could disrupt expression of this pro-inflammatory cytokine critical for predisposing 
responding T cells towards a pro-inflammatory Th 1-type cytokine production profile 
(299). The envelope protein E2 is thought to act in several ways with host cells to 
subvert or limit immune responses. Inhibition of NK cell activity through CDS! 
interaction (300, 301) and DC-SIGN (25) are two possible mechanisms. 
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Non-structural proteins have been associated with altered IFN signalling. A 
region of the HCV non-structural protein NS5A has potential immunoregulatory activity 
through inhibition of the antiviral cytokine IFN-a (302). The IFN-sensitivity 
determining region (ISDR) in NS5A is more likely to be mutated in those persons 
responding to IFN-a treatment (303). Wild type ISDR' s are proposed to inhibit IFN 
function via both IFN-inducible double stranded RNA dependent kinase (PKR)-
dependent and PKR- independent mechanisms (304). NS3/4A acts through interferon 
regulatory factor-3 (IRF-3), retinoic acid inducible gene I (RIG-I) and the toll-like 
receptor 3 (TLR-3) adaptor protein TRIF to limit IFN-related signalling (240-242). Most 
recently, NS4B has been shown to inhibit IFN signalling when overexpressed in HCV 
rep Iicon supporting cell I ines (305). 
In summary, subversion of both intracellular and extracellular mechanisms of 
innate immunity may contribute directly and indirectly to viral persistence. Whether other 
mechanisms of immune subversion, including sequestration of effector cells in secondary 
lymphoid tissue, clonotypic restriction of CDS+ T cell receptors (TCRs), and T cell 
deletion, play a role remains to be determined (306). 
2.5. Summary 
In most cases, acute HCV infection progresses to chronic infection despite 
humoral and cellular antiviral immune responses. Viral diversification through rapid 
mutation and replication is probably a key viral strategy for persistence, but the high 
virus loads of acute infection and direct effects of viral proteins on cytokine production 
can also compromise the generation of pro-inflammatory Th 1 type responses associated 
,------;------------------------------------
47 
with viral clearance. Individuals who clear HCV infection tend to have stronger T cell 
responses and higher levels of antibodies against the putative principal neutralizing 
determinant of HCV following acute infection. The T cell responses that arise in acute 
infection rapidly decline and often become undetectable in those clearing the virus and 
fall to much lower levels in those with chronic infection. In chronic infection, HCV-
specific T cells in peripheral blood are more likely to produce Th2-type (IL-l 0, IL-2) 
cytokines, while T cells infiltrating the liver maintain a pro-inflammatory, Thl-like 
phenotype. HIV coinfection mcreases the prevalence of chronic HCV infection, 
mcreases plasma virus loads, mcreases the frequency of serologically silent HCV 
infection, and accelerates the rate of progressive liver disease. It is unclear whether the 
increased frequency of chronic and serologically silent infection simply reflects HCV 
infection in the setting of previous immunodeficiency or if a natural propensity of HCV 
to stimulate immunosuppressive cytokines is exacerbated by HIV infection. It also 
remains unclear whether the accelerated rate of disease progression is due primarily to 
increased HCV replication or if the increased immune activation, especially CD8+ T cell 
activation, in HIV infection hastens immunopathological liver damage. HIV coinfection 
complicates treatment of HCV infection as both ribavi1in and interferon-a can produce 
side effects especially troublesome in HIV infected individuals. However, preliminary 
studies suggest that healthy HIV-infected individuals tolerate and respond to HCV 
treatment equally as well as non HIV-infected individuals. The liver damage associated 
with chronic HCV infection also reduces tolerance for antiretroviral drug regimes, 
creating a worsening spiral in which neither infection can be effectively treated and rapid 
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clinical disease progression follows. As a result, liver disease has become one of the 
leading causes of death for HIV -infected individuals in North America. 
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Figure 2.1. HCV genome and polyprotein processing. HCV has a 9600 base pair 
open reading frame genome that is translated as a polyprotein. The 4 structural proteins 
are cleaved by host peptidases (light grey arrows), and the remainder of the nonstructura1 
proteins are cleaved by HCV peptidases (darker grey arrows). Most of the proteins have 
known functions in viral replication (indicated in text below each protein), but also 
functions related to immune regulation that are described in the text. Core, core protein; 
El, envelope 1 protein; E2, envelope 2 protein; 7, protein 7; NS2, nonstructural protein 2; 
NS3, nonstructural protein 3; NS4A/B, nonstructural proteins A and B; NS5A/B, 
nonstructural proteins A and B. 
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Figure 2.2. Worldwide distribution of HCV genotypes. While it has been difficult to 
establish the clinical significance of various genotypes, it is clear that infection with 
genotype I b carries a worse prognosis than infection with other genotypes, as well as a 
poor response to the best available HCV treatments. Certain genotypes are more 
common in blood transfusion recipients and IV drug users, and may be associated with 
different routes of transmission. 
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An estimated 170 million people are infected with HCV - approximately 1 0 million 
of these individuals could develop HCC or liver disease requiring a transplant. 
Figure 2.3. Natural history of HCV infection. Estimates for the proportion of acutely 
infected individuals that become chronically infected range from 50%-85%. Many 
factors affect the time course of disease progression for those with chronic HCV 
infection, including HIV coinfection, concurrent alcohol abuse, age at time of infection, 
and gender. 
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CHAPTER3 
CIRCULATING CD14-CD36+ PERIPHERAL BLOOD MONONUCLEAR CELLS 
CONSTITUTIVELY PRODUCE INTERLEUKIN-10 
Running Title: Constitutive IL-l 0 production 
Lisa Barrett*, Chunming Dai *, Jane Gam berg*, Maureen Gallant*, Michael Grant* 
*Immunology Program, Division ofBasic Medical Sciences, Faculty of Medicine, 
Memorial University of Newfoundland, St. John' s, Newfoundland, Canada 
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3.1. Abstract 
The impact of immune regulatory imbalance covers surpnsmg physiological 
breadth. While dominance of anti-inflammatory cytokines such as interleukin-1 0 (IL-l 0) 
is associated with reduced immune responsiveness and susceptibility to persistent 
infection, conditions such as cardiovascular disease and diabetes are linked to chronic 
inflammation and lower IL-l 0 levels. An appropriate threshold for immune activation is 
critical for optimal protection from infection and conversely, from short and long-tenn 
side effects of immune effector mechanisms. To assess the possibility that IL-l 0 plays a 
role in setting this threshold and that healthy maintenance of immune silence may involve 
low level immune suppression, we sought out and characterized human peripheral blood 
cells constitutively producing the immunosuppressive cytokine IL-l 0. We determined 
the surface phenotype of circulating petipheral blood mononuclear cells (PBMC) 
constitutively producing IL-l 0 by surface and intracellular flow cytometry and visualized 
their ultrastructure by electron microscopy. The frequency of IL-l 0 producing and 
secreting cells was estimated by enzyme-linked immunospot (ELISPOT) and flow 
cytometry. Up to 1 percent of PBMC constitutively produce IL-10. These CD14-
CD36+CD61 + non-adherent cells expressed general markers of hematopoietic and 
progenitor cells (CD45 and CD7) but no stem cell, T cell, B cell , NK cell, monocyte, or 
dendritic cell specific markers. Inflammation-associated toll-like receptors were also 
absent. The IL-l 0 producing cells had prominent nuclei, multiple mitochondria, and 
abundant rough endoplasmic reticulum. Healthy individuals have PBMC constitutively 
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producing IL-l 0. While the lineage of these cells remains unclear, their properties and 
frequency suggest a potential role in homeostatic or innate immune suppression. 
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3.2. Introduction 
Activation of innate and adaptive immunity is essential for combating the 
constant challenge of invasive viral, bacterial, parasitic and fungal pathogens. 
Conversely, preventing inappropriate activation of tmmune responses and 
downregulating appropriate immune responses, once pathogens are cleared or other 
antigenic stimuli dissipate, is equally essential for avoiding immunopathology. Pathogen 
clearance by multiple arms of the immune system passively downregulates immune 
responses by decreasing antigenic stimuli, but when antigen persists, unresolved immune 
responses may be more damaging than the infection itself. In such situations, or when 
immune responses arise and propagate in the absence of infection, active 
immunoregulation by cytokines, regulatory cells or phannacological intervention may be 
appropriate to prevent or limit pathology. 
The immunoregulatory cytokine interleukin-1 0 (IL-l 0) plays an essential role in 
down-modulating both adaptive and im1ate immune responses (307). A variety of 
hematopoietic cells including monocytes, mast cells, T helper 2 (Th2) type T cells, 
regulatory T cells (Tr), dendritic cells (DC) and B cells produce IL-l 0, usually in 
response to particular stimuli (308). Interleukin-1 0 indirectly inhibits Th 1 responses by 
blocking IL-12 production and major histocompatibility complex (MHC) class II 
upregulation by antigen presenting cells (APC) (309-311 ). lnterleukin-1 0 also suppresses 
inflammation by inhibiting production of IL-l , tumor necrosis factor (TNF) and a variety 
of chemokines by APC, T cells and neutrophils (309, 312, 313). The physiological 
relevance of the immunoregulatory effect of IL-l 0 has been clearly demonstrated in 
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animal models of disease. Too little IL-l 0 renders mice more susceptible to chronic 
enterocolitis (314), but more resistant to intracellular pathogens such as Listeria and 
Chlamydia (315, 316), while IL-l 0 overexpression reduces intravascular inflammation 
and delays development of atherosclerosis in low density lipoprotein (LDL)-receptor 
deficient mice (317). In human studies, lower levels of TL-1 0 production are similarly 
associated with diseases thought to have an inflammatory component, such as 
atherosclerosis and diabetes (318, 319). Administration of exogenous IL-l 0 reduces 
symptoms in colitis and inflammatory bowel disease (IBD) and can moderate disease 
severity (320, 321 ). However, elevated IL-1 0 levels are associated with chronic bacterial 
' 
infection (322-324), decreased dendritic cell maturation (325-328), and less effective 
immune surveillance against tumors (329). Thus, the broad range of IL-l 0-mediated 
immunoregulation constitutes a double edged sword with the beneficial effect of limiting 
immunopathology counterbalanced by increased susceptibility to infectious disease and 
cancer. While the regulatory role of IL-l 0 in various pathological states has been well 
described, there has been little investigation of IL-l 0 as a potential homeostatic regulator 
of the immune response. In this light, we report on the frequency, phenotype and 
ultrastructure of PBMC that constitutively produce and secrete IL-l 0 in healthy 
individuals. Constitutive production of IL-l 0 by a relatively large number of circulating 
cells in healthy individuals suggests that these cells could play a role in homeostatic 
immune regulation. 
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3.3. Materials and Methods 
3.3.1. Subjects 
Acid citrate dextrose (ACD)-preserved whole blood was collected by 
venipuncture from 12 apparently healthy volunteers (6 male, 6 female; ages 26 to 55 
years) recruited from Memorial University Faculty of Medicine personnel. Informed 
consent was obtained from individuals for drawing blood, and ethical approval was 
obtained from the Memorial University Faculty of Medicine human investigation 
committee. PBMC were isolated by Ficoll-HyPaque Plus (Amersham Biosciences, Baie 
d'Urfe, Quebec, Canada) density gradient centrifugation. Cells were washed and 
suspended at 1x106/mL in lymphocyte medium (RPMI supplemented with 10% fetal calf 
serum (FCS), 10 mM HEPES, 2 mM L-glutamine, 1% penicillin/streptomycin, and 20 
f.lM 2-mercaptoethanol; all from Invitrogen, Burlington, Ont). 
3.3.2. Flow cytometry 
Surface staining. The phenotype of fresh PBMC subpopulations were determined by 
extracellular flow cytometry using antibodies against human myeloid and lymphoid 
lineage-specific surface markers, as listed in Table 3.1. All steps were perfonned at 4°C, 
and incubations were performed in the dark to prevent fluorochrome photobleaching. 
Freshly isolated PBMC (5x 1 05) were washed with cold PBS supplemented with 0.1% 
bovine -serum albumin (BSA; Sigma Chemical Co., St. Louis, Missouri, USA), 5 mM 
EDTA (Sigma) and 0.02% sodium azide (Sigma), resuspended in a total volume of 600 
f.lL and incubated for 20 minutes with 0.5 f.lg specific antibody again t urface antigens or 
0.5 pg of appropriate isotype controls (Table 3.1 ). When the pri-mary antibodies were 
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unlabelled, fluorochrome labelled secondary antibodies were added for 20 minutes and 
cells were washed before fixation. Cells were fixed with 0.5 mL 1% paraformaldehyde 
(Sigma) in PBS for 20 minutes, · washed again, and resuspended in 250 )lL of 1% 
paraformaldehyde. Fixed, stained cells were stored at 4°C until analysis of at least 
100,000 events on a F ACScan flow cytometer (Becton Dickinson, San Jose, CA). 
Intracellular staining . Cells were labelled as above for detection of surface antigens with 
an additional permeabilization step after fixation . Cells were incubated with 0.5 mL 
DAKOCytomation (Mississauga, Ontario) permeabilization reagent together with 
antibodies against either various cytokines or appropriate isotype control antibodies 
(Table 3.1) for 20 minutes. After washing, cells were resuspended in 1% 
paraformaldehyde in PBS until analysis as above. CellQuest Pro was used for data 
analysis. 
3.3.3. Detection ofJL-10 mR.NA 
The presence of IL-l 0 mRNA in freshly isolated PBMC subsets was demonstrated by 
reverse transcriptase polymerase chain reaction (RT-PCR). Aliquots of 1x107 PBMC 
were washed with separation buffer (PBS supplemented with 5 mM EDTA and 0.5% 
BSA) and incubated for 30 min at 4°C with 0.5 )lg of isotype control, anti-CD14 or anti-
CD36 antibodies (Table 3.1 ). The cells were washed again and incubated at 3x 106/ml for · 
45 min at 4°C in separation buffer with sufficient goat anti-mouse IgG or rat-anti-mouse 
lgM conjugated magnetic beads (Dynal ASA, Oslo, Norway) for a 10:1 bead-to-target 
cell ratio. A magnet was used to separate bead-bound and unbound cells and flow 
cytometry indicated depletion of >90% of the targeted subset. Total RNA from bead-
------------------- --------------
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bound and unbound cells was extracted with Trizol reagent (Invitrogen) according to the 
manufacturer's instructions. Complementary DNA (eDNA) was synthesized using the 
Amersham eDNA synthesis kit (Amersham Biosciences, Baie d' Urfe, Quebec). Specific 
primers for PCR were previously described; antisense and sense IL-1 0 ptimer sequences 
were 5'-ACCTGCTCCACGGCCTTGCTCT-3' and 5'-
CACCCAGTCTGAACAGCTGC-3', respectively (330). Anti-sense and sense primers 
for the P-actin housekeeping gene were 5' -CAACCGTGAGAAGA TGACC-3' and .5'-
ATCTCCTGCTCGAAGTCC-3' respectively. PCR conditions for each 50 JlL reaction 
were: 1 X PCR buffer, 2.5 mM MgCh, 200 ~LM dNTPs, 2.5 U Taq DNA polymerase, and 
20 pmol each of the sense and antisense p1imer (all from Invitrogen). Reactions ran for 
35 cycles for IL-l 0 and 30 cycles for P-actin with the following cycle times and 
temperatures: 40 seconds at 95°C, 30 seconds at 60°C (IL-l 0) or 55°C (p-actin), 1 
minute at 72°C, with a final extension of 7 minutes at 72°C. The expected product sizes 
were approximately 360 and 339 base pairs (bp) for IL-l 0 and P-actin respectively. 
Products were separated by electrophoresis on 2% agarose gels with 0.5 Jlg/mL ethidium 
bromide (Sigma Chemical Co.) and visualized by ultraviolet light. Gels were analysed 
using a CCD camera and Chemilmager (Aiphalnnotech, San Leandro, CA) software. 
3.3.4. Depletion ofCD61+ PBMC 
Ten million fresh PBMC were incubated for 20 minutes with 5 Jlg purified anti-
CD61 antibody (Table 3.1) in 0.5 mL flow cytometry buffer at 4°C. Cells were washed, 
and suspended in separation buffer with a I 0: I bead-to-target cell ratio of goat anti-
61 
mouse lgG coated magnetic beads (Dynal) for 45 minutes at 4°C. A magnet was used to 
remove bead-bound CD61 + cells from the remaining PBMC. Depletion efficiency (98%) 
was determined by flow cytometric CD61 staining of the remaining PBMC. 
3.3.5. Depletion of adherent cells 
In some experiments, PBMC were depleted of adherent monocytes cells by plastic 
adherence. Freshly-isolated PBMC at 1 x 106/well were incubated in 24 well tissue culture 
treated flat bottom plates (Coming Costar, Coming NY) at 37°C, 5% C02 for 60 minutes. 
Non-adherent cells were removed by gently resuspending settled PBMC in 1 mL of 
medium. Efficiency of monocyte removal (97%) was determined by flow cytometry. 
3.3.6. ELJSPOTfor IL-10 production 
The number of IL-l 0 producing cells within intact or CD61-depleted PBMC was 
detem1ined by ELISPOT. Flat bottom polyvinylidene difluoride (PVDF)-coated 96-well 
plates (Millipore, Bedford, MA) were prewet with 100 flL 70% ethanol/well (Sigma 
Chemical Co.), washed with PBS, and coated either overnight at 4°C or for one hour at 
37°C with 1.5 Jlg/well anti-IL-10 antibody (clone 9D7, Mabtech, Stockholm, Sweden) in 
PBS. Plates were washed five times with PBS and 2x 105 intact PBMC or approximately 
1.9x I 05 CD6 1-depleted PBMC were added to each well in triplicate. Plates were 
incubated at 37°C, 5% C02 for 18 hours, washed with PBS, and incubated for 2 hour 
with 0.1 ~Lg/well ofbiotinylated anti-IL-10 antibody (clone 12G8, Mabtech). Plates were 
washed, and I 00 flL of a 1:1000 dilution of streptavidin-alkaline phosphatase (Mabtech) 
was added for I hour. After washing, 100 flL fresh ly prepared nitro blue tetrazolium 
chl01ide (NBT) 3 mg/mL /5-bromo-4-chloro-3-indolyl phosphate-p-toluidine (BCIP) 1.5 
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mg/mL substrate (BioRad, Hercules, CA) in Tris buffer (pH 9.5) was added to each well 
for approximately 20 minutes. Plates were washed with distilled water to stop the color 
reaction and air-dried overnight before spot enumeration using the high resolution Zeiss 
reader system and associated KS software (Carl Zeiss Canada Ontario, Canada). The 
number of IL-10 producing cells per million PBMC was determined by multiplying the 
average number of spots/duplicate well x 5. 
3.3. 7. Electron microscopy 
The IL-l 0 producing PBMC population was enriched for visualization by electron 
microscopy through depletion ofT cells, B cells, monocytes, and NK cells. 1.25x 108 
PBMC were obtained from a healthy donor, divided into l.Ox 107 aliquots and incubated 
with the following antibodies for 25 minutes at 4°C: 7 J-lg anti-CD2; 6 J-lg anti-CD3 ; 6 J-lg 
anti-CD14; and 7 J-lg anti-CD19 (Table 3.1 ). Cells were washed and goat anti-mouse lgG 
coated magnetic beads (Dynal) added at a bead to PBMC ratio of 1 0: I for 45 minutes at 
4°C. Bead-bound cells were magnetically removed, and red cells lysed from the 
remaining unlabelled PBMC by 3 minute room incubation at room temperature with 0.5 
mL erythrocyte lysis buffer (0.15 M ammonium chloride, 10 mM potassium bicarbonate, 
and 0.1 mM ethylenediaminetetraacetic acid (EDTA) in distilled water), followed by 2 
PBS washes. The remaining cells (- 3.5xl 06/aliquot) were incubated with 3.5 J-lg lgM 
anti-CD36 mAb (Table 3.1) for 25 minutes at 4°C, washed in flow buffer, and labelled 
with 12 nm gold particle conjugated goat anti-mouse IgM beads (Jackson Immunotech 
Laboratories, West Grove, PA) for 40 minutes at 4°C. Cells were washed twice, and 
fixed m I mL of Kamovsky's fixative (4 g paraformaldehyde, 5% glutaraldehyde in 
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0.2M sodium cacodylate). After 6 hours, cells were placed in 1% osmium tetraoxide for 
20 minutes and washed. Cells were dehydrated with increasing alcohol concentrations 
from 75%-100% followed by an acetone wash and embedded in epoxide resin ovemight 
at 70°C. 90 nm sections were cut, stained with uranite acetate, and examined with a Jeol 
1220X electron microscope. 
3.3.8. Statistical analyses 
All statistical analyses were performed usmg SPSS versiOn 9 (SPSS Inc., 
Chicago, IL). Means were compared using either the non-parametric Mann-Whitney U 
test or the parametric Student' s t-test. Nonparametric tests were used when either the 
populations were not normal or the number of samples each group was less than 12. 
Parametric tests were used if the population was normal and the group contained more 
than 12 individuals. 
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3.4. Results 
3.4.1. A PBMC subset in healthy individuals constitutively produces and secretes IL-10 
To investigate background levels of pro- and anti-inflammatory cytokine 
production by circulating PBMC, we used intracellular flow cytometry to evaluate 
constitutive IL-2, IL-l 0, IL-12, and IFN-y production by freshly isolated PBMC from 
healthy individuals. None of the pro-immune or pro-inflammatory cytokines IL-2, IL-12, 
or IFN-y were constitutively produced by freshly isolated PBMC from any individual, but 
CD3-negative PBMC with lymphoid light scatter characteristics constitutively producing 
IL-10 were detected ex vivo in every individual tested (Figure 3.la). A significant 
fraction of CD36+ PBMC with lymphoid light scatter characteristics (moderate forward 
scatter and low side scatter) expressed varying levels of IL-1 0, whi le a much smaller 
fraction of CD36+ monocytoid cells (CD 14+, high forward and side scatter) produced low 
levels of IL-10 (Figure 3.lb). Intracellular flow cytometry indicated approximately 1% 
(range 0.37%-1.14%) ofPBMC from healthy individuals (n= 12) constitutively producing 
IL-l 0 (Figure 3.2). Following PBMC isolation, IL-l 0 production decreased such that 
after 18 hours of cell culture, intracellular IL-l 0 was detectable in <0.1% of total PBMC 
(data not shown). 
We used an IL-l 0 ELlS POT assay to confim1 constitutive IL-l 0 production and 
to demonstrate IL-l 0 secretion by freshly isolated PBMC. For the 6 individuals tested, 
318-1171 cells/1 06 PBMC secreted IL- l 0 detectable by ELI SPOT (Figure 3.2). 
Negligible numbers of spots developed in the control wel ls. While the ELISPOT data 
confirms spontaneous production of IL- l 0 by PBMC from healthy individuals, the 
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frequency of IL-l 0 producing cells detected is around one-tenth of that observed by 
intracellular flow cytometry, reflecting either greater sensitivity of flow cytometry or 
fairly rapid cessation of IL-l 0 secretion in vitro. There was a weak but significant 
correlation between the frequency of IL-l 0 producing PBMC detected by intracellular 
flow cytometry and ELISPOT (r = 0.88, p<0.05). Constitutive production of IL-l 0 
protein was also reflected by detection of IL- I 0 mRNA in freshly isolated PBMC subsets 
by RT-PCR (Figure 3.3). The C014+ monocyte population and moreso, the CD36+ 
monocyte and lymphoid cell population accounted for IL-l 0 mRNA in freshly-isolated 
PBMC. 
3.4. 2. Detailed phenotype of PBMC constitutively producing IL-l 0 
Initial flow cytometry studies identified the majority of IL-l 0 producing PBMC 
as non-T cells with lymphoid light scatter characteristics. We used the panel of 
antibodies listed in Table 3.1 to more extensively phenotype the e IL-l 0 producing 
PBMC. None of the early precursor and stem cell markers (C034, CD 117), lymphoid 
lineage-specific markers (C02, CD3 and CD 19) or the myeloid lineage marker CD33 
were present on the IL-l 0 producing cells (Figure 3.4). The general leukocyte marker 
CD45 was present, together with the non-lineage-specific adhesion molecules C054 and 
CD62L. In the absence of other T cell subset makers such as CD4 or CD8, the 
thymocyte and T cell subset antigen CD? was expressed on the IL-l 0 producing cells. 
None ofhuman leukocyte antigen (HLA) class II, COlle, CD40, CD68, CD80, C083 or 
CD86 (molecules found primarily on professional APCs) were present on the IL- l 0 
producing cells. Of several activation markers examined (CD25, CD38 and CD69), only 
,--------------------------- --- -------
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CD38, an activation marker increased on T cells and APC after antigen specific 
stimulation, was found on the IL-1 0 producing cells. These data indicate that the 
lymphoid PBMC constitutively producing IL-l 0 do not belong to any commonly 
recognized NK cell, B lymphocyte, T lymphocyte, or dendritic cell subset and they are 
not professional APC. 
Two cell surface markers best defined the constitutive IL-1 0 producing cells and 
clearly distinguished them from other PBMC with lymphoid scatter characteristics. All 
the IL-l 0 producing cells expressed CD36 (Figure 3.5a) and low levels of CD61 (Figure 
3.5b). Cells with high level CD36 expression (mean channel fluorescence ~ 102) were 
unifonnly positive for intracellular IL-l 0 and 50%-80% of the CD36+CD61 + cells 
expressed IL-l 0 (Figure 3 .5b ). To demonstrate constitutive IL-l 0 production by 
circulating CD36+CD61 + cells, CD61+ cells were magnetically depleted from freshly 
isolated PBMC. This removed greater than 98% of the CD36+IL-1 0+ population in fresh 
PBMC (Figure 3.6a) as measured by flow cytometry. When PBMC depleted of CD61 + 
cells were incubated for 18 hours in an IL-l 0 ELISPOT assay, significantly fewer spots 
were formed (318 IL-l 0 producing spots/1 06 cells) than with intact PBMC (733 spots/1 06 
PBMC) (Figure 3.6b; t = 2.67, p < 0.03). This degree of reduction in the ELISPOT assay 
relative to the 98% reduction in the immediate ex vivo flow cytometry assay indicates 
partial, but incomplete overlap between the PBMC producing IL-1 0 ex vivo as detectable 
by flow cytometry and the PBMC producing IL-10 in vitro as detected by ovemight 
ELISPOT assay. 
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3.4.3. Relationship between phenotype and.function of IL-l 0 producing PBMC 
Since monocytes are the major PBMC population previously reported to express 
the CD36 and CD61 molecules distinguishing our IL-10 producing PBMC, we examined 
phenotypic and physical characteristics of the CD36+ IL-l 0 producing lymphoid cells 
that might further differentiate them from monocytes. Monocytes and lymphocytes have 
very different forward (size) and side (granularity) light scatter characteristics when 
analyzed by flow cytometry. Most of the PBMC constitutively producing IL-l 0 have 
light scatter characteristics similar to lymphocytes (Figure 3.1 b), indicating they are 
smaller and less granular than monocytes. They also do not express the monocyte marker 
CD14 (Figure 3.7). Non-adherence to plastic further distinguishes the CD14-
+ + . I.e: . + + + CD36 CD61 IL-10 producmg eels trom CD14 CD36 CD61 monocytes, as there was 
no depletion of IL-l 0 producing cells following 2 hour PBMC incubation on plastic 
dishes (data not shown). 
As previously shown, CD36 is present on the IL-l 0 producing cells and high 
CD36 expression appears to be associated with IL-l 0 production. CD36 is a scavenger 
receptor for apoptotic bodies and may play an evolutionary role in the innate immune 
response. Absence of CD14, the lipopolysaccharide (LPS) receptor that stimulates a 
monocyte pro-inflan1matory response, phenotypically distinguishes the IL-l 0 producing 
cells from CD36+ monocytes. Since CD 14 is functionally related to the family of toll-
like receptors (TLR) that recognize pathogen-associate molecular patterns, we 
investigated expression of several common TLRs on the CD36+ IL-l 0 producing 
lymphoid cells. In contrast to the CD 14+CD36+CD61 + monocytes, 
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CD14-CD36+CD61 +IL10+ cells did not express TLR-2, TLR-4 or TLR-9 (Figure 3.7). 
The absence of these primarily pro-inflammatory receptors on the surface of the IL-l 0 
producing cells is consistent with their production of the anti-inflammatory cytokine IL-
l 0 and with a potential immunoregulatory role for these cells. 
3. 4. 4. Ultrastructural characteristics of the IL- I 0 producing cells 
To examine the ultrastructure of the IL-l 0 producing cells, we eruiched for this 
population by depleting PBMC of T cells, B cells, monocytes and NK cells with 
magnetic beads and antibodies against CD2, CD3, CD14 and CD19. Remaining cells 
were incubated with gold bead-conjugated anti-CD36 antibodies and the CD36+ cells 
were visualized by electron microscopy. The CD36+ cells were approximately 6 f..Lm in 
diameter, similar to resting lymphocytes, with a high nucleus:cytoplasm ratio and large 
amount of heterochromatin (Figure 3.8). Mitochondria were plentiful and rough 
endoplasmic reticulum was very prominent in the cytoplasm, suggesting these were 
highly synthetic, metabolically active cells. 
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3.5. Discussion 
Induction of inflammatory and immune responses must be carefully regulated to 
allow for effective protective immunity while avoiding unnecessary inflammation and 
immunopathology. Stimuli must individually and collectively breach a certain threshold 
to initiate or sustain inflammation and immunity. Whether an appropriate threshold for 
immune activation is maintained simply through the requirement for accumulation of 
positive signals or whether low level basal immune suppression may be involved is an 
important issue in relation to susceptibility to chronic infection or chronic inflammation. 
Consistent with the general view that immune responses do not arise in the absence of 
stimuli, we found little or no constitutive production of pro-inflammatory cytokines IL-2, 
IL-12 or IFN-y by PBMC from healthy individuals. However, up to 1% of freshly 
isolated PBMC constitutively produced and secreted IL-l 0, an important negative 
regulator of inflammatory and cellular immune responses. Phenotypic and ultrastructural 
characterization of the cells spontaneously producing IL-l 0 indicated a previously 
undescribed PBMC subset resisting inclusion in any common recognized lineage 
Constitutive production of IL- l 0 by freshly isolated, non-stimulated PBMC was 
readily apparent by ex vivo intracellular flow cytometry or by ELISPOT, following 
overnight incubation in unsupplemented lymphocyte medium. Surprisingly, despite the 
widespread application of sensitive ELISPOT assays, only one group has previously 
reported constitutive IL-l 0 production by PBMC, and in this case only at the mRNA 
level (331). Counterstaining the IL-1 0+ PBMC by flow cytometry demonstrated. 
consistent expression of the common leukocyte antigen, CD45, suggesting hematopoietic 
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ongm. While Th2 cells are a common source of IL-l 0 in response to specific antigens, 
none of the IL-10+ cells expressed CD2, CD3, CD4, CD8 or CD19, ruling out their 
assignment within NK, Tor B cell subsets. Immature DC and monocytes also produce 
IL-l 0, but the characteristics of the lymphoid IL-l 0+ cells were inconsistent with either of 
these PBMC subsets. Unlike immature DC, the IL-l 0+ cells expressed no HLA-DR or 
CDl a, a MHC-related protein expressed on antigen presenting cells that presents self 
proteins to T cells. In contrast to monocytes, the IL-l 0+ cells had lymphoid cell light 
scatter characteristics and didn ' t express CD14, CD33 , CD68 or myeloperoxidase. The 
IL-1 0+ cells are easily distinguished from virtually all other PBMC by their lymphoid 
light scatter (smaller and less complex than monocytes) and expression of CD36 in the 
absence of CD14. Expression of other surface markers such as CDS, CD7, CD38, CD54, 
CD59 and CD61 is interesting and useful for depletion or isolation, but offers little 
obvious insight into the origin or ro le of these cells. The constitutive IL-l 0 production is 
consistent with a role for these cells in low level basal immunosuppression and 
expression of CD62L indicates an ability exit the blood stream through high endothelial 
venules and modulate immune responsiveness within the lymph nodes, where primary 
immune responses generally originate. 
As noted in the results section, a small proportion of circulating monocytoid cells 
were also IL-1 0+ positive. These cells were very easily differentiated from the 
CD36+CD14~ population of lymphoid cells, and removal of CD14+ monocytes through 
plastic adherence or magnetic beads did not deplete IL-l 0 protein or mRNA beat;ng cells 
respectively. Absence of CDI4, a primarily pro-inflammatory molecule related to the 
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Toll-like receptors (TLR), phenotypically distinguishes the CD36+IL-1 0+ cells from 
monocytes and also supports their characterization as potentially immunosuppressive, 
rather than pro-inflammatory cells. While signalling through CD 14 also can result in late 
production of IL-l 0, the phenotypic polarization of these CD36+IL-l 0+ cells away from 
immune activation is further reflected by the absence of TLR 2, 4 and 9, additional pro-
inflammatory receptors that are consistently expressed on CD36+ monocytes and are 
generally associated with immune activation. In the CD14-CD36+ PBMC subset, we 
observed a general relationship between IL-1 0 production and CD36 expression in that 
all CD36bright cells were producing IL-1 0 and that the CD36bright cells produced more IL-
l 0 than CD36dim cells. This relationship raises the possibility of a mechanistic link 
between CD36 expression and the function of these cells. One function of CD36 is in the 
uptake of apoptotic bodies by macrophages and dendritic cells (332, 333) and subsequent 
modulation of immune responses (334). The relationship between high CD36 expression 
and high IL-l 0 production could preferentially deliver apoptotic bodies to IL-l 0 
producing cells, favouring immune suppression over inflammation. Delivery of early 
apoptotic cells to a macrophage subset producing IL-1 0 was recently demonstrated and 
proposed as a mechanism to prevent autoimmunity under steady-state conditions (335). 
Another CD36 ligand is oxidized LDL (oxLDL), a factor associated with the 
pathogenesis of atherosclerosis (336, 337). Selective delivery of oxLDL to IL-10 
producing cells through this interaction with CD36 could play a protective role against 
the putative inflammatory component of atherosclerosis. The malaria- causing parasite, 
Plasmodium falciparum, also interacts with CD36 and through this interaction could 
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exploit localized immunosuppression to evade immunity and establish chronic infection 
(334). 
While circulating monocytes express relatively low levels of CD36, few were 
constitutively producing IL-l 0, therefore, cell-specific factors other than just expression 
of CD36 are involved in constitutive IL-l 0 production. Monocytes exposed in vitro to 
thiazolidinediones, peroxisomal proliferator associated receptor-y (PPAR-y) agonists 
commonly used to treat type II diabetes associated insulin resistance, express higher 
levels of CD36 and develop an anti-inflammatory cytokine release profile (338). A rat 
model of type II diabetes and hypertension has a dominant CD36 mutation that precludes 
expression of CD36 at the transcriptional level (339), supporting a immunomodulatory 
role for CD36 in inflammatory diseases such as diabetes. In humans, the null mutation of 
a human blood group polymorphism, Naka ~esults in loss ofCD36 expression (340). This 
phenotype is prevalent in African and Japanese populations, and it would be interesting to 
compare circulating IL-l 0+ PBMC and the rates of various inflammatory diseases 
between Naka null (with impaired CD36 expression) and appropriate control groups. 
Local delivery or production of IL-l 0 may be the mechanism by which CD36 
engagement, in some cases, dampens inflammatory responses (334, 341). We speculate 
that the IL-l O+CD36+ cells provide a low level innate barrier to immune responses and 
inflammation, suggesting that lower circulating levels of these cells could predispose to 
development of autoimmune or pro-inflammatory diseases. Homeostatic regulation of 
the immune system similar to what we are suggesting by these IL-l 0+ cells is mimicked 
in the interaction between lung alveolar epithelial cells (AEC) and alveolar macrophages 
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(AM) (342). Transforming growth factor beta (TGF-~ produced by AEC maintains a 
homeostatic suppressive environment in normal lung by inhibiting AM. However, AM 
are still able to respond to and clear microbial pathogens when necessary by using protein 
conformational change to disengage from the AEC inhibition. AM inhibition is restored 
as the pathogen is cleared, resulting in minimal damage to nearby lung tissue. We 
suggest that constitutive production of IL-l 0 by the cells described in this study provides 
a similar tonic checkpoint on the immune system to downregulate unnecessary responses 
in the steady state. 
The concept of immune regulatory cells has evolved through various incarnations 
of suppressor T cells to the relatively well-defined CD4+CD25+FoxP3+ regulatory T cells 
of today. These cells develop spontaneously and in some cases mediate their effector 
functions through non-specific cytokines such as IL-l 0 and TGF-~. However, they are 
activated through antigen-specific receptors and, therefore, constitute an adaptive 
immunosuppressive response that can approptiately protect against autoimmunity and 
inappropriately increase susceptibility to infection and cancer. The existence of 
circulating antigen-non-specific cells spontaneously producing the immunosuppressive 
cytokine IL-1 0 suggests that like immune reactivity, immune suppression may be 
organized in innate and adaptive layers with a similar seties of interconnections still to be 
elucidated. 
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Table 3.1. Antibodies for fresh PBMC phenotyping 
Anti en Fluorochrome I so e Clone Com an 
CDla FITC mlgG 1 NA1 /34 DakoCytomation 
CD2 Purified mlgG2b RPA-2.10 BD Pharmingen 
CD3 Purified, FITC mlgG 1 UCHT1 DakoCytomation 
CD4 FITC mlgG 1 RPA-T4 BD Pharmingen 
CDS APC mlgG, VI-PL2 BD Pharmingen 
CD7 FITC migG1 M-T701 BD Pham1ingen 
CD8 PerCP mlgG 1 HIT3a BD Pharmingen 
CDIO PE mlgG 1 HllOa BD Pharmingen 
CD11b PE mlgG 1 ICRF44 BD Pharmingen 
CD11c PE mlgG 1 B-ly6 BD Pharmingen 
CD13 PE mlgG 1 WM15 BD Pharmingen 
CD14 Purified, FITC mlgG2a M5E2 BD Phanningen 
CD19 Purified mlgG 1 HIB19 BD Phanningen 
CD20 FITC mlgG2b 2H7 BD Pharmingen 
CD25 PE mlgG 1 M-A251 BD Pham1ingen 
CD33 PE mlgG 1 WM53 BD Pham1ingen 
CD34 FITC migG 1 581 BD Pham1ingen 
CD36 Purified, PE mlgM CB38 BD Phanningen 
CD38 APC mlgG 1 HIT2 BD Pharmingen 
CD40 Purified mlgG 1 E5-A Calbiochem 
CD45 APC mlgG, HI30 BD Pham1ingen 
CD 54 Purified mlgG 1 HA58 BD Pharmingen 
CD 56 FITC mlgG 1 8159 BD Pha1mingen 
CD 57 FITC migM NK-1 BD Pham1ingen 
CD 59 FITC mlgG2a p282 BD Pharmingen 
CD61 Purified, PerCP mlgG 1 VI-PL2 BD Phanningen 
CD64 FITC mlgG 1 10.1 Cal tag 
CD62L FITC mlgG 1 DREG 56 BD Phanningen 
CD66abce FITC mlgG, Kat4C DakoCytomation 
CD68 FITC mlgG 1 KPI DakoCytomation 
CD69 FITC mlgG 1 FN50 BD Pharmingen 
CD7 1 FITC mlgGI YDJ1.2 .2 Immunotech 
CD80 Purified mlgG 1 DAL-1 Cal tag 
CD83 FITC mlgG 1 PNIM2410 Immunotech 
CD86 Purified mlgG 1 BU63 Cal tag 
CD 117 PE mlgG 1 YB5.B8 BD Pharmingen 
TLR-2 FITC mlgG2a TLR.l eBioscience 
TLR-4 PE mlgG2a HTA 125 eBio cience 
TLR-9 Purified mlgG, 26C593 Bio/Can Scientific 
HLA Class I Supematant mlgG 1 PA2.6 ATCC 
HLA Class II Supematant mlgG 1 L243 ATCC 
Table 3.1. (con't) 
A . I ntlgen Fluorochrome Clone Company 
Myeloperoxidase PE lBIO BD Pharmingen 
Isotype Controls 
Mouse IgG1 FITC BD Phanningen 
Mouse lgM PE BD Pharmingen 
Mouse IgG2 FITC BD Pham1ingen 
Rat IgG2 FITC Caltag 
Secondary 
Antibodies 
Goat anti-mouse FITC, PE Jackson 
lgG ImmunoResearch 
Goat anti-mouse FITC Jackson 
IgM ImmunoResearch 
Goat anti-mouse FITC Sigma 
IgA 
Cytokines 
Interferon-gamma FITC mlgG 1 B27 Caltag 
(IFN-y) 
Interleukin-2 (IL- FITC rlgG2a MQ1-17Hl2 Cal tag 
2) 
Interleukin-1 0 FITC rigG 1 JES9D7 Caltag 
(IL-l 0) 
Interleukin-12 FITC rlgG 1 C8.6 Cal tag 
(IL-12) 
1 Antibodies are against human antigens unless otherwise indicated. 
2FITC-fluorescein isothiocyanate; PE-phycoerythrin; PerCP - peridinin chlorophyll 
protein; APC - allophycocyanin 
3m-mouse; r-rat; g-goat 
4Becton Dickinson Biosciences Pharmingen, San Diego, California; Bio/Can Scientific, 
Montreal, Quebec; Caltag, Burlingame, CA; DakoCytomation, Mississauga, Ontario; 
eBioscience, San Diego, CA; Immunotech, Mississauga, Ontario; Jackson 
ImmunoResearch, West Grove, Pennsylvania; Sigma, St. Louis, Missouri , USA 
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Figure 3.1. Ex vivo cytokine production by CD3- PBMC from a healthy individual. 
(a) Constitutive production oflL-2, IFN-y, IL-12 and IL-l 0 by CD3+ and CD3-
PBMC with lymphoid scatter characteristics was assessed by intracellular flow 
cytometry. Results are representative of 12 individuals. 
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Figure 3.1. (con't) (b) Production of IL-10 by lymphoid and monocytoid cells was 
distinguished by side scatter. Isotype controls are shown in the lower panels. 
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Figure 3.2. Comparison of IL-10+ cell frequency in PBMC determined by flow 
cytometry or ELISPOT in 6 representative individuals. The picture depicts test wells 
with PBMC from a representative individual with control wells underneath. 
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Figure 3.3. Relative levels of IL-10 mRNA in PBMC subsets. An equal amount of 
RNA isolated from PBMC (lane 1), CD14+ PBMC (lane 2), CD36+ PBMC (lane 3), 
PBMC depleted of CD14+ cells (lane 4) and PBMC depleted of CD36+ cells (lane 5) was 
converted to eDNA, subjected to IL-l 0 and P-actin specific PCR and separated on an 
a~arose gel. The relative intensity of th IL-l 0 band com par d to the P-actin band is 
shown in the bar graph below the gel. 
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Figure 3.4. Flow cytometric evaluation of relevant protein expression by PBMC 
constitutively producing IL-10. CD markers shown in enlarged text were expressed on 
the surface of IL-l 0+ cells. Myeloperoxidase (MPO) was absent. 
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Figure 3.5. Relationship between IL-19 production, CD36 expression and CD61 
expression on PBMC. (a) Cells within the lymphoid scatter region were analyzed for 
extracellular CD36 and intracellular IL- l 0. The lower right panel shows isotype controls. 
(b) Cells with lymphoid scatter expressing IL-1 0 were analyzed for CD36 and CD6.1 
expression. The lower right panel· shows isotype controls. 
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Figure 3.6. Comparison of IL-10 producing cells in PBMC before and after 
depletion of CD61+ cells. (a) Cells within the lymphoid scatter region were analyzed 
for extracellular CD36 and intracellular IL-l 0 with and without depletion of CD61 + cells. 
(b) The number of JL-1 0 secreting cells per 106 PBMC (n=6) was enumerated by 
ELI SPOT before and after depletion of CD61 + cells. 
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Figure 3.7. Comparison of expression of TLR 2, 4, 9 and CD14 on CD36+ 
monocytes and CD36+ cells with lymphoid scatter characteristics. Results shown are 
representative of those obtained with 12 individuals. 
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Figure 3.8. Electron micrograph of CD36+CD14- cells. Freshly isolated PBMC were 
depleted of T cells, B cells, NK cells and monocytes, labelled with anti-CD36 followed 
by 12 nm gold particle conjugated goat anti-mouse lgM beads and then visualized by 
electron microscopy. Arrows on the right panels indicate gold beads associated with 
CD36. 
--------· -- -----------------
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ENHANCED IL-10 PRODUCTION IN RESPONSE TO HEPATITIS C VIRUS 
PROTEINS BY PERIPHERAL BLOOD MONONUCLEAR CELLS FROM 
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4.1. Abstract 
Multiple immune evasion strategies by which HCV establishes chronic infection 
have been proposed, including manipulation of cytokine responses. Prior infection with 
HIV increases the likelihood of chronic HCV infection and accelerates development of 
HCV-related morbidity. Therefore, we investigated in vitro cytokine responses to HCV 
structural and non-structural proteins in peripheral blood mononuclear cells (PBMC) 
from uninfected, HIV-infected, HCV-infected and HIV/HCV-coinfected individuals. 
Intracellular flow cytometry was used to assess IL-2, IL-l 0, IL-12, and IFN-y production 
by freshly isolated PBMC incubated for 16 hours with recombinant HCV core, non-
structural protein 3 (NS3), and NS4 proteins. Anti-HCV cellular responses were assessed 
in HIV/HCV-coinfected individuals by 3H-thymidine proliferation assay. Exposure to 
HCV antigens increased IL-10 production by PBMC, especially in uninfected and HIV-
monoinfected individuals. This IL-l 0 response was attenuated in chronic HCV infection 
even with HCV/HIV-coinfection. The cells producing IL-10 in response to HCV 
proteins in vitro matched a PBMC subset recently shown to constitutively produce IL-l 0 
in vivo. This subset was found at simi lar frequencies in uninfected, HIV-infected, HCV-
infected and HIV/HCV-coinfected individuals before exposure to HCV proteins. HCV-
specific T cell proliferation was detectable in only one HIV /HCV -co infected individual 
who demonstrated no H CV -induced IL-l 0 resp011se. This pattern suggests that selective 
induction of IL- l 0 in uninfected individuals and especially in HIV -monoinfected 
individuals plays a role in establishing chronic HCV infection and conversely, that 
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attenuation of this response, once chronic infection is established, favours development 
of hepatic immunopathology. 
-------------
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4.2. Introduction 
Most viral infections induce cellular and humoral immune responses that act in 
concert to limit viral spread, clear infection and provide protective immunity against 
reinfection with the same virus. However, a number of viruses have evolved varied and 
sophisticated mechanisms to establish persistent infection, even in immunocompetent 
hosts (343-346). Epstein-Ban virus (EBV), for example, produces an interleukin-1 0-like 
virokine that functionally mimics IL-1 0 in downregulating cellular immune responses 
(346). 
Hepatitis C virus (HCV) causes significant morbidity and mortali ty. Approximately 
80% of HCV-exposed individuals develop life-long infection and in many cases, 
progressive liver disease (55). Immune escape through mutations introduced by the error 
prone HCV RNA-dependent RNA polymerase is believed to play a major role in the 
establishment of persistent HCV infection as strong, broadly directed cellul ar responses 
during acute infection are associated with HCV clearance, while nanow, qualitatively 
impaired anti-HCV responses occur in chronic infection (199, 200, 202, 229, 347-349). 
Clearance of HCV after interferon-alpha (IFN-a) and ribavirin therapy is also associated 
with greater breadth and amplitude of anti-HCV cellular immunity (350, 35 1 ). These 
associations suggest that development of appropriate adaptive immune responses relates 
closely to HCV clearance. 
The relatively small RNA genome of HCV encodes few proteins, all of which are 
involved in some way with virion structure or virus replication. Hence, any 
immunosuppressive activity must reflect secondary functions of the structural or non-
--- -· ---- - · - - -- --------------- ------
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structural HCV proteins. Core, non-structural protein 3 (NS3), NS4 and NS5 have been 
investigated for a variety of secondary functions. The 20 kDa HCV core protein is 
associated with cellular transformation in vitro and modulation of cytokine signalling and 
cellular immune responses (294, 352, 353). The NS3 serine protease downregulates 
immunoproteosome activity in vitro and may impair immune recognition (354). NS4 is 
comprised of NS4A and NS4B, two proteins involved in viral replication. NS4A acts as 
a cofactor in forming the active protease NS4AINS3 that participates in polyprotein 
processing during HCV replication (39), while NS4B is essential for replication and 
seems to affect the intracellular membranous web where viral replication occurs (355). 
NS5A inhibits antiviral PKR activity through its interferon sensitivity determining region 
(ISDR) (356). Thus, multiple HCV proteins appear to have evolved secondary functions 
affecting both innate and adaptive immune responses. 
Viral infection generally triggers production of pro-inflammatory cytokines, but 
as described above, viruses have evolved gene products that promote persistent infection 
by tipping the cytokine balance towards immunosuppression. The setting in which viral 
exposure initially occurs is also relevant, therefore, we compared induction of cytokines 
by HCV proteins in PBMC from uninfected, HCV-infected, HIV-infected and HIV/HCV-
coinfected individuals. Production of the immunosuppressive cytokine IL-l 0 was 
selectively triggered by HCV proteins, and the response was greater in HIY-
monoinfected and uninfected individuals than in those exposed to HCV. This pattem 
suggests that selective induction of IL-l 0 in uninfected individuals and especially in 
HIV-monoinfected individuals plays a role in establishing chronic HCV infection and 
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conversely, that attenuation of this response, once chronic infection IS established, 
favours development ofhepatic immunopathology. 
4.3. Materials and Methods 
4.3.1. Study participants 
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HIV-infected and HIV/HCV-coinfected individuals were recruited from the St. John' s 
General Hospital Infectious Disease Clinic, St. John's, NL, Canada. HCV-infected 
individuals were recruited from the Capital Health Queen Elizabeth Hospital Hepatitis 
Clinic in Halifax, NS, Canada. Ethics approval for this project was obtained from the 
Human Investigation Committee at each institution and all subjects provided informed 
written consent for blood collection and immunological studies. Uninfected individuals 
were recruited from Memorial University of Newfoundland Faculty of Medicine 
personnel. 
4.3.2. Ident(fication of HCV infection 
HCV exposure was ascertained by testing for serum anti-HCV antibodies using 
second or third generation EIA assays from Ortho Diagnostics (Mississauga, ON). HIV 
status was determined by commercially available PCR testing by Abbott Diagnostics 
(Mississauga, ON). 
To demonstrate the presence of HCV RNA, total nucleic acids were extracted from 
plasma samples, using NucliSens Lysis Buffer and the Nuclisens® Isolation Kit 
(Organon Teknika, Durham, NC). Briefly, 200 !J.L of plasma was added to I mL of lysis 
buffer. Silica beads were added to bind free nucleic acids, followed by successive 
washes with 70% ethanol, 95% ethanol, and acetone. Nucleic acids were removed from 
the silica at 56°C with the elution buffer provided. Thirty !J.L of eluant was frozen at -
20°C if not used immediately for eDNA synthesis. 
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Complementary DNA (eDNA) was produced from isolated RNA using a first-strand 
eDNA synthesis kit (Amersham Biosciences, Baie d'Urfe, Quebec). Eight IlL of 
extracted nucleic acid was denatured at 65°C for 5 minutes and added to a reaction mix 
containing random hexamer primer, deoxyribonucleotides, and Moloney Murine 
Leukemia Virus reverse transcriptase (MMLV-RT). Reactions were placed at 37°C for l 
hour followed by MMLV-RT inactivation at 95°C for 5 minutes. eDNA was stored at -
80°C until needed. 
eDNA was amplified by polymerase chain reaction (PCR) with primers specific for 
the highly conserved HCV 5'-untranslated region. Primers and PCR conditions were 
modified from Shindo et a!. (357) as follows: forward pnmer 5'-
GGCGACACTCCACCATAGA TC-3' and . reverse pnmer 5'-
GGTGCACGGTCTACGAGACCT-3'. The expected amplicon size was 324 bp. Final 
reactions included 20 mM TRIS-HCI buffer (pH 8.4), 50 mM KCI , 0.5 mM MgCh, 0.025 
U/11L DNA polymerase (Invitrogen, Burlington, Ontario), and 0.5 11M MG18 and 
MG321 primers (Invitrogen, Burlington, Ontario) in 50 11L. Samples were initially 
denatured at 95°C for 2 minutes, followed by thirty cycles of amplification (95°C for one 
minute, 60°C for one minute, and 72°C for one minute). PCR products were analyzed on 
2% agarose gels with ethidium bromide visualization and stored at - 20°C. 
4.3.3. PBMC isolation and in vitro stimulatiol'l 
Acid citrate dextrose (ACD)-treated whole blood was obtained by venipuncture from 
each individual and PBMC were isolated by Ficoll-HyPaque Plus (GE Health Care, Baie 
d 'Urfe, PQ, CA) density gradient centrifugation. Cells were washed, counted and 
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suspended at 1 x 106 /mL in lymphocyte medium (RPMI supplemented with 10% FCS, 1 0 
mM HEPES, 2 mM L-glutamine, 1% penicillin/streptomycin, and 2x 1 o-5 M 2-
mercaptoethanol; all from Invitrogen, Burlington, ON, CA). 
To determine the effect of HCV proteins on PBMC from healthy and infected 
individuals, 1.5x 106 freshly isolated PBMC were incubated in lymphocyte medium at 
37°C for 16 hours with 10 ~tg/mL Brefeldin A (Sigma Chemical Co., St. Louis, MO, 
USA) and 2.5 ~tg/mL recombinant HCV core, NS3, and NS4 proteins (Virogen, 
Watertown, MA), 2.5 ~g/mL recombinant HIV p24 from the same source (Virogen) or 
2.5 ~g/mL various control proteins. Initially, various concentrations (1 , 2.5, 5, and 7.5 
~g/mL) were tested in 3 individuals to detennine if there was a dose response. All 
concentrations tested demonstrated results within 0.01% of each other in each individual 
(data not shown), and 2.5 ~g/mL was used in subsequent studies as it was comparable to 
other studies ofHCV proteins in human PBMC. The HCV antigens were expressed in E. 
coli as ~-galactosidase fusion proteins, and supplied in a urea-based buffer, therefore, 
negative controls included ~-galactosidase (Calbiochem, La Jolla, CA) in the same buffer 
as the viral antigens. Polymyxin B sulfate (PMB; Sigma) was added at 100 ~Lg/mL to 
block any endotoxin-induced cytokine production as described previously (358). For 
some experiments, the lysosomal antigen processing pathway inhibitor chloroquine 
(Sigma) was added at 50 ~LM to PBMC 30 minutes before addition of HCV antigens to 
investigate whether antigen processing was involved in IL-l 0 induction. Cytokine 
production was assessed by intracellular flow cytometry. 
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4.3.4. T cell depletion 
For some experiments, CD3+ T cells were removed from fresh PBMC by 
depletion with magnetic beads. Ten million fresh PBMC were washed and resuspended 
in cold depletion buffer (PBS supplemented with 5 mM EDTA and 0.5% BSA) at 
3x106/mL, and a 10:1 bead-to-target cell ratio with mouse anti-human CD3-coated 
magnetic beads (Dynal ASA, Lake Success, NY). Cells and beads were rotated together 
for 45 minutes at 4°C, and bead bound CD3+ cells were removed using a magnet. 
Depletion efficiency was >97% as determined by flow cytometry. The remaining cells 
were resuspended in lymphocyte medium and exposed to HCV and HIV proteins as 
described above. 
4.3.5. Flow cy tometry 
Surface staining 
PBMC subpopulations were phenotyped by surface and intracellular flow cytometry 
usmg the following antibodies: CD3-phycoerythrin (PE; Clone UCHTl , 
DakoCytomation, Mississauga, ON), CD4-fluorescein isothiocyanate (FITC; Clone RPA-
T4, BD Pharmingen, San Diego, CA), CD8-peridinin chlorophyll (PerCP; Clone RPA-
T8, BD Pharmingen), CD14-FITC or CD14-PE (Clone M5E2, BD Pharmingen), CD36-
PE (Clone CB38, BD Pharmingen), CD19-FITC (Clone HIB19, BD Pham1ingen), CD56-
FITC (Clone HA58, BD Pharmingen) and CD61-PerCP (clone VI-PL2, BD Pharmingen). 
To each tube, IL-10 and CD36 were added, along with one other surface marker for each 
major cell type (e.g. CD36, IL-l 0, and CD3). Through this strategy, 3 color flow 
cytometry was used to identify-the cell population of interest. All steps were performed 
96 
at 4°C, and incubations were carried out in the dark to prevent fluorochrome 
photobleaching. Approximately 5x 105 PBMC were washed with flow cytometry buffer 
(PBS supplemented with 0.1% bovine serum albumin (BSA), 5 mM EDTA and 0.02% 
sodium azide, all from Sigma), resuspended in 600 f.lL and incubated for 20 minutes with 
0.5 f.lg antibody against surface antigens or appropriate isotype controls. Cells were 
washed, fixed with 0.5 mL 1% paraformaldehyde (Sigma) for 20 minutes, resuspended in 
250 f.lL of I% parafonnaldehyde, and stored at 4°C until collection of at least I 00,000 
events on a FACScan flow cytometer (Becton Deckinson). CellQuest Pro™ and 
WinMDI™ were used for data analysis. 
Intracellular staining 
Cells were stained as above for surface antigens with an additional 
permeabilization step after fixation. Cells were incubated with either 0.5 mL 0.2% 
saponin (Sigma) in PBS or DAKO permeabilization reagent and anti-IL-10 FITC (clone 
JES907 Caltag, Burlingame, CA), anti-IFN-y FITC, (clone B27, Caltag), anti-IL-2 FITC, 
(clone MQ1-17Hl2 Caltag) anti-IL-12 FITC (clone C8.6 Caltag) antibodies or 
appropriate isotype controls for 20 minutes at 4°C in the dark. After washing with 3 mL 
flow buffer, cells were resuspended in I% paraformaldehyde until analysis. 
Total PBMC were incubated for 16 hours with either 5 ~Lg/mL 
phytohemagglutinin, 10 nM phorbol 12-myristate 13-acetate (PMA)/1 00 nM ionomycin, 
or 200 ng/mL lipopolysaccaride to provide positive controls for IFN-y, IL-2, IL-l 0, and 
IL-12 production, respectively. Brefeldin A was added one hour after the various 
r-- - ---
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stimulants. Lymphoid cells were gated and stained for CD8 and IFN-y production, total 
PBMC for IL-2 production, and monocytes were gated for IL-12 and IL-1 0 production. 
4.3.6. Proliferation assays 
Cellular immune responses were measured by standard 5 day thymidine 
incorporation assay. PBMC were washed twice with proliferation medium (lymphocyte 
medium with 10% human AB serum (Atlanta Biologicals, lot number M0102) substituted 
for FBS) and 1 x 105 cells/well were incubated in triplicate with either plain medium, 5 
~Lg/mL phytohemagglutinin (ICN Biomedicals Inc., Costa Mesa, CA), 2.5 ~g/mL 
Candida albicans (Greer Laboratories Inc., Lenoir, NC), or 2 ~g/mL HCV core, NS3, 
NS4 or HIV p24 (all Virogen) for 5 days. One ~Ci of tritiated eH)-thymidine (Perkin 
Elmer Life Sciences, Boston, MA) was added to each well on day 4, and the assay was 
harvested onto glass fiber mats 18 hours later using a semi-automated harvester (Tomtec 
Harvester 96 Mach M III, Hamden, CT). Incorporated 3H-thymidine was measured by a 
96 well scintillation counter (TopCount, Packard, Meriden, CT). Stimulation indices 
were calculated as follows: 
Stimulation Index = cpmantigen 
cpmbackground 
Background counts were defined as the number of cpm 111 the weJJs containing only 
medium. 
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4.3. 7. Statistical analyses 
All statistical analyses were performed using SPSS version 9 (SPSS Inc., Chicago, IL). 
In Figure 4.2, the group sizes were small and unequal. Therefore, nonparametric tests 
were used to compare means. W ithin a group, the Mann-Whitney U test was used, while 
the Kruskal-Walli test was used to test for differences between groups, as there were 
greater than 3 groups. Neither test depends on the data distribution for calculation, and 
the Kruskal-Wallis for multiple comparisons adjusts the alpha value to avoid inflation of 
type I error. The Fi her' s exact test was used to compare the categorical data. All graphs 
indicate mean values and error bars repre ent tandard error of the mean. 
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4.4. Results 
4. 4.1. Study participants 
Eight healthy volunteers from St. John's NL, Canada provided blood samples for 
the study. Twenty-four HIV-infected, 10 HIV/HCV-coinfected, and 3 HCV-infected 
individuals were also recruited, and Table 4.1 describes the baseline characteristics of the 
infected groups. The age and sex of participants was similar across groups. Most 
individuals exposed to HCV developed chronic infection, although 2 of the HIV/HCV-
coinfected individuals had cleared the virus and were anti-HCV antibody positive but 
HCV RNA negative. HIV related clinical parameters were similar between groups, 
although there was a statistically nonsignificant trend toward higher CD4+ T cell counts 
in the coinfected group. Most HIV -infected individuals were on antiviral therapy and had 
achieved viral suppression at the time of participation. Only one of the HIV/HCV-
coinfected individuals had been treated (unsuccessfully) with HCV antiviral therapy, and 
the remainder ofHCV exposed patients were untreated. 
4.4.2. Exposure to HCV proteins induces IL-10 production in PBMC 
To investigate the cytokine response of PBMC from different groups of individuals 
to HCV proteins, we incubated PBMC from uninfected, HIV-infected, HCV-infected and 
HIV/HCV-coinfected individuals for 16 hours with HCV core, NS3 and NS4 protein . 
Production of IL-2, IL-12, IFN-y and IL-l 0 was then assessed by intracellular flow 
cytometry. In no case did any of the HCV antigens; individually or together, induce IL-2, 
IL-1 0, IFN-y, or lL-12 production (Figure 4.1 a). Positive controls for each of these four 
cytokines demonstrated the efficacy of the antibodies (Figure 4.1 b). However, IL- · 
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10+CD3-CD 19-CD 14-CD36+CD61 + cells with lymphoid light scatter characteristics 
increased in number following 16 hour exposure to HCV proteins (Figure 4.2a, dark 
bars). We previously described these IL-l 0+ cells in freshly-isolated PBMC from 
uninfected individuals, but found that their number fell to almost undetectable levels 
following 16 hour incubation in unsupplemented lymphocyte medium (359). All of the 
individuals in this study (uninfected n=6, HIV-infected n=24, HIV/HCV-coinfected 
n= lO, HCV monoinfected n=3) had circulating CD36+CD61 + PBMC constitutively 
producing IL-l 0 (Figure 4.2a, black bars). The average percentage of PBMC producing 
IL-10 ex vivo ranged from 0.37% (range 0.22-0.6%) in the HCV-infected group to 0.75% 
(range 0.2-1.2%) in the uninfected group. Although there was a trend towards a lower 
frequency of these cells in the HIV-infected, HCV-infected and HIV/HCV-coinfected 
groups, there was no statistically significant difference (Figure 4.2a). As previously 
described, in the absence of stimulation, the percentage of PBMC producing IL-l 0 in 
vitro decreased over time in infected and uninfected individuals (Figure 4.2a, light grey 
bars). The uninfected group had the highest frequency of IL-1 0 producing cells ex vivo 
(Figure 4.2a, black bars), however, after 16 hours incubation in lymphocyte medium 
alone, IL-1 0+ cell frequency fell to similar levels in al l groups (Figure 4.2a, light grey 
bars). The mean frequencies were slightly lower in the uninfected and HCV-infected 
groups compared to the HIV-infected and HIV/HCV-coinfected groups (Figure 4.2a, 
light grey bars, 0.12% and 0.12% versus 0.25%, and 0.24% · respectively) but not 
significantly different. The pattern of IL-1 0 production in response to HCV proteins 
differed substantially between groups (Figure 4.2a, dark grey bars). After 16 hour 
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exposure to HCV proteins, the average frequency of IL-l 0+ cells rose to 1.63% (n= l 2; 
range 0.1% to 6.6%) in PBMC from a subgroup of HIV-infected individuals, 1.02% 
(n=6; range 0.02% to 3%) in uninfected individuals, 0.27% (n= l 0; range 0.01% to 
1.56%) in HIV /HCV -co infected individuals, and 0.18% (n=3; range 0.06% to 0.26%) in 
HCV -infected individuals. The number of IL- 1 o+ cells d tected by flow cytometry 
following 16 hour exposure to the HCV proteins was significantly higher in the 1-IIV-
infected group compared to the HCV-infected (H=33, p=0.03) and HIV/HCV coinfected 
(H=15.5, p=0.001) groups (Figure 4.2a). The effect of 16 hour exposure to HCV proteins 
on the number oflL-10+ PBMC was substantial (5-10 fold increase) in HIV-infected and 
uninfected control groups, while the increase in HCV -infected individuals, with or 
without HIV co infection, was marginal (Figure 4.2a). If all the chronic HCV -infected 
individuals from the HIV/HCV and HCV monoinfected groups are combined into one 
group (n= 13 ), there is still a significant difference between IL-l 0 induction in the HIV 
monoinfected group and the combined HCV chronic infection group (p=O.O 16). IL-l 0 
induction when HCV proteins were added together or individually was not different 
(Figure 4.2b ). 
There were two clear populations oflL-1 0 positive cells based on the level of CD36 
expression. Approximately 30% of the IL-1 0 positive cells had a CD36 mean chatmel 
fluorescence (MCF) greater than 1 00, and the remainder were between 1 0 and 1 00 
(Figure 4.3a). Cells with higher CD36 mean channel fluorescence (MCF) were more 
likely to be IL-l 0 positive, with 100% of CD36hi cells IL-l 0+ versus 50-70% CD361ow 
cells IL-l 0+ in various individuals (Figure 4.3a). There is a tatistically significant 
- -··----------------------------
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difference in the mean channel fluorescence of the CD3610IL-1 010 group compared to the 
CD3611ilL-1 011i group (Figure 4.3b; Fisher' s exact test, p<O.OOO). This association raises 
the possibility of a mechanistic link between high CD36 expression and IL-l 0 
production. 
4.4.3. IL-10 induction is specific to HCV proteins, and independent ofT cells and 
lysosomal antigen processing 
To determine whether induction of IL-l 0 was selective for HCV proteins, we also 
exposed PBMC from 5 uninfected and 5 HIV-infected individuals to HIV p24 protein. 
Unlike the HCV proteins, HIV p24 did not increase IL-l 0 production in PBMC relative 
to the ~-galactosidase controls (Figure 4.4a, black bars). Therefore, HCV core, NS3 and 
NS4 selectively induce IL-l 0 production in PBMC. To confirm that IL-l 0 induction did 
not result from endotoxin contamination of the HCV an6gen preparations, we incubated 
PBMC from 5 uninfected and 3 HIV/HCV coinfected individuals with HCV protein in 
the presence of polymyxin B, an endotoxin blocker. Inclusion of polymyxin B in the 
assays had no effect on induction of IL-10 in HCV-exposed PBMC (Figure 4.4a, light 
grey bars). To test whether antigen processing of the HCV proteins was required for 
induction of IL-l 0, we inhibited the I ysosomal antigen processing pathway with 
chloroquine in PBMC from uninfected, HIV -infected and HIV /H CV -co infected 
individuals exposed to HCV proteins (n=3, n=4, n=4 respectively). Chloroquine 
treatment did not significantly affect the IL-l 0+ cell frequency in PBMC from uninfected, 
HIV-infected or HIV/HCV-coinfected groups exposed to HCV proteins (Figure 4.4b, 
grey bars with diagonal hatch). 
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Since the HCV proteins had the greatest effect on IL-l 0 induction in PBMC from 
HIV -infected individuals and reduced CD4+ and total T cell numbers is an integral aspect 
of HIV infection, we decided to test if the absence ofT cells affected the IL-l 0 response 
to HCV proteins. Therefore, we depleted CD3+ T cells from the PBMC of 2 individuals 
in each of the HIV-infected and HIV/HCV-coinfected groups (Figure 4.4b, horizontal 
hatch bars) and assessed IL-l 0 production with and without exposure to HCV proteins 
(white or grey background bars respectively). The percentage of PBMC producing IL-l 0 
constitutively or in response to HCV proteins was essentially unaffected by T cell 
depletion after correction forT cell depletion. 
4. 4. 4. Relationship between IL-10 induction and HCV-specific T cell prol(feration 
Since lL-1 0 is an immunomodulatory cytokine that suppresses Th 1 type adaptive 
immunity, we investigated the relationship between IL-l 0 induction by HCV proteins and 
HCV-specific T cell proliferation in 10 HlV/HCV-coinfected individuals. A positive 
HCV -specific proliferation response (stimulation index greater than or equal to 3) was 
observed in only one individual (0 18, Figure 4.5a, black bar), who demonstrated a 
positive response to HCV core but not NS3 and NS4. After 16 hour exposure to HCV 
antigens, 6 of the 10 coinfected individuals tested demonstrated an HCV protein-induced 
increase in the number of IL-l 0+ cells (grey bars, Figure 4.5b ). Of note, subject 018 was 
one of the four individuals who did not have increased numbers of IL-l 0+ cells following 
exposure to HCV proteins. 
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4.5. Discussion 
In this study, we demonstrated that HCV core, NS3 and NS4 proteins specifically 
and selectively induce IL-l 0 production when incubated for 16 hours with PBMC. The 
cells producing IL-l 0 in response to HCV proteins were identified by flow cytometry as 
CD14.CD36+ with lymphoid light scatter characteristics. We previously reported 
constitutive ex vivo production of IL-l 0 by this PBMC subset and that this production 
rapidly stops in vitro (359). These cells do not fit into one of the major subpopulations of 
circulating immune cells, but can be reliably isolated from all healthy individuals tested 
at a frequency of up to 1%. The ex vivo frequency of IL-1 0-producing PBMC was 
generally equivalent in the four distinct groups we studied, indicating that the differences 
seen after 16 hour culture were caused by differential responses to the HCV proteins. 
While 16 hour culture with HCV proteins increased the number of IL-l 0-producing cells 
in all groups, the frequency of IL-10+ cells was higher in PBMC from HIV-infected 
individuals and uninfected controls compared to PBMC from HIV/HCV coinfected 
individuals or HCV-infected individuals. This demonstrates a propensity for HCV-
induced IL-1 0 production by PBMC from uninfected individuals that is exaggerated by 
HIV infection and attenuated by chronic HCV infection, even in the setting of HIV 
coinfection. 
We used recombinant HCV core, NS3 and NS4 to investigate cytokine production 
m response to HCV proteins. Although these three proteins have little sequence or 
structural similarity and their known functions in HCY replication are very different 
(360, 361 ), we found that, collectively or individually, HCV core, NS3 and S4 proteins 
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induced IL-l 0 production in CD 14-CD36+ PBMC. Others have also reported that 
recombinant HCV core, NS3 and NS4 proteins all induce IL-10 production (294, 295, 
362). However, in these studies, monocytes were identified as the responding cells and, 
in direct contrast to our results, there was a greater effect on monocytes from HCV-
infected individuals than on monocytes from uninfected controls (294, 363). These 
studies utilized monocytes isolated by overnight adherence to plastic, rather than freshly 
isolated PBMC. Despite varying protocols and different characteristics of the responding 
cells, the central point is that multiple distinct HCV proteins stimulate IL-l 0 production 
by PBMC. There are other examples of redundancy in HCV protein effects, as mice 
transgenic for hepatic HCV structural or non-structural polyproteins develop hepatic 
steatosis characteristic of chronic HCV infection (364). Such functional redundancy of 
viral proteins is not unique to HCV, as three different HIV proteins (nef, tat and vpr) have 
all been reported to induce IL-l 0 production by various PBMC subsets (365-369). 
In our study, structural and non-structural HCV proteins induced IL-l 0. Having both 
structural and non-structural proteins with redundant immunosuppressive functions may 
be important in sustaining infection. The availability of these proteins in circulation is 
temporally separated, and not concurrent. Non-structural proteins are only expressed in 
actively infected cells, while the core protein can be found in plasma at moderately high 
levels throughout chronic infection (370, 371). Having multiple proteins that induce IL-
l 0 supports production of an immunosuppressive cytokine whether or not HCV 
replication is upregulated or infectious virions are present. 
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In parallel with the redundancy in HCV protein-induced IL-l 0 production, additional 
HCV escape mechanisms within both the innate and adaptive immune system have been 
extensively described. Subversion of the eukaryotic anti-viral interferon-inducible 
system is a potent evasion strategy employed by many viruses, and several HCV proteins 
suppress host proteins in this system. HCV E2 inactivates PKR (372), and the HCV 
serine protease NS3/4A causes proteolysis of Toll-IL-l receptor domain-containing 
adaptor inducing IFN-~ (TRIF) (242), and inhibits phosphorylation of IRF-3 , preventing 
nuclear translocation and IFN-~ gene activation (241). HCV E2 has also been associated 
with decreased NK cell function and HCV core stabilizes HLA-E expression and 
subsequently downregulates NK-mediated cytotoxicity (300, 301 , 373). HCV core, El , 
NS3, and NS4 are all associated with impaired dendritic cell maturation, thus potentially 
modulating the function of this integral link to adaptive cellular immunity (294, 363, 
374). HCV core also downregulates in vitro anti-HCV T cell responses (298, 353, 375). 
While the exact mechanism of HCV protein interaction is unclear, IL-l 0 inl1ibits 
dendritic cell maturation, resulting in an immature phenotype similar to that seen after 
exposure to HCV core (376). Not only do HCV proteins modulate immune responses, it 
is clear that more than one protein has evolved to share similar functions. Production of 
IL-l 0 by the cell population described in this paper may stunt dendritic cell maturation, 
and impair development of anti-HCV cellular immunity through this pathway as well as 
through a direct effect on responding T cells. 
The mechanism for IL-l 0 induction in PBMC by HCV proteins is unknown, but 
processing of soluble HCV antigens through the endocytic pathway is unnecessary as 
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blocking antigen processing had no effect on constitutive or induced IL-l 0 production. A 
higher percentage of cells from HIV -infected individuals than uninfected controls 
produced IL-l 0 in response to HCV proteins. This appears unrelated to lower T cell 
function in HIV infection as depletion of CD3+ PBMC also did not affect constitutive or 
HCV-induced IL-10 production by the CD14-CD36+ PBMC. 
The direct correlation between intracellular IL-l 0 production and intensity of cell 
surface CD36 expression supports a possible connection between these molecules. 
Ligands of CD36, a scavenger receptor, include oxidized low density lipoproteins 
(oxLDL), thrombospondin, collagen types I and IV, apoptotic cells, long chain fatty acids 
and Plasmodium-infected erythrocytes (377-385). At least 2 of these ligands, 
thrombospondin and apoptotic cells, have immunosuppressive or anti-inflammatory 
effects (334, 386). In addition, peroxisomal proliferator associated receptor-y (PPAR-y) 
mediated differentiation of monocytes towards a less inflammatory status is accompanied 
by upregulation of CD36, which has been used to clinical advantage in cerebral malaria 
(387). 
While there is circumstantial evidence for a link between CD36 and induction of IL-
l 0, there has been no reported evidence of interactions between HCV or any of its 
individual components and CD36. HCV associates with low density lipoproteins in 
circulation, and uses the LDL receptor and CD81 to enter cells (21 ). CD36 is not an 
HCV cellular receptor however, recent studies suggest that HCV and the CD36 ligand 
oxLDL do interact (388). HCV proteins may indirectly activate IL-l 0 production 
through a- CD36 related mechanism. 
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IL-l 0 is an important immunomodulatory cytokine, and recent experiments in the 
LCMV model of chronic viral infection showed that manipulating levels of IL-l 0 alone 
was sufficient to dictate LCMV clearance or persistence (389). However, studies 
comparing plasma IL-l 0 levels in HCV -infected and healthy individuals have been less 
definitive, with some studies describing control levels of serum IL-l 0 in chronic HCV 
infection, while other groups describe a marked increase in IL-l 0 in chronic infection 
(390-392). This raises questions about the value of serum IL-l 0 measurements, as IL-l 0 
has important localized paracrine effects that are not reflected by these generalized IL-l 0 
determinations. As· well, none of these studies determine IL-l 0 levels during acute 
infection when it may be pivotal in the establishment of chronic infection. We 
demonstrated that exposure to HCV antigens in chronically infected individuals produced 
less IL-10 than seen in HCV nai"ve individuals. Longer term exposure to HCV antigens 
apparently conditions the CD36+ population of IL-l 0+ cells, attenuating HCV protein 
specific IL-l 0 induction. Thus, IL-l 0 levels during acute infection may be more relevant 
to the establishment of persistent infection than to maintaining chronic infection. 
The transience of IL-l 0 responses to HCV proteins may allow emergence of 
cellular immune responses that are pathological in the context of chronic HCV infection. 
Several studies indicate a protective role for IL-l 0 in the immunopathology of HCV 
infection including a clinical trial of exogenous IL-l 0 administration, accumulation of IL-
l 0 producing CDS+ B cells in HCV-infected individuals with mild disease and an 
association between high IL-l 0 gene polymorphism and decreased rates of HCV -related 
liver fibrosis (130, 393-395). The diminution in IL-l 0 induction seen in chronic HCV 
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infection after HCV protein exposure appears to parallel, and possibly support, 
insidiously progressive liver disease. 
Coinfection with HIV is an important Issue m HCV infection because of its 
relatively high prevalence, higher HCV virus loads in HIV/HCV coinfected individuals 
and because of increased HCV -related morbidity in HIV coinfected individuals (396-
398). The higher level of IL-l 0 induction in PBMC from HIV -infected individuals may 
allow the establishment of more aggressive HCV infection, with dowmegulation of anti-
HCV responses permitting increased HCV replication and higher HCV virus loads. 
However, this could depend on the order of HCV and HIV infection, with stronger anti-
HCV cellular immunity developing when HCV infection precedes HIV-associated CD8+ 
T cell activation during the asymptomatic phase of HIV infection. Enhanced CD8+ T cell 
immunity against HCV in HCV/HIV coinfected individuals is likely to accelerate liv r 
disease, while those who acquire HCV following the generalized decline in cellular 
immunity associated with progressive HIV infection are likely to have especially weak 
HCV-specific cellular immunity. Thus, there are 2 distinct groups of HIV/HCV 
coinfected individuals with respect to HCV-specific cellular immunity and its potential 
role in viral suppression and in the pathogenesis ofliver disease. 
Chronic HCV infection mitigates IL-l 0 production induced by HCV proteins. 
This is true in the group of three HCV monoinfected individuals, as well as the 10 
HIV/HCV coinfected people. Though the monoinfected group is small, the two groups 
with chronic HCV infection have a total of thirteen individuals, and both have similar 
results. The limited IL-l 0 response is even more marked considering that the HIV 
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mono infected group has the highest IL-l 0 induction of all groups. Therefore, the lack of 
IL-l 0 induction in the setting of chronic infection is likely not an artifact of the small 
sample size, but a real phenomenon that can even supplant the expected HIV -associated 
IL-l 0 induction. The mechanism is unclear, and perhaps reflects an 'exhaustion ' of this 
cell type in the context of chronic stimulation. 
Consistent with previous reports, we found that HCY-specific T cell proliferation is 
rare in chronic HCV infection with HIV coinfection (284, 399). In fact, the only 
individual with anti-HCV proliferative responses is also one of the individuals with the 
least number of IL-1 0 producing cells after HCV protein exposure. 
We have demonstrated the presence of a novel population of PBMC that act 
differentially in response to HCV proteins in uninfected and HIV- or HCY-infected 
individuals. This differential IL-l 0 response to HCV antigens is consistent with the 
generation of an immunoregulatory environment that promotes viral persistence in acute 
exposure while allowing disease progression in the chronic state. The behaviour of this 
CD36+CD 14· population offers insight into how HCV establishes viral persistence 
through decreased cellular immune responses and how this is exacerbated by HIV 
infection. 
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Table 4.1. Patient characteristics 
HIV HIV/HCV Chronic HCV 
Number (n) 24 10 3 
Age (yrs±SD) 41.7±7.0 39.2±3.85 49±15 
Sex(%) 
M 75 80 66.7 
F 25 20 33.3 
HCV Genotype 
(%) 
N/A 100 0 
Non- I N/A 0 0 
Unknown N/A 0 100 
HCV status(%) 
Chronic infection N/A 
80 100 
(HCV RNA +) 
Clearance N/A 
20 0 
(HCV RNA-) 
HCV Risk Factor 
(%) 
IVDU N/A 30 66.7 
Transfusion N/A 20 33.3 
Tattoo N/A 0 0 
Endemic area N/A 0 0 
113 
Table 4.1. (con't) 
HIV HIV/HCV ChronicHCV 
Unknown N/A 50 0 
Estimated duration of 
infection (yrs±SD)1 
HIV 18±5.1 10±2.1 NIA 
HCV N/A 18±3.4 24±8 
Antiviral therapy(%) 
HIV 58 90 N/A 
HCV N/A 0 0 
Suppressed viralload2 (%) 
HIV 75 70 N/A 
HCV N/A 20 Unk. 
CD4+ T cell coune. (median 
409, 422 608,80 N/A 
cells/ !J.L, interquartile range) 
CD4+ T cell nadir4 (median 
252, 296 247,350 N/A 
cells/!J.L, interquartile range) 
Abbreviations: A vg average; N/ A not applicable; SD standard deviation; Unlc unknown. 
1The time since clinically confirmed infection or, in the case of HCV, high risk activity. 
2Undetectable viral load by Roche Amplicor RT-PCR test for HIV and in house PCR for 
I-;ICV at the time of participation. This also includes those who have spontaneously 
cleared the virus in the case of HCV. 3Measured on the day of participation. 4Lowest 
documented count over the course of followup. 
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Figure 4.1. Cytokine production following 16 hour exposure of PBMC to HCV 
proteins. (a) Freshly isolated PBMC from HIV-infected, HCV-infected, HIV/HCV 
coinfected and uninfected controls were incubated for 16 hours with HCV proteins, then 
analyzed by intracellular flow cytometry for cytokine production as shown in 
representative plots. Selective IL-l 0 production by a small subset of CD3- PBMC with 
lymphoid scatter characteristics occurred in each case. 
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Figure 4.1. (con't) (b) Positive controls for cytokine production. (A) IL-2 production 
in total PBMC after PMNionomycin treatment. (B) IFN-y production by CDS+ and 
CDS- lymphoid gated PBMC after phytohemagglutinin treatment. (C) IL-1 2 production 
in CD 14+ cells after LPS stimulation. (D) IL-l 0 production in CD 14+ cell after LPS 
stimulation. 
(a) 
2.5 
2.0 
u 
~ 1.5 m 
H 
p=0.01 
a.. 
+ 0 
..... 
I 
....I 1.0 
~ 0 
0.5 
0.0 .....___ _ _ 
Control 
n=6 
H 
p=0.002 
HIV 
n=24 
p=0.001 
- Exvivo 
c:::J p-galactosidase 
HCV proteins 
p=0.03 
HIV/HCV HCV 
n=10 n=3 
116 
Figure 4.2. Mean percentage of PBMC from different groups expressing IL-10 ex 
vivo and foiJowing 16 hour incubation with HCV proteins. (a) The percentage of IL-
l 0 producing cells (mean±SE) was assessed by intracellular flow cytometry in freshly 
isolated PBMC and following 16 hour incubation with HCV proteins. Black bars 
represent fresh PBMC, dark grey bars represent PBMC incubated for 16 hours with 
recombinant HCV core, NS3 and NS4 and lighter grey bars represent the same PBMC 
incubated for 16 hours with ~-galactosidase control protein. Statistical comparisons are 
made within groups using the Mann-Whitney U test and between groups using the 
Kruskal-Wallis test. 
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Figure 4.2. (con't) (b) Representative flow plots of IL-l 0 production in PBMC from an 
HIV/HCV-coinfected individual after incubation ofPBMC with individual HCV proteins 
at 2.5 llg/mL. ·Numbers represent the percentage ofiL-1 0 positive PBMC. 
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Figure 4.3. Relationship between CD36 expression and ex vivo IL-10 production by PBMC. (a) Representative flow 
cytometry plot showing IL-l 0 production in freshly-isolated CD36+ PBMC cells with lymphoid light scatter characteristics. 
The percentage of CD36+ cells that are IL-l 011i is indicated. (b) Mean channel fluorescence (MCF) for CD36 plotted against 
IL-l 0 MCF for seven individuals. Open circles represent the CD3611i subset and dark circles represent the CD3610w subset as 
shown in Figure 4.3a. -00 
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Figure 4.4. Effect of polymyxin B, chloroquine and T cell depletion on IL-10 
production by PBMC exposed to recombinant HCV proteins. (a) Cells from 
uninfected individuals (n=5) were pretreated with polymyxin B (grey bars) before 
incubation with recombinant HCV proteins to block the effects of any endotoxin 
contamination of the recombinant proteins. The effect of 16 hour exposure to 
recombinant HIV p24 on IL-l 0 induction was also assessed, but incubation with 
polymyxin B was not performed. 
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Figure 4A. (con't) (b) The mean percentage PBMC expressmg IL-10 {±SE) from 
control, HIV -infected and HIV /H CV coinfected individuals was assessed after exposure 
to either ~-galactosidase (white background bars) or HCV proteins (grey background 
bars). Effects of treating PBMC with chloroquine (diagonal hatch) or depleting CD3+ T 
cells (horizontal hatch) are also shown for comparison with the HCV protein group (grey 
bars). Each individual was tested on at least 2 different visits. 
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Figure 4.5. Anti-HCV cellular responses and IL-10 induction in HIV/HCV 
coinfected individuals. (a) 3H-thymidine incorporation by PBMC from 10 HIV/HCV 
coinfected individuals incubated for 5 days with HCV core (black bar), NS3 (medium 
grey bar), or NS4 (dark grey bar). A stimulation index of 2 3 was considered positive. 
Individuals 18 and 150 were anti-HCV positive but HCV RNA negative at the time of 
testing. 
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Figure 4.5. (con't) (b) IL-10 production in 10 HIV/HCV coinfected individuals after 16 
hour incubation with either p-galactosidase or HCV proteins. The percentage of IL-l 0+ 
PBMC within the lymphoid gate is represented on the y axis. Testing was done on the 
same day as the proliferation data was collected. Individuals 18 and 150 were anti-HCV 
positive but HCV RNA negative at the time of testing. 
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5.1. Abstract 
Hepatitis C virus (HCV) is a common chronic infection associated with human 
immunodeficiency virus (HIV) infection through similar routes of transmission. 
Clinically apparent liver disease arises within years in HIV/HCV coinfection, compared 
to decades in HCV monoinfection. In this study, we compared frequency, magnitude, 
breadth, specificity and vigor of peripheral blood CD4+ and CD8+ T cell responses 
between HCV monoinfected and HIVIHCV coinfected individuals as well as between 
HIV/HCV coinfected subgroups with variable anti-HCV antibody and RNA status. 
Coinfection with HIV marginally decreased the frequency and breadth of anti-HCV 
CD8+ T cell responses overall, but when present, responses were stronger than in 
monoinfection. This suggests two distinct groups of HIV/HCV coinfected individuals 
bracketing monoinfected individuals in terms the strength of their HCV -specific CD8+ T 
cell responses. HCV-specific CD4+ T cell responses were rare and weak in both groups 
independent of either nadir or concurrent CD4+ T cell counts ofHIY-infected individuals. 
Although CD8+ T cell responses occurred in isolation, the magnitude of HCY-specific 
CD4+ and CD8+ T cell responses was positively correlated in HIV/HCV coinfection. 
Subgroup analysis demonstrated restricted breadth of CD8+ HCV -specific T cell 
responses and lower B cell counts in HIVIHCV coinfected individuals with no detectable 
anti-HCV antibodies. The greatest difference between HIV/HCV coinfected and HCV 
mono infected groups was stronger HCV -specific CD8+ T cell responses in the HIV 
coinfected group, which may relate to the accelerated liver disease in this setting. Factors 
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beyond breadth and specificity of anti-HCV CD8+ T cell responses likely play an 
important role in disease course and low HCV clearance rates of in HIV co infection. 
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5.2. Introduction 
Hepatitis C virus (HCV) is a global health concern, with over 170 million people 
infected worldwide. The insidious nature of early HCV infection and high rate of chronic 
infection dictate that a large percentage of infected individuals are unaware of their 
status. As they share similar routes of transmission, HIV infection often coexists with 
HCV infection. In this context, the clinical course of HCV disease is accelerated and 
response to HCV therapy may be compromised. With the increased life expectancy 
afforded in HIV infection by highly active antiretroviral therapy (HAART), HCV-related 
disease has become a significant cause of morbidity and mortality in HIV/HCV 
coinfected individuals. 
A substantial body of research has addressed the role of the immune system in 
HCV clearance, chronicity and disease. Multiple studies in humans (198-200, 229) and 
chimpanzees (21 0, 400) link viral clearance to strong anti-HCV CD4+ and CD8+ T cell 
responses in acute infection, suggesting a central role for adaptive immunity in viral 
clearance. Vigorous and broadly directed HCV -specific CD4+ and CD8+ T cell responses 
occur during spontaneous clearance (199, 401, 402), while in chronic HCV infection, 
these responses appear much less robust. Most studies found HCV-specific CD4+ T cell 
responses to be rare (202, 403) in persistent infection, both by tetramer and ELISPOT 
analysis, and that CD8+ T cells have impaired proliferative capacity (404). There is some 
evidence that CD4+CD25+ regulatory T ceJis suppress anti-HCV CD8+ T cell responses 
and promote chronic HCV chronic infection (272, 273, 405). 
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HCV-specific CD4+ and CD8+ T cell re ponses in the context ofHIV coinfection 
have been investigated by several groups (252, 282, 284, 285, 399, 406). In short, 
peripheral T cell responses are weak and narrow, but somewhat stronger in the liver. No 
apparent differences in the specificity of the responses have been reported. Some studies 
report similar frequencies of CD4+ and CD8+ T cell responses in monoinfection and 
HIV/HCV coinfection (282), while others report very rare (284, 407) CD4+ T cell 
responses in the presence of weak but detectable CD8+ T cell responses in HIV/HCV 
coinfection. The exact role of CD4+ and CD8+ T cell responses in this coinfected group 
remain unclear. In addition, there are several subgroups within the overall HCV exposed 
group based on plasma HCV RNA and anti-HCV antibodies. There are HCV exposed, 
anti-HCV antibody positive, HCV RNA negative individuals (spontaneous clearers), 
chronic infections (anti-HCV positive, HCV RNA positive) and chronically HCV 
.infected people without detectable anti-HCV antibodies (serosilent group). These 
subgroups have not been thoroughly studied in the context of HIV infection, and may 
have distinct adaptive immune responses unappreciated through global analysis. 
In this study, we compared the frequency, magnitude, breadth and specificity of 
HCV-specific CD4+ and CD8+ T cell responses between HIV/HCV coinfected 
individuals and chronically infected HCV individuals. We also investigated the character 
of CD8+ T cell r~sponses in HIV/HCV subgroups. HIV coinfection slightly decreased 
the frequency and breadth of anti-HCV CD8+ T cell responses compared to chronic HCV 
monoinfection but the magnitude of responses we observed was higher than previously 
reported. Strong CD8+ T cell responses that correlated with CD4+ T cell response 
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magnitude were observed in coinfection but not in monoinfection. CD4+ T cell responses 
were rare and weak in both groups, independent of CD4+ nadir or CD4+ T cell count for 
HIV -infected individuals. Not all coinfected groups were similar, with subgroup analysis 
indicating narrow anti-HCV CD8+ T cell response breadth and lower B cell counts in 
serosilent coinfected individuals. 
HIV coinfection was associated with stronger HCV-specific CD8+ T cell 
responses in this group of HCV coinfected individuals. Vigorous immune responses in 
the context of persistent infection may contribute to rapid progression of liver disease in 
this group. 
5.3. Materials and Methods 
5.3.1. Study participants 
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HIV -infected and HIV /HCV -co infected individuals were recruited from the St. 
John's General Hospital Infectious Disease Clinic, St. John's, NL, Canada. HCV-
infected individuals were recruited from the Capital Health Queen Elizabeth Hospital 
Hepatitis Clinic in Halifax, NS, Canada. Ethics approval for this project was obtained 
from the Human Investigation Committee at each institution, and all subjects provided 
informed written consent for blood collection and immunological studies. 
5.3.2. Identification of HCV infection 
HCV exposure was ascertained by testing for serum anti-HCV antibodies using 
second or third generation EIA assays from Ortho Diagnostics. 
To demonstrate the presence of HCV RNA, total nucleic acids were extracted 
from plasma samples, using NucliSens® Lysis Buffer and the Nuclisens® Isolation Kit 
(Organon Teknika, Durham, NC). Briefly, 200 ~-tL of plasma was added to 1 mL of lysis 
buffer. Silica beads were added to bind free nucleic acids, followed by successive 
washes with 70% ethanol, 95% ethanol, and acetone. Nucleic acids were removed from 
the silica at 56°C with the elution buffer provided. Thirty ~-tL of eluant was frozen at -
20°C if not used immediately for eDNA synthesis. 
Complementary DNA (eDNA) was produced from isolated RNA using a first-
strand eDNA synthesis kit (Amersham Biosciences, Baie d'Urfe, Quebec). Eight ~tL of 
extracted nucleic acid was denatured at 65°C for 5 minutes and added to a reaction mix 
containing random hexamer primer, deoxyribonucleotides, and Moloney Murine 
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Leukemia Virus reverse transcriptase (MML V -RT). Reactions were placed at 37°C for I 
hour followed by MMLV-RT inactivation at 95°C for 5 minutes. eDNA was stored at -
80°C until needed. 
eDNA was amplified by polymerase chain reaction (PCR) with primers specific 
for the highly conserved HCV 5'-untranslated region. Primers and PCR conditions were 
modified from Shindo et al. (357) as follows: forward pnmer 5'-
GGCGACACTCCACCATAGATC-3' and reverse pnmer 5'-
GGTGCACGGTCTACGAGACCT-3'. The expected amplicon size was 324 bp. Final 
reactions included 20 mM TRIS-HCl buffer (pH 8.4), 50 mM KCl, 0.5 mM MgCl2. 0.025 
U/~-tL DNA polymerase (Invitrogen, Burlington, Ontario), and 0.5 ~-tM MG 18 and 
MG321 primers (Invitrogen, Burlington, Ontario) in 50 ~-tL. Samples were initially 
denatured at 95°C for 2 minutes, followed by thirty cycles of amplification (95°C for one 
minute, 60°C for one minute, and 72°C for one minute). PCR products were analyzed on 
2% agarose gels with ethidium bromide visualization and stored at - 20°C. 
5.3.3. PBMC isolation 
Acid citrate dextrose (ACD) treated whole blood was obtained by venipuncture 
from each individual and peripheral blood mononuclear cells (PBMC) were isolated by 
Ficoll-HyPaque Plus (GE Health Care, Baie d' Urfe, PQ, CA) density gradient 
centrifugation. Cells were washed, counted and suspended at 1 x 1 06/mL in lymphocyte 
medium (RPMI supplemented with I 0% FCS, 10 mM HEPES, 2 mM L-g1utamine, 1% 
penicillin/streptomycin, and 2x 1 o-5 M 2-mercaptoethanol; all from Invitrogen, 
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Burlington, ON, CA) until use. In some cases, cells were frozen at -80°C until use. 
Samples with less than 80% viability when thawed were discarded. 
5.3.4. Peptide preparation 
A set of 18-mer peptides spanning the entire HCV genotype 1 a polyprotein was 
obtained from the NIH AIDS Research and Reference Reagent Program. A total of 441 
peptides overlapping by 11 amino acids were reconstituted in 80-l 00% sterile 
dimethylsulphoxide (DMSO), diluted to 200 J..Lg/mL in lymphocyte medium, and then 
pooled together in groups of 10 consecutive peptides at a concentration of 20 
J..Lg/mL/peptide. Peptides were stored at -80°C until use, and added to cells at a final 
individual concentration of I 0 J..Lg/mL. Control wells contained 0.5% DMSO. The 
composition of the peptide pools is found in Appendix A. 
5.3.5. ELISPOTfor IFN-yproduction 
The number of IFN-y producing cells in PBMC was determined by ELISPOT. 
Flat bottom polyvinylidene difluoride (PVDF)-coated 96-weil plates (Millipore, Bedford, 
MA) were prewet with 100 J..LL 70% ethanol/well (Sigma Chemical Co.), washed with 
PBS, and coated either overnight at 4°C or for one hour at 37°C with 1.5 ~Lg/well anti-
IFN-y antibody (clone 1D1K, Mabtech, Stockholm, Sweden) in PBS. Plates were 
washed five times with PBS and 1.0-2.0x 105 intact or CD4+ depleted PBMC were added 
to each well in duplicate. Peptide pools were added to each test well, and 2 J..Lg/mL PHA 
or 100 IFN-y positive C1 0/MJ cells (NIH AIDS Research and Reference Reagent 
Program, Popovic et al. (408)) served as a positive control. Plates were incubated at 
37°C, 5% C02 for 16 hours, washed with PBS, and incubated for 2 hours with 0.1 
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~Lg/well of biotinylated anti-IFN-y antibody (clone 7-B6-1, Mabtech). Plates were 
washed, and 100 ~L of a 1:1000 dilution of streptavidin-alkaline phosphatase (Mabtech) 
was added for 1 hour. After washing, 100 ~L freshly prepared 3 mg/mL nitro blue 
tetrazolium chloride (NBT)/1.5 mg/mL 5-bromo-4-chloro-3-indolyl phosphate-p-
toluidine (BCIP) substrate (BioRad, Hercules, CA) in Tris buffer (pH 9.5) was added to 
each well for approximately 20 minutes. Plates were washed with distilled water to stop 
the color reaction and air-dried overnight before spot enumeration using the high 
resolution Zeiss reader system and associated KS software (Carl Zeiss Canada, Ontario, 
Canada). The number of IFN-y producing cells per million PBMC was detennined by 
multiplying the average number of spots/duplicate well x 10 or x 5, depending if 1 xi 05 or 
2x 105 cells were used. A peptide pool response was considered positive if the number of 
spots was greater than 10 spot forming cells (SFC), and twice the background count. 
CD4+ depletion was done with 2 coinfected samples; there was no difference in the 
number of peptide induced IFN-t spots with or without depletion (data not shown). As 
each spot represents one cell, the area of the spot is related to IFN-y production per cell 
( 409, 41 0). Average spot area in arbitrary units was used as a relative measure of IFN-y 
production per cell. Spot area is determined electronically by calculating the number of 
pixels in a well with color. 
5.3.6. Prol~feration assays 
Cellular immune responses were measured by standard 5 day thymidine 
incorporation assay. PBMC were washed twice with proliferation medium (lymphocyte 
medium with 10% human AB serum (Atlanta Biologicals, lot number MOl 02) substituted 
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for FBS) and 1 x 105 cells/well were incubated in triplicate with either plain medium, 5 
1-lg/mL phytohemagglutinin (ICN Biomedicals Inc., Costa Mesa, CA), 2.5 or 5 1-!g/mL 
Candida albicans (Greer Laboratories Inc., Lenoir, NC), or 2 1-lg/mL HCV core, NS3, 
NS4 or HIV p24 (all Virogen) for 5 days. One !-!Ci of tritiated eH) thymidine (Perkin 
Elmer Life Sciences, Boston, MA) was added to each well on day 4, and the assay was 
harvested onto glass fiber filter mats 18 hours later using a semi-automated harvester 
{Tomtec Harvester 96 Mach M III, Hamden, CT). Incorporated 3H-thymidine was 
measured by a 96 well scintillation counter (TopCount, Packard, Meriden, CT). 
Stimulation indices were calculated as follows: 
5.3. 7. Statistical analyses 
Stimulation Index = cpmantigcn 
cpmbackground 
All statistical analyses were performed using SPSS version 9 (SPSS Inc. , Chicago, IL). 
Means were compared using either the Mann-Whitney U test or Student' s !-test. All 
graphs indicate average values, and error bars are the standard error of the mean. 
Pearson' s correlation coefficients were used to assess relationships between independent 
continuous variables by linear regression. 
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5.4. Results 
5. 4.1. Study participants 
Twelve individuals coinfected with HIV and HCV were recruited and 22 people 
with chronic HCV infection. Demographic and baseline clinical parameters are reported 
in Table 5.1. Mean age (40 years in the HIV/HCV gioups and 47 years in the HCV 
group) and gender distribution (75% and 77% male respectively) did not differ 
significantly between the two groups. 
Most HCV genotypes were unknown, but those tested were predominantly 
subtype 1, as expected for North American populations. Intravenous drug use (IVDU), 
blood product transfusion and organ transplant were predominant tisk factors in both 
groups. Estimated duration of HCV infection was similar in both groups with 
approximately 20 years as the average time since infection. Liver enzymes were reported 
as elevated if the plasma level was greater than twice the upper limit of normal. All 
individuals in the coinfected group and 68% in the chronic group had normal plasma liver 
enzyme levels on the sampling date. 
Overall, the monoinfected and HIV/HCV coinfected groups were similar m 
demographics and HCV- related clinical parameters. 
5.4. 2. HCV does not affect HIV related immune parameters 
Table 5.2 distinguishes three groups ofHIV infected individuals exposed to HCV: 
those who were HCV seropositive and HCV RNA positive (chronic infection, n=5); those 
who were HCV seropositive and HCV RNA negative (spontaneous clearers, n=3), and 
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those who were HCV seronegative and HCV RNA positive (serosilent HCV infection, 
n=4). 
HIV-associated parameters are described for the HIV/HCV coinfected group in 
Table 5.2. HCV related parameters are discussed above. All subgroups were similar in 
age, gender distribution, duration of HIV infection, and type of antiretroviral therapy at 
the time of testing. Only one individual, HIV -087, was not receiving antiretroviral 
therapy at the study time point. There were no statistically significant differences in 
either CD4+ T cell nadir or CD4+ T cell count. HIV viral load was not significantly 
different between groups, and ranged between undetectable (<50 or <400 copies/mL) and 
130,000 HIV RNA copies/mL plasma. All liver function tests and plasma liver enzyme 
levels were normal on the test date. There was no significant difference in HIV related 
parameters such as CD4+ T cell count, CD4+ T cell nadir or HIV plasma viral load in the 
serosilent group (lack of anti-HCV antibodies), spontaneous clearance group (plasma 
HCV RNA negativity), or chronic HCV infection group. 
We compared HIV related clinical data for the group of 12 HIV/HCV coinfected 
individuals with a group of 75 HIV monoinfected individuals enrolled concurrently for 
HIV immunology studies (Figure 5.1 a). Mean CD4+ T cell counts were comparable 
(370±245 in the HIV group, 380±259 in the HIV/HCV group) as were CD4+ T cell nadir 
(181 ±175 and 255±197 respectively), HIV viral loads (3.27±1.1 and 3.8±1.2 
respectively) and CD8+ T cell counts (886±445 and 892±582 respectively). B cell counts 
(CD20+) were also similar in the HIV/HCV group and HIV monoinfected group 
(248±163 vs. 194±134; respectively). Of note, the 4 HCV seronegative, HCV RNA 
------------------------- ----------------
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positive individuals had B cell counts that were below the HIV/HCV seroevident 
coinfected group mean (Figure 5.1 b; 306± 187 versus 134±65). HCV infection does not 
appear to affect HIY-related clinical laboratory parameters in our study group, except for 
a trend toward lower B cell counts associated with a selective lack of HCV antibodies. 
5.4.3. HCV NS3 is immunodominant in HIVIHCV coinfection, chronic HCV 
monoinfection and in HIV coinfected spontaneous clearers. 
We assessed the specificity, breadth and magnitude of anti-HCV CD8+ T cell 
responses in PBMC from HIV /HCV coinfected and HCV monoinfected individuals using 
an overlapping set of 441 18-mer peptides spanning the entire HCV polyprotein in an 
IFN-y ELISPOT assay. Peptides were grouped in 44 sequential pools of 10 beginning 
from the amino terminus and running through the carboxy tenninus of the HCV 
polyprotein. Results are expressed in terms of pools and protein regions, with different 
numbers of peptide pools in relation to the protein size: 3 pools for core; 2 for El; 6 for 
E2; 1 for p7; 3 for NS2; 9 for NS3 ; 2 for NS4A; 3 for NS4B; 7 for NS5A; 8 for NS5B. 
Eighteen of the enrolled 22 chronic HCV infected individuals and 11 of the 12 
HIY/HCV coinfected individuals were tested. Figure 5.2 illustrates differences in the 
specificity and frequency of HCY -specific CD8+ T cell responses between groups, 
depicted as the proportion of individuals from each group responding to each individual 
peptide pool. More than 40% of the coinfected group responded to NS3 pool 18 and at 
· least 30% responded to NS3 pool 16, NS3 pool 22 and NS5B pool 44. There were no 
responses to pools 2, 10-13, 15, 17, 31 , 34, 36, 37, and 41. In the chronic HCV 
monoinfected group (Figure 5.2, panel 1 ), 40% of individuals responded to core pool 2 
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and NS3 pool 19. More than 30% responded to NS3 pool16, NS3 pool17, NS4A pool 
25 and NS5A pool 30. There were no responses to pools I 0, 36, and 38. Of note, no 
responses to pools 10 or 36 were detected in either group. 
5.4.4. Restricted breadth anti-HCV CD8+ T cell responses in HIVIHCV coinfection and 
chronic HCV infection 
Breadth is the percentage of peptide pools to which an individual responds. The 
proportion of individuals responding to at least one HCV peptide pool was similar 
between groups, as 8/11 HIV coinfected (72%) and 14/18 HCV-infected individuals 
(78%) had anti-HCV IFN-y responses. On average, the HIV coinfected group had 
responses to 11% of the peptide pools (range 0-38%) compared to 17% (range 0-64%) for 
the HCV mono infected group, suggesting a somewhat restricted breadth to the HCV-
specific CDS+ T cell responses in the HIV coinfected group. When responses were 
compared on the basis of HCV proteins (Figures 5.3a and 5.3b), there was little 
difference between HIV coinfected and HCV infected groups. In the HIV coinfected 
group, we observed responses against 9/10 proteins, however, the proportion of 
individuals with responses to any one region was generally low (<50%). The exception 
was the NS3 region, where 82% of coinfected individuals responded (Figure 5.3a, dark 
bars). Responses were detected against 1 Oil 0 proteins in the chronic HCV group (Figure 
5.3b, dark bars). As in the coinfected group, the highest proportion of individuals 
responded to NS3 (67%), with greater than 53% of individuals also responding to NS4A. 
Since the size of the protein is one factor affecting the probability of generating 
immunogenic peptides, we adjusted for the effect of protein size. After this correction 
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(grey bars of Figure 5.3b ), it was clear that one of the reasons NS3 was so dominant was 
because it is the largest region in the genome. The response breadth did not change with 
size correction but differences in proportions between groups equalized. El became the 
most frequent response on a per peptide basis in HIV coinfected group, and NS4A in the 
chronic group. 
Figure 5.4 illustrates differences in the specificity and frequency of anti-HCV 
IFN-y responses between HIV coinfected subgroups. In the HIV chronic HCV group 
(n=5), there were responses to all regions except p7 and NS2 (black bars) with responses 
most frequently against NS3 and NS5B. In the HCV serosilent group (n=2), responses 
were limited to NS3 and NS5A. The spontaneous clearers (n=2) had responses against 
all proteins except p7, with both individuals demonstrating responses against NS3. 
In summary, NS3 region T cell responses are found in all of those who 
spontaneously cleared the virus. NS5 region T cell responses were common in both 
HIV/HCV coinfection and HCV monoinfection, however NS2 and NS4A T cell 
responses were more prevalent in the monoinfected group. Responses to NS3 are most 
frequent, in part because of its large size. However, the most commonly recognized 
peptide pool for all groups is in the NS3 region, suggesting that there is a true 
immunological hotspot in NS3. 
5.4.5. High magnitude anti-HCV CDB+ T cell responses in HJVIHCV coinfection 
Magnitude is the number of IFN-y producing cells elicited by HCV peptides. The 
average magnitude of anti-HCV responses per peptide pool , as well as cumulative 
magnitude, was compared between HIV coinfected and HCV-infected group after 
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background subtraction. More IFN-y-producing cells/positive pool were observed in the 
HIV co infected group (72±22 SFC/1 06 PBMC versus 21 ±4.2 SFC/1 06 PBMC, p=0.02; 
Figure 5.5a). The cumulative magnitude of the response was significantly higher in the 
HIV coinfected group (1 050±369 SFC/1 06 PBMC versus 162±47 SFC/1 06 PBMC 
p=0.003; Figure 5.5b). 
5.4.6. HCV response vigor 
Vigor is measured in arbitrary units relative to IFN-y spot size that correlates with 
IFN production per cell. Larger spot size indicates increased IFN-y production, therefore, 
spot size was analyzed in this study as a measure of the vigor of the IFN response. Spot 
area was measured in arbitrary units, and the average IFN-y spot area per group 
detem1ined. There was no significant difference in average spot area between the HIV 
co infected group and the HCV -infected group, with large standard deviations in each 
group (Figure 5.6a). We then assessed whether spot area was associated with the 
cumulative magnitude of the response in each group. Response magnitude correlated 
with spot area in the HIV coinfected group (R2=0.42; p=0.0001) but not the HCV 
infected group (Figure 5.6b). In the coinfected group; cells from individuals with higher 
magnitude responses produce more IFN-y per cell than those with lower magnitude 
responses. 
5.4. 7. CD4+ T cell response magnitude, frequency and spec~ficity 
CD4+ T cell responses against mitogen, recall antigen and HCV viral antigens 
were assessed in all groups by standard 5 day proliferation assay. An HIV monoinfected 
group (n=75) was included to compare mitogen and recall antigen responses to those of 
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the HIV/HCV coinfected group. The average magnitude of the mitogen responses, 
shown on the right hand axis of Figure 5.7, was not significantly different between HIV-
infected and HIV/HCV coinfected groups (160±21.1 and 129±37.1, respectively). The 
HCV monoinfection group average (473±242) was higher than either HIV-infected group 
but the difference was not significant, with large high standard deviations. This suggests 
overall CD4+ T cell function in the HIV/HCV group is marginally reduced compared to 
the HCV monoinfected group. The antigen specific response magnitude measured 
against Candida antigen differed between groups in a pattern similar to the PHA 
responses (Figure 5.7). The HIV/HCV coinfected group had a somewhat lower average 
stimulation index in response to low dose recall antigen (mean±SE; l 0.9±4.6) than the 
HCV-infected group (27.5±9.4; p=0.06). The same trend was seen with the high dose 
Candida response. HCV antigen-specific responses were only seen against HCV core, 
and these were of low magnitude. 
In summary, the frequency and magnitude of CD4+ T cell responses was 
decreased in HIV/HCV coinfected individuals compared to HCV monoinfected 
individuals but similar to the HIV monoinfected group. Anti-HCV -specific respon es 
were rare, and seen only to HCV core and NS3. 
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5.5. Discussion 
HCV evades eradication by the immune system and establishes chronic infection 
in a majority of exposed individuals. In the context of HIV coinfection, HCV infection 
not only becomes chronic more frequently, but also accelerates development of liver 
disease. The role of immunity against HCV, particularly in the context of HIV 
coinfection, is not well understood, and few studies have used complete sets of HCV 
peptides to examine T cell responses in this setting. We investigated whether HIV 
coinfection affects the overall character of the cell mediated immunity against HCV by 
comparing the breadth, frequency, specificity and magnitude of anti-HCV responses in 
HCV-infected and HIV/HCV coinfected individuals with a comprehensive set ofpeptides 
spanning the entire HCV polyprotein. CD4+ T cell responses were rare in both groups, 
and CD8+ T cell response breadth was reduced in a subgroup of serosi lent coinfected 
individuals. Otherwise, the frequency, breadth and specificity of HCV-specific CD8+ T 
cell responses in the 2 groups did not differ significantly. The coinfected individuals had 
significantly stronger responses, which may amplify the immunopathogenesis of HCV in 
HIV coinfection. 
Approximately 70% of individuals in both the HCV-infected and HIV/HCV 
coinfected groups had detectable HCV-specific CD8+ T cell responses, which was a 
higher frequency than reported in some previous studies. Dutoit et al. found 
approximately 40% of individuals produced IFN-y responses (282), and Kim et al. 
described anti-HCV CD8+ T cell responses in only 50% of HIV/HCV coinfected 
individuals (252). An earlier study reported HCV -specific CD8+ T cell responses in only 
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2/32 chronically infected individuals and 0/ 11 HIV/HCV coinfected people (399). All 
groups used similar experimental conditions to this study, however, their definition of a 
positive response required a minimum 20-50 pots/106 PBMC, and greater than 3 times 
background levels. This absolute value would correspond to a frequency of 0.002% of 
PBMC, which i 100 fold less than that found in other viral infections (eg. EBV with up 
to 0.2%). On the assumption that extrahepatic CD8+ anti-HCV T cell responses are rare 
in chronic low level infection, we decided this high threshold may miss responses 
relevant to overall outcome. We chose a threshold of greater than twice background and 
an absolute minimum of 10 spots as our cutoff. If we applied th crit ria from other 
studies, responder frequency was unaffected in the HIV coinfected group, but fell from 
70% to 50% in the HCV monoinfected group. The responses of the HCY monoinfected 
individuals were broadly directed but low magnitude, and often twice, but not thr e 
times, background. Therefore, with the more exclusive criteria previously u ed, our 
coinfected group still had more frequent re ponses than previou ly reported and more 
frequent responses than the HCV monoinfected group. 
The ELISPOT method we used may underestimate CD8~ T c II responses by 
relying only on ability to produce IFN-y. Functionally cytotoxic anti-HCV CD8+ T cell 
can have a stunned phenotype and produce less IFN-y in both acute ( 411) and chronic 
(349) infection. The estimate is further limited by the use of a consensus sequence to 
generate peptides, and not endogenous sequences found in individual patients. 
As r ported previously, we found the breadth and pecificity of CD8+ T c II 
responses similar in coinfected and chronic monoinfected group (252). Before 
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correction for size, NS3 responses were most common on a per protein basis, as 
previously described by many groups. However, after con·ection for size, the hierarchy 
of response frequency in each group shifts to smaller protein regions. The subgroup of 
HIV coinfected individuals who appear to have spontaneously cleared their HCV 
infection all have responses to NS3, reinforcing suggestions that anti-NS3 responses may 
play a role in viral clearance ( 412, 413). One particular region ofNS3 (pool 18/ 19) had a 
large number of responders in each group. These pools contain amino acids 1240-1390, 
where 12 human CTL epitopes have been defined (Los Almos HCV database, 
http://hcv.lanl.gov), therefore, a high frequency of responders would be expected in this 
area. Even after the effect of size is removed, the number of epitopes defined is higher in 
NS3 region than other HCV proteins, suggesting immunological hotspots within that 
region. Maintenance of NS3 immunodominance in HIV coinfection further underscores 
the importance of this region in efforts to develop vaccine strategies. 
In contrast to previous studies (252, 282, 284), the magnitude of HCV-specific 
CD8+ T cell responses was elevated in HIV coinfection compared to chronic HCV 
infection, independent of either current or nadir CD4+ T cell count. This may 
significantly contribute to disease pathogenesis in the context of persistent infection. 
Several mechanisms have been proposed to explain the decrease in effective clearance of 
HCV despite the presence, and perhaps even higher than usual, levels of anti-HCV-
specific CD8+ T cells. These include impaired effector function (282), incomplete 
. differentiation (213), and decreased CD28-mediated costimulation in the context of HIV 
co infection ( 414). Our study indicates the number of HCV -specific CD8+ T cells is 
----------------------------- -
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higher in HIV coinfection than chronic HCV infection, but still low in absolute numbers 
compared to other chronic viral infections. This may reflect hepatic localization of HCV-
specific CD8+ T cells. 
The frequency of CD4+ T cell responses was low in both the coinfected and HCV 
chronic infection groups. Core specific responses were most frequent in the 
monoinfected group, while NS3-specific responses were more common in the HIV/HCV 
group. The magnitude of the HCV core response in the coinfected group was lower than 
that of the monoinfected group. A recent study of HCV-specific CD4+ T cells in HIV 
coinfection noted attenuated IFN-y production independent of CD4+ T cell count (407). 
In our study, proliferation of HCV-specific CD4+ T cells was not related to the absolute 
CD4+ T cell count as long as the number of PBMC/well of those individuals with <200 
CD4+ T cells was increased to control for total CD4+ T cell numbers. The proliferation 
assay reflects IL-2 production more than IFN-y production, therefore, parallel attenuation 
in each assay would not necessarily be expected based on differential cytokine production 
attributed to various T cell memory subsets. This study was cross sectional and only 
provided CD4+ T cell counts and HCV -specific CD4+ T cell reactivity at one time point 
in a disease process that spans decades. The status of CD4+ T cell responses change over 
time from acute through chronic HCV infection depending on viral replication and stage 
of liver disease, as well as the state of the host immune system as affected by concurrent 
HIV infection. The lack of CD4+ T cell responses in the periphery in the context of 
detectable CD8+ T cell responses may be a result of enhanced CD8+ T cell responses 
favored by the high CD8+ T cells counts characteristic of HIV infection, 
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compartmentalization of CD4+ T cells to the liver, subset exhaustion with constant 
antigenic stimulation, or very low frequency that is not detectable by proliferation assay. 
HIV-associated immune dysregulation affects the vigor and magnitude of the 
HCY-specific CD8+ T cell responses and also affects HCV-specific humoral responses. 
There were 3 individuals with plasma HCY RNA in the absence of detectable anti-HCV 
antibodies. These individuals had detectable but extremely narrow anti-HCV CD8+ T 
cell responses, and no detectable CD4+ T cell responses. Thus, they have a different 
profile from the other HIV/HCV coinfected individuals in terms of both humoral and 
cellular HCY-specific immunity and provide an opportunity for further study into HCV 
disease processes in a novel immunological setting. They may have a different course of 
clinical disease and need selective monitoring, while also providing a ' natural ' 
experiment to assess the viral and host factors that may impact their impaired immune 
response. 
Our studies were conducted on peripheral blood samples. The frequency of 
HCV-specific CD4+ and CD8+ T cells is many fold higher in the liver of HCY-infected 
individuals (406, 415, 416), and this also holds true in the context of HIV coinfection 
(285). HCV -specific T cell responses in the periphery differ not only quantitatively from 
liver infiltrating lymphocytes but also qualitatively. Intrahepatic T cells produce less 
IFN-y and have a phenotype consistent with T cell exhaustion (PD-1 high, CD 127'0 w) 
compared to the effector phenotype observed in periphery (PD-1 +, CD 12T) (276, 417). 
This may reflect differences in HCV antigen levels or the different characteristics of viral 
quasispecies within intra- and extra-hepatic compartments although a recent study 
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showed the same viral sequences predominate in the liver and peripherally in chronic 
HCV monoinfection (276). Therefore, responses in the peripheral blood may not directly 
relate to intrahepatic environments. 
Cells outside the liver that have been associated with autonomous HCV 
replication and infection include PBMC ( 418) and neutrophils (187), and higher levels of 
lymphoid infection have also been associated with HIV coinfection (30, 419). This 
potential for increased extrahepatic viral antigen in the context of HIV coinfection may 
by the stimulus for greater magnitude anti-HCV CD8+ T cell responses observed in our 
group. Neither treatment-associated ' cure' nor spontaneous clearance of HCV infection 
appears to truly eradicate HCV ( 125) from the extrahepatic compartment. In these cases, 
peripheral T cell responses may be good indicators not only of ongoing viral replication 
but also provide direction in developing vaccines to target quasispecies that come to 
predominate in the post-treatment era. 
We have demonstrated an increase in the magnitude of anti-HCV CD8+ T cell 
responses 111 HIV coinfection that ts consistent with accelerated hepatic 
immunopathology. This further highlights that HIV related immune dysregulation and 
immune reconstitution can lead to overly vigorous responses to some.pathogens. Further 
studies to elucidate the mechanisms of HCV persistence and disease pathogenesis in the 
context of the HIV coinfection will be necessary to fully treat individuals with residual 
infection in the IFN-a era. 
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Table 5.1. Baseline demographics and characteristics in the HIV/HCV 
coinfection and HCV monoinfection groups 
HIV/HCV Chronic HCV 
Number (n) 12 22 
Age (yrs) 40±5 47±10 
Sex(%) 
M 75 77 
F 25 23 
HCV Genotype 
(%) 
1 100 40 
Non-1 0 5 
Unknown 0 55 
HCV Risk Factor 
(%) 
IVDU 25 50 
Transfusion 17 14 
Tattoo 0 5 
Endemic area 0 14 
Unknown 58 23 
Est. duration of 
infection (yrs) 
HIV 11 ±5 N/A 
HCV Unk 26±10 
Liver enzymes 
(%) 
Nonnal 100 68 
>2ULN 1 0 27 
Unknown 0 5 
12ULN Twice the upper limit of normal 
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Table 5.2. Cohort demographics and baseline characteristics in HIV/HCV coinfected subgroups. 
Est. CD4 CD4 HIV viral Liver 
Age Anti- HCV HCV HCV risk 
duration HIV count nadir load enzymes Patient ID Sex HCV HIV/HCV or fxn (yrs) 
ab RNA genotype factors infection treatment (cells (cells (copies (AST4/ALT5 
( rs) /J.LL) /J.LL) /mL) /Alb6) 
HCV exposed, RNA negative, n=3 
HIV-0 18 33 M + IVDU 12/unk 2 Pls
1
, 1 608 92 <50 N NRTI2 
HIV-095 43 M + unk/unk 627 580 <400 N 
1 PI, 1 
HIV-150 34 M + Transfusion 16/unk NRTI, 1 644 468 <50 
NNRTI3 
Mean ±SD 36±5 626 ± 380± 18 255 
Chronic HCV infection, n=S 
HIV-042 40 M + + IVDU 14/unk 2 Pis, 2 308 70 <50 NRTis 
HIV-070 36 M IVDU 6/9 2 NRTls I 580 264 <400 + + NNRTI 
HIV-077 46 M + + Transfusion 18/4 2 NRTls 660 81 4600 
HIV-087 38 M + + IVDU 18/unk 
2 NRTis, I 360 162 3000 N NNRTI 
.j>. 
\0 
Table 5.2. (con't) 
Est. CD4 HIV Liver 
Anti- duration coun viral enzymes 
Patient ill Age Sex HCV HCV HCV HCV risk HIVIHCV HIV t CD4 nadir load or fxn (yrs) 
ab RNA genotype factors infection treatment (cell (cells I!J.L) (copie (ASTIALTI 
(yrs) s s lmL) Alb) I L 
HIV-167 44 F + + unk/unk 264 N 
Mean±SD 40±4 477± 168±94 169 
Serosilent chronic HCV infection, n=4 
HIV-096 40 F + 121unk 2 NRTis 780 442 <50 N 
HIV-105 41 M + 61unk None 608 490 130,00 N 0 
HIV-119 41 M + Slunk 2 Pis, 2 736 229 <50 N NRTis 
HIV-153 51 F + 41unk 3 NRTis 400 198 <400 N 
Mean ±SD 43±5 633± 340± 147 170 
Overall 573 ± 12640 
40±5 75% M 11±5.5/unk 278±175 ± Mean ±SD 152 38952 
'PI-protease inhibitor 2NRTI-Nucleoside reverse transcriptase inhibitors 3 NNRTI-Non-nucleoside reverse transcriptase inhibitors 4AST-Aspartate 
aminotransferase 5 AL T-Alanine aminotranferase 6 Alb-Albumin 
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Figure 5.1. Comparison of immunological parameters in HIV-infected and 
HIV/HCV coinfected study groups. (a) CD4+ and CD8+ T cell . counts, B cell counts 
and HIV plasma virus loads (right sided axis) are shown for the peripheral blood 
sampling date. The CD4+ T cell nadir was the lowest CD4+ T cell count documented at 
any time in clinical records. Vertical bars represent the mean value for each parameter 
compared between study groups with error bars showing standard error of the mean. (b) 
B cell counts are shown for each HCV seropositive and seronegative HCV-exposed, HIV 
coinfected individual with h01izontal bars denoting the mean B cell count for each group. 
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Figure 5.2. Distribution of HCV-specific CDS+ T cell responses in HCV and HIV/HCV coinfected study groups. 
Peripheral blood mononuclear cells were incubated with pools of ten overlapping 18-mer HCV peptides for 18 hours and IFN-
y producing cells enumerated by ELISPOT. The percentage of each group responding to individual pools is indicated bars 
above pool number and the average response rate indicated by the final bar. Pools corresponding to each protein region are 
distinguished by different hatching. 
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Figure 5.3. Distribution of HCV-specific CDS+ T cell r esponses by region in HCV and H IV/HCV coinfected study 
groups. Peripheral blood mononuclear cells were incubated with pools of ten overlapping 18-mer HCV peptides for 18 hours 
and IFN-y producing cells enumerated by ELISPOT. (a) The percentage of HIV/HCV coinfected individuals responding to 
peptides from each HCV protein are shown in black bars with grey bars showing percentages adjusted for protein size (number 
of peptide pools/region). (b) The percentage of HCV monoinfected individuals responding to peptides from each HCV protein 
are shown in black bars with grey bars showing percentages adjusted for protein size by dividing each proportion by the 
relative number of pools represented by each protein region. 
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Figure 5.4. Distribution of HCV-specific CDS+ T cell responses in HIV/HCV 
coinfected subgroups. HIV-infected, HCV-exposed individuals were divided into 
chronic HCV infection (top left panel), chronically infected but HCV seronegative 
(serosilent, bottom panel), and HCV eropo itive but HCV RNA negative (top right 
panel). The p rcentage of individuals in each group with positive re ponses against each 
protein region is shown by black bar . 
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Figure 5.5. Comparison of pool-specific and cumulative magnitude of HCV-specific CDS+ T cell responses in HIV/HCV 
coinfected and HCV-infected individuals. Peripheral blood mononuclear cells were incubated with pools of ten overlapping 
18-mer HCV peptides for 18 hours and IFN-y producing cells enumerated by ELISPOT. (a) Grey bars indicate the mean 
number of IFN-y producing cells responding to each positive pool in HIV/HCV coinfected and HCV-infected groups with 
standard error of the mean shown. (b) Grey bars indicate the mean cumulative number of IFN-y producing cells responding to 
the entire set ofHCV peptides in HIV/HCV coinfected and HCV-infected group. 
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Figure 5.6. Relationship between IFN-y spot size and cumulative magnitude of the HCV-specific CD8+ T cell response. 
Peripheral blood mononuclear cells were incubated with pools of ten overlapping 18-mer HCV peptides for 18 hours and IF -
y producing cells enumerated by ELISPOT. The magnitude of the IFN-y response was plotted against mean spot size for the 
HIV/HCV coinfected (a) and HCV-infected (b) groups and correlation assessed by linear regression. 
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Figure 5.7. HCV-specific CD4+ T cell responses to mitogen, recall antigen, and HCV 
proteins. Peripheral blood mononuclear cells were incubated in triplicate for 5 days with 
phytohemagglutinin, Candida albicans antigen or HCV proteins and proliferation 
measured by 3H thymidine uptake. Responses were reported as stimulation indices 
calculated as the ratio of 3H counts in test wells divided by background 3H incorporation. 
Each bar shows the average for each group (SE). * - statistically significant differences 
between groups. 
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6.1. Abstract 
Hepatitis C virus (HCV) is a common infection with approximately 170 million 
individuals infected worldwide. Most exposed individuals develop chronic infection and 
even with the newest antiviral therapies, only 50-75% of treated individuals sustain 
virologic responses. The role of adaptive immunity, particularly cell-mediated immunity, 
is well established in other viral infections, but is unclear in HCV infection. This makes 
design and development of prophylactic and therapeutic vaccine strategies difficult. We 
compared the character (breadth, specificity, vigor, and magnitude) of anti-HCV T cell 
respon es in four groups of HCV exposed individuals: 18 chronically HCV-infected 
(HCV antibodies and HCV RNA); 5 pontaneous clearers (HCV antibodies, no H V 
RNA); 16 sustained virologic responders (HCV antibodies, no HCV RNA post 
treatment); and 5 non-responders (HCV antibodies and HCV RNA post treatment). 
Interferon-gamma (IFN-y) ELISPOT revealed relatively low number of HCV- pecific 
CD8+ T cells in peripheral blood, especially in the non-responders. Anti-HCV CD4+ T 
cell responses, measured by 3H-thymidine proliferation, were rare, weak, and restricted to 
HCV core in all groups. The overall character of the anti-HCV CD8+ T cell response was 
strongest in virus clearers and weak t in those who failed treatment. However, 
individual components of character differed between spontaneou clearers and treated 
responders. The character of the anti-HCY T cell respon differ between chronic 
infection and clearance and also between spontaneous and treatment-associated HCV 
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clearance. Therefore, therapeutic and prophylactic vaccine strategies may need to engage 
different characteristics of cell-mediated immunity against HCY. 
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6.2. Introduction 
Hepatitis C virus is a global health problem, with over 170 million chronically 
infected people worldwide. The often insidious nature of early HCV infection and the 
high rate of chronic infection results in a large percentage of infected individuals who are 
unaware of their status. Approximately 80% of exposed individuals develop chronic 
infection, with detectable antibodies against HCV and detectable HCV RNA. The other 
20%, termed spontaneous clearers, have anti-HCV antibodies, but no detectable serum 
HCV RNA. Standard of care treatment for chronic HCV infection is 24-48 weeks of 
pegylated interferon-alpha (PEG-IFN-a) and ribavirin. Depending on the HCV genotype 
they carry, between 50% and 75% of treated individuals have sustained virologic 
responses, meaning they are HCV RNA negative at treatment weeks 24 and 48 and 
remain so afterwards. Thus, the natural history of HCV infection and different treatment 
outcomes create four distinct groups of HCV exposed individuals: those who clear the 
virus spontaneously; those who develop chronic HCV infection; those who clear the virus 
with treatment, and treated individuals who fail to clear the virus. 
Cell-mediated immunity is integral to clearance of viral infections. Not only is 
activation and expansion of virus-specific CD4+ and CD8+ T cell responses important, but 
the overall character of the cell-mediated response illso appears key to the outcome of 
infection. People who spontaneously clear HCV have robust, broadly directed HCV-
specific CD8+ and CD4+ T cell responses (199, 229, 347), while highly attenuated CD4+ 
and CD8+ T cell responses develop in chronic infection (198, 216, 411 , 420). Several 
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studies have shown augmentation of CD4+ and CDS+ T cell responses during successful 
HCV treatment with IFN-a and ribavirin (351 , 421, 422); however, reciprocal 
interactions between pharmacological and immunological suppression of HCV within the 
setting of successful treatment remain unclear. 
Chronic HCV infection leads to significant morbidity and mortality, therefore, a 
prophylactic vaccine and more efficient immunotherapy would be highly beneficial. 
Since CD4+ and CD8+ T cell responses are associated with viral clearance, and may be 
augmented during immunostimulatory treatment with IFN-a, further delineation of the 
role HCV -specific T cell responses play in spontaneous and treatment-induced HCV 
clearance is required. 
Most previous studies used individual peptides for assessing HCV -specific CD8+ 
T cell responses and did not directly compare the character of anti-HCV CD8+ T cell 
immune responses in spontaneous versus treatment-induced clearance. We used sets of 
peptides spanning the entire HCV polyprotein to assess HCV-specific T cell response 
character as a composite of four features: breadth, specificity, magnitude, and vigor. We 
then compared the composite character of anti-HCV CD8+ T cell responses in HCV 
persistence, treatment-induced clearance and spontaneous clearance. The composite 
character of the CD8+ T cell responses was stronger in the two groups that cleared the 
virus, but different components of character predominated in each group. 
6.3. Materials and Methods 
6.3.1. Study participants 
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HCV -infected individuals were recruited from the Capital Health Queen 
Elizabeth Hospital Hepatitis Clinic in Halifax, NS, Canada. Ethics approval for this 
project was obtained from the Human Investigation Committee at the institution and all 
subjects provided written informed consent for blood collection and immunological 
studies. Liver enzymes (AST and ALT) as well as liver function tests (INR, total 
bilirubin and albumin) were obtained on the same day as PBMC were collected for the 
study. Elevated AST and ALT is indicative of hepatic inflammation, while increased 
INR and total bilirubin or decreased albumin is suggestive of impaired hepatic function. 
6. 3. 2. identification of HCV infection 
HCV exposure was determined using second or third generation EIA assays from 
Ortho Diagnostics to detect serum anti-HCV antibodies. HCV RNA viral load testing 
was performed using the Cobra Amplicor HCV Monitor v2.0 system (Roche Diagnostics, 
Laval, QC, Canada). 
6.3.3. PBMC isolation 
Acid citrate dextrose (ACD) treated whole blood was obtained by venipuncture 
from each individual and peripheral blood mononuclear cells (PBMC) isolated by Ficoll-
HyPaque Plus (GE Health Care, Baie d 'Urfe, PQ, CA) density gradient centrifugation. 
Cells were washed, counted, and frozen at -80°C until use. Samples with less than 50% 
viability when thawed were discarded. 
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6.3.4. Peptide preparation 
A set of 18-mer peptides spanning the entire HCV genotype 1 a polyprotein was 
obtained from the NIH AIDS Research and Reference Reagent Program. A total of 441 
peptides overlapping by 11 amino acids were reconstituted in 80-100% sterile 
dimethylsulphoxide (DMSO), diluted to 200 !J.g/mL in lymphocyte medium, and then 
pooled together in groups of I 0 consecutive peptides at a concentration of 20 
!J.g/mL/peptide. Peptides were stored at -80°C until use, and added to cells at a final 
individual concentration of 10 ~Lg/mL. Control wells contained 0.5% DMSO. The 
composition of each peptide pool is detailed in Appendix A. 
6.3.5. ELISPOT for JFN-yproduction 
The number of IFN-y producing cells in PBMC was determined by ELISPOT. 
Flat bottom polyvinylidene difluoride (PVDF)-coated 96-well plates (Millipore, Bedford, 
MA) were prewet with I 00 !J.L 70% ethanol/well (Sigma Chemical Co.), washed with 
PBS, and coated either overnight at 4°C or for one hour at 37°C with 1.5 !J.g/well anti-
IFN-y antibody (clone lDIK, Mabtech, Stockholm, Sweden) in PBS. Plates were washed 
five times with PBS and l.0-2.0x105 intact or CD4+ T cell depleted PBMC were added to 
each well in duplicate. Peptide pools were added to each test well, and 2 !J.g/mL PHA or 
I 00 IFN-y positive C1 0/MJ cells (NIH AIDS Research and Reference Reagent Program, 
Popovic et al. (408)) served as a positive controls. Plates were incubated at 37°C, 5% 
C02 for 16 hours, washed with PBS, and incubated for 2 hours with 0.1 !J.g/well of 
biotinylated anti-IFN-y antibody (clone 7-B6-1, Mabtech). Plates were washed, and 100 
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11L of a 1:1000 dilution of streptavidin-alkaline phosphatase (Mabtech) was added for 1 
hour. After washing, 100 11L freshly prepared 3 mg/mL nitro blue tetrazolium chloride 
(NBT)/1.5 mg/mL 5-bromo-4-chloro-3-indolyl phosphate-p-toluidine (BCIP) substrate 
(BioRad, Hercules, CA) in Tris buffer (pH 9.5) was added to each well for approximately 
20 minutes. Plates were washed with distilled water to stop the color reaction and air-
dried overnight before spot enumeration using the high resolution Zeiss reader system and 
associated KS software (Carl Zeiss Canada, Ontario, Canada). The number of IFN-y 
producing cells per 106 PBMC was determined by multiplying the average number 
spots/duplicate well x 10 or x 5, depending if I x 105 or 2x 105 cells were used. A peptide 
pool response was considered positive if the number of spots was greater than or equal to 
10 spots and twice the background count. CD4+ T cell depletion done with two samples 
produced no difference in the number of peptide-induced IFN-/ spots (data not shown). 
As each spot represents one cell, the area of the spot is related to IFN-y production per 
cell ( 409, 41 0). Average spot area in arbitrary units was used as a relative measure of 
JFN-y production per cell. 
We assessed anti-HCV CD8+ T cell response character using four components: 
breadth, specificity, magnitude, and vigor. Breadth is the percentage of peptide pools to 
which an individual has a positive response. An individual peptide pool or HCV protein 
region was considered as a positive contributor to specificity if greater than 50% of 
individuals in the group had positive responses to that individual pool or within that HCV 
protein region. Vigor was measured in arbitrary units related to IFN-y spot size that 
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correlate with lFN-y production, and magnitude was the number oflFN-y producing cells 
elicited by HCV peptides, per individual pool and cumulatively for the 44 pools. These 
factors were graded relative to the other groups, and the sum total used as a semi-
quantitative assessment of anti-HCV T cell character. 
6. 3. 6. Prol~feration assays 
CD4+ T cell immune responses were measured by standard 5 day 3H thymidine 
incorporation assays. PBMC were washed twice with proliferation medium (lymphocyte 
medium with 10% human AB serum (Atlanta Biologicals, lot number M0102) substituted 
for FBS) and 1xl05 cells/well were incubated in triplicate with either plain medium, 5 
f!g/mL phytohemagglutinin (ICN Biomedicals Inc., Costa Mesa, CA), 2.5 or 5 f!g/mL 
Candida albicans (Greer Laboratories Inc., Lenoir, NC), or 2 ~tg/mL HCV core, NS3, or 
NS4 (all from Virogen) for 5 days. One ~tCi 3H thymidine (Perkin Elmer Life Sciences, 
Boston, MA) was added to each well on day 4, and the assay was harvested onto glass 
fiber filter mats 18 hours later using a semi-automated harvester (Tomtec Harvester 96 
Mach M Ill, Hamden, CT). incorporated 3H-thymidine was measured by a 96 well 
scintillation counter (TopCount, Packard, M eriden, CT). Stimulation indices were 
calculated as follows: 
Stimulation Index = cpmantigcn 
cpmbackground 
-------------------------------------------------
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6.3. 7. Statistical analyses 
All statistical analyses were performed using SPSS version 9 (SPSS Inc., Chicago, IL). 
Means were compared using either the Mann-Whitney U test or Student' s t-test. All 
graphs indicate average values, and error bars represent standard error of the mean. 
Pearson's correlation coefficients were used to assess relationships between independent 
continuous variables for linear regression. 
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6.4. Results 
6. 4.1. Study participants 
Eighteen individuals were chronically HCV-infected, 5 were spontaneous clearers, 
and 22 were treated for HCV infection (Table 6.1 ). Seventeen of the treated 22 had 
sustained virologic responses while 5 did not have a virologic response. All individuals 
in each group were assessed for HCV-specific cell-mediated immunity, except for 
sustained virologic responders where only 16117 were available for assessment. Age and 
gender distribution were similar in the 5 groups, except for the spontaneous clearers, of 
whom four of five were female. All other groups were predominantly male. Similar 
proportions of individuals in the treated groups received each type of therapy. Forty-one 
percent of treated responders and 40% of the treated non-responders received PEG-IFN-a 
and ribavirin while 53% of the responders and 60% of the non-responders were treated 
with IFN-a and ribavirin. Risk factors for HCV infection were unknown for the majority 
of individuals. in all groups; however, intravenous drug use (IVDU), blood product 
transfusion and organ transplant were the predominant risk factors identified in all 
groups. HCV viral load testing was done in treated individuals to monitor response to 
therapy, but only some of these results (8/ 17 treatment responders and 3/5 non-
responders) were available. The vanance was large and there was no significant 
difference in baseline HCV viral loads. Estimated duration of HCV infection was similar 
in all groups (mid-20 year range). 
--~-~---------------------------------- --- ---------
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The majority of individuals in all except the treated non-responder group had 
normal liver enzymes on the sampling date. Two of five treated non-responders (40%) 
had abnonnally elevated liver enzymes compared with 6% of treated responders and 27% 
of the chronic HCV group. Average AST and ALT levels were above normal limits in 
the chronically infected and the treated non-responder group. INR was nonnal in all 
groups, however albumin was decreased in the treated non-responder group. Overall, the 
treated non-responders had more liver enzyme elevation and decreased albumin, 
suggesting worse liver function . Available liver biopsy data indicated that the average 
stage and grade of liver pathology was similar in the treated non-responder and treated 
responder groups (data not shown). 
6. 4. 2. Breadth o.f HCV-specific CD8+ T cell responses 
We assessed the breadth of HCV-specific CD8+ T cell responses in PBMC from 
HCV exposed individuals using 44 pools of 10 overlapping 18-mer peptides spanning the 
entire HCV polyprotein in an IFN-y ELISPOT assay. Results are expressed in terms of 
protein regions, which have different numbers of corresponding peptide pools depending 
on the protein size: 3 pools for core; 2 for El; 6 for E2; 1 for p7; 3 for NS2; 9 for NS3; 2 
for NS4A; 3 for NS4B; 7 for NS5A; 8 for NS5B. 
The proportion of individuals responding to HCV peptides was not significantly 
different between groups. Only 14/18 (78%) chronic HCV individuals had HCV peptide-
specific IFN-y responses compared to 15116 (94%) treated responders, 5/5 (1 00%) treated 
non-responders, and 5/5 (1 00%) spontaneous clearers. We compared the breadth of 
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HCV -specific responses by calculating the average percentage of positive pools in each of 
the 4 groups (Figure 6.1 ). There was no statistically significant difference between the 
groups, however, there was a trend toward broader responses in the spontaneous clearer 
(n=5; 26%±7.23%) and treated responder groups (n= 16; 21.5%±4.2%). The chronically 
infected individuals had more restricted responses (n=5; 18%±4.57), while treated non-
responders had very restricted responses (n=5; 8.6o/o±2.97%). The difference between 
spontaneous clearer and treated non-responder groups approached statistical significance 
(t=2.22, p=0.0567). All spontaneous clearers had responses against one or more of the 9 
peptide pools spanning NS3 . At the opposite end of the spectrum, peptide pools from p7 
were rarely recognized by CD8+ T cells from any group. A hierarchy of response breadth 
was apparent, with broader HCV-specific responses associated with HCV clearance and 
the narrowest responses occurring in treated non-responders (Table 6.2). 
6.4.3. HCV peptide pool and region specificity o.fCD8+ T cell responses 
Figure 6.2 illustrates differences in the specificity of the CD8+ T cell response 
between groups at both the individual HCV peptide pool and HCV region levels. 
Regions and pools with greater than fifty percent responsive individuals were considered 
positive. Core, E I and E2 are the 3 structural HCV proteins. All groups had responses to 
core and E2, however, neither the spontaneous clearers nor non-responders had detectable 
El - specific responses (Figure 6.2a). All five non-structural proteins elicited responses 
from all groups except for NS4A, with no observed reactivity from non-responders. p7 is 
a small protein with unknown function against which only a small proportion (<20%) of 
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individuals in the chronic infection and treated responder groups reacted. All spontaneous 
clearers responded against at least one NS3 pool and the majority of spontaneous clearers 
also responded to 4 other regions (core, NS4B NS5A and NS5B). Treated responders had 
frequent responses to 3 regions (core, NS3 , and NS5A). Chronically infected individuals 
responded to 2 regions, NS3 and NS4A. Responses against the NS2 region were most 
common in treated non-responders, though no regions met the positivity criterion. 
To compare fine specificity between groups, we compared the frequency of 
responses to individual peptide pools. Those with greater than 50% of the individuals 
responding were considered positive (Figure 6.2b ). Spontaneous clearers had frequent 
responses to 7 peptide pools overall : core pool 3; NS3 pools 16, 19, 20 and 22; NS4B 
pool 29; and NS5A pool 31. Treated responders had frequent responses to 1 peptide pool 
overall: NS5A pool 30. In the chronically infected and treated non-responder groups, no 
individual pools were positive in greater than 50% of individuals. In summary, NS3 
responses were found in all who spontaneously cleared the virus (Table 6.2), and 
responses against pool 18119 were particularly common among those who cleared the 
virus. Similar regions are frequently recognized among those who clear HCV, either 
through treatment or spontaneously. Treated non-responders lacked core and NS5 
responses relative to the groups with spontaneous or treatment-induced HCV clearance. 
6.4.4. HCV-spec(fzc CD8+ T cell response magnitude 
The average magnitude of CD8+ T cell responses per peptide pool, as well as the 
cumulative magnitude, was calculated from ELISPOT results. Background was 
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subtracted from the responses seen to individual peptide pools and results for the 
magnitude presented as spots per 106 PBMC (Figure 6.3a). The magnitude of the average 
response per pool was not significantly different between the chronically infected HCV, 
spontaneous clearer, treated responder and treated non-responder groups (average±SE; 
21±4.2, 23±3.1, 32±11, and 27±6.5 respectively). All responses were weak, with a mean 
of less than 50 antigen specific cells in most cases. There was a trend toward higher 
magnitude responses for a given pool in the treated responder group. 
The cumulative magnitude of the CD8+ HCV-specific T cell response was also 
examined (Figure 6.3b). A similar trend was seen as per pool. Cumulative responses 
were highest in the treated responder group, followed by spontaneous clearers and the 
chronic HCV group (average ± SE; 441±281, 250±77 and 162±47, respectively). 
Cumulative magnitude was least in the treated non-responders group (60±13), but not 
significantly so. Some individuals were tested with only a subgroup of peptide pools due 
to limited PBMC numbers, and in those cases pools that had been shown to have frequent 
responses were used. The magnitude of the anti-HCV CD8+ T cell response to any given 
pool was low regardless of whether there was ongoing chronic infection or not (Table 
6.2). The cumulative magnitude trends toward being least in the treated non-responders, 
and successively higher in the chronic infection, spontaneous clearer and treated 
responder groups respectively. 
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6.4.5. HCV-specific CD8+ T cell response vigor 
Larger spot size in the TFN-y ELISPOT indicates more IFN-y production, 
therefore, spot size was analyzed in this study as a measure of response vigor. Spot area 
was measured in arbitrary units, and the average spot area per group calculated (Figure 
6.4a). Average spot area was greatest in the treated responder group ( 4126±211 ), and the 
range of values in this group was noticeably higher than in other groups. Maximum spot 
areas in the other 3 groups never exceeded 8000 while maximum values in the treated 
responders groups reached 12000 (Figure 6.4b ). Although the treated responders trended 
toward a more vigorous response, there were no significant differences between the mean 
IFN-y spot areas of the different groups overall. We also tested for associations between 
IFN-y spot area and response magnitude in each group (Figure 6.4b ). Average area per 
spot ranged from 1730 to 3980 in treated non-responders, 1451 to 7531 in chronically 
infected, 1805 to 11926 in treated responders, and 1787 to 5213 in the spontaneous 
clearers. There was more variance in spot area in the lower magnitude responses, with 
some of the largest spot areas associated with low magnitude responses. Anti-HCV CD8+ 
T cell response vigor in terms of JFN-y production/responding cell was not associated 
with overall response magnitude in any group. Our results indicate that even in low 
cumulative magnitude responses, IFN-y production/HCV-specific CD8+ T cell is not 
compromised. Table 6.2 summarizes the relationship between the groups with respect to 
VIgor. 
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6. 4. 6. CD4+ T cell responses 
CD4+ T cell responses against mitogen (PHA), recall antigen (C. albicans) and 
HCV viral antigens (core, NS3 and NS4) were assessed by standard 5 day proliferation 
assay. The frequency of CD4+ T cell responses to each form of stimulation was 
determined in all groups except treated non-responders, and presented as the percentage 
of individuals with stimulation indices >3 (Figure 6.5a). Almost all individuals had PHA 
and recall antigen responses. However, only core protein stimulated HCV -specific 
proliferative responses, and the frequency was low in all groups. One of the two 
spontaneous clearers responded (light grey bars, 50%), compared to three of eight treated 
responders (dark grey bars, 38%) and 3 of 12 chronically infected individuals (black bars, 
25%). The mean stimulation indices for responses to mitogen, and specific antigen for 
each group are shown in Figure 6.5b. Mitogen-induced proliferation did not differ 
significantly between groups. Responses against Candida were lower in spontaneous 
clearers (average±SE; 4.75±0.25) than in the chronically infected group (27.5±9.4). 
Core-specific responses were marginal for all groups tested (range of 3.5-5.5), compared 
with the vigorous recall antigen (range 4-41) and mitogen (range 373-641) responses. 
Mean HCV core-specific stimulation indices were not significantly different between the 
chronic HCV, spontaneous clearer, and treated responder groups (mean±SE; 3.5± 1.5, 
5.5±3.5, and 4.1±1.8, respectively). In general, HCV-specific CD4+ T cell responses 
were rare, weak and detectable only against core. The relative magnitude of the 
responses did not differ significantly between groups (Table 6.2). 
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6.4. 7. Overall T cell response character 
Table 6.2 summarizes HCV -specific CD4+ and CD8+ T cell response 
characteristics in the four groups tested, and semi-quantitatively compares the character 
of the groups. CD4+ T cell responses were not assessed in the treated non-responder 
group, therefore, overall character was assessed both with and without CD4+ T cell 
responses to allow comparison across all groups. The character of HCV-specific T cell 
responses was strongest in the treated responder and spontaneous clearance groups (14+ 
and 13+ cumulatively) and least in the treated non-responder group (4+). 
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6.5. Discussion 
HCV is a prevalent cause of liver disease and is associated with high rates of 
morbidity and mortality. It is rarely cleared by the immune system, and even the newest 
therapies remain ineffective for many chronically infected individuals. While it appears 
clear that cell-mediated immunity is important to viral clearance and control in other 
infections, its role in HCV infection is not well defined. Cases of spontaneous and 
treatment-induced viral clearance offer an opportunity to examine different roles and 
differential evolution of HCV-specific CD4+ and CD8+ T cell responses in these distinct 
settings. In this paper, we compared the character of the HCV -specific T cell immune 
responses in individuals who spontaneously cleared the virus, treatment responder , 
treatment non-responders, and untreated individuals with chronic HCV infection. The 
strength of individual anti-HCV CD8+ T cell features used to assess character (breadth, 
specificity, magnitude, vigor) differed between persistent and resolved infection, as well 
as between HCV -negative groups that cleared the virus. However, the overall strength 
was greater in the HCV RNA negative groups than the HCV RNA positive groups. 
Spontaneous clearance of acute HCV infection is associated with broadly directed, 
high magnitude HCV-specific CD8+ T cells responses (224, 229). Although CD8+ T cell 
responses are stronger and more frequent shortly after viral clearance than years later, 
they remain detectable by ELISPOT (423) at an average frequency of 0.15% of 
circulating CD8+ T cells even in those with resolved infection. In the case of treatment 
associated viral clearance in acute and chronic infection, the kinetics of CD8+ T cell 
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responses vary between studies. Some studies report augmentation of peripheral CD8+ T 
cell responses (290, 351) while other studies describe a rapid decline in HCV-specific 
CD8+ T cells after treatment response (350, 424, 425). Our results support higher 
magnitude CD8+ T cell responses after successful treatment than in chronic infection. 
Treated responders are likely immunologically different than spontaneous clearers, as 
they are unable to clear HCV without IFN and ribavirin therapy. It may be that treated 
responders have relatively weak pre-treatment CD8+ T cell responses that are boosted 
indirectly by IFN-a treatment. It is also possible that these individuals benefit from the 
direct viral suppression of phannacologic HCV treatment, and reduced viral antigenemia 
allows otherwise ' stunned' HCV-specific cells to respond. 
We utilized spot area as a measure of IFN-y secretion per reactive cell to estimate 
response vigor. Vigor was greatest in treated responders and appeared somewhat blunted 
in spontaneous clearers. At the individual cell level, IFN-y response magnitude may not 
be critical for clearance, but may more closely reflect recent viremia, as vigor is higher in 
chronically infected patients. Also contributing may be that CD8+ T cells observed in the 
longstanding spontaneous clearers are central memory cells, which produce less JFN-y 
than the effector memory cells more likely found in those with ongoing infection. This 
also suggests that persistent infection is not just a product of impaired IFN-y production 
by HCV -specific cells, but also involves other defects in the cellular response, as detailed 
by other groups (347, 411). 
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Overall, the HCV-specific CD8+ T cell response was greatest in those clearing the 
virus, but herein, breadth was the distinguishing feature in spontaneous clearers, while 
magnitude and vigor were the distinguishing features in treated responders. Our results 
suggest that in varied settings, different aspects of the immune response can be of 
selective value towards HCV clearance and the overall character of the response, as 
opposed to any of just magnitude, breadth, specificity or vigor alone is key. For example, 
a CD8+ T cell response diminished in one component (breadth, specificity, magnitude or 
vigor) may effectively clear the virus if other components compensate. The T cell 
response overall was strongest in the groups that were HCV RNA negative, reinforcing 
the perceived role for HCV -specific CD8+ T cells in viral clearance. 
We also examined CD4+ T cell responses in the different groups, as these are 
important components of immunity and aid in the development of effective CD8+ T cell 
responses. Previous studies compared the character of CD4+ T cell responses in acute 
infection before viral clearance, with the CD4+ T cell character observed in chronic HCV 
infection. Responses to NS3 were associated with clearance in one study (413), while 
core responses were more frequent in another ( 426). These studies used recombinant 
HCY proteins and proliferation assays similar to ours to assess CD4+ T cell responses. 
However, they observed a higher frequency, magnitude and breadth of responses in 
spontaneous clearers than we did (stimulation indices of 14 and 20 compared to 3 and 4 in 
our study). Results for the chronic group were similar to ours with respect to magnitude, 
but not specificity. 
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Another group used a combination of proliferation assays, ex vivo intracellular 
IFN-y staining, and bulk in vitro stimulation to examine CD4+ T cell responses in 
spontaneously resolved infection (348). The three spontaneous clearers in this study had 
cleared HCV relatively recently (between 7 months and 2.5 years), and a 5-fold higher 
recombinant HCV protein concentration was used for proliferation assays than in our 
study. They observed broad reactivity against all HCV regions, with stimulation indices 
frequently greater than 20 and as high as 120. This is in stark contrast to our findings of 
limited specificity and magnitude CD4+ T cell responses, even in spontaneous resolution. 
This may relate to the duration since viral clearance and to the very high HCV protein 
concentrations used. The mean time since HCV infection in our study was greater than 
20 years in each group, significantly longer than most other studies. Not all studies 
publish estimates of the time of infection or of probable spontaneous clearance, and 
therefore, it is difficult to estimate how different our cohort is in this regard. The low 
numbers of spontaneous clearers available for comparison may also be an issue. One 
study of HCV-exposed health care workers that followed HCY-specific proliferative 
responses over the course of acute infection and resolution (200) found that CD4+ T cell 
responses peaked 12 weeks after exposure and decreased to <25% of maximum by 27 
weeks (only 4 weeks post clearance). Another study followed 2 individuals with the 
same known exposure and either spontaneous or treatment-induced HCY clearance (427). 
The person with spontaneous clearance had. broad, but low magnitude CD4+ T cell 
responses extending to 24 months, while low magnitude CD4+ T cell responses in the 
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treated responder were only detected after treatment. Other viral infections, such as the 
highly infonnative and influential lymphocytic choriomeningitis virus (LCMV) model, 
have documented declining CD4+ T cell memory over time (428), which may reflect the 
situation after viral clearance in HCV infection as well. 
Treatment with IFN-a and ribavirin appears to augment HCV-specific CD4+ T 
cell responses measured by either proliferation (421) or IFN-y production (351). One 
study compared treatment-associated clearance with spontaneous clearance prospectively 
by proliferation and ELISPOT assay (429). PEG-IFN-a plus ribavirin treatment was 
associated with increased breadth, frequency and magnitude of HCV -specific CD4+ T cell 
responses compared to those chronically infected, but the character of the response was 
similar to spontaneous clearers. The subjects in this study had an unusually high 
treatment response rate, probably reflecting a preponderance of HCV genotype 4, while 
HCV genotype 1 is most common among our study subjects. The absolute magnitude of 
the CD4+ T cell response was higher in our spontaneous clearance group, and lower in the 
treated responders group, even though some of the individuals were just finishing 
treatment and likely at the peak of the CD4+ T cell response according to published CD4+ 
T cell response kinetics (429). Even at their maximum, the responses we observed were 
lower in magnitude and breadth, suggesting that in cleared infection, regardless of the 
route, HCV-specific CD4+ T cell responses do not have to be maintained at readily 
detectable levels in peripheral circulation for continued viral suppression. 
..--- -----------------------------------------
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There are certain limitations to this study. While comprehensive in that we 
examined peptides spanning the entire HCV polyprotein, we used peripheral cells only, 
and it is clear that intrahepatic T cell responses may differ in magnitude and specificity 
( 415, 416). Even so, we would expect differences between groups to be maintained in the 
periphery. Also, our peptides were derived from HCV genotype la consensus sequence 
and although most of our individuals were identified as HCV genotype 1, it is possible 
that autologous sequences were different enough that we missed some immunologically 
significant T cell responses. This would be most likely in non-genotype 1 a individuals or 
those who are chronically infected and have high virus loads where ongoing viral 
replication and speciation are common. Duration since clearance is also significantly 
different between the spontaneous and treated clearer groups in our study. Therefore, the 
magnitude of the response may be relatively reduced in the spontaneous clearer group just 
because of greater degeneration time. It will be interesting to compare the evolution of 
immune responses in spontaneous clearers with those of treatment-induced clearers from 
an equivalent starting point over the course of years. 
Chimpanzee studies have demonstrated the importance of CD8+ T cell responses 
in HCV infection ( 400), and a recent T cell directed vaccine trial in chimpanzees linked 
viral clearance after challenge with robust T cell responses (430). When designing 
vaccines, research often focuses on a few highly immunogenic target regions. Our results 
suggest that there may be other ways to promote viral clearance in HCV infection. 
Although overall magnitude and NS3 reactivity appear most important, the general 
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character of the response may hold the key to clearance. We found qualitative and 
quantitative differences in the character of HCV -specific CD8+ T cell responses in 
comparing individuals who effectively cleared the virus by two different mechanisms. 
This raises the possibility of multiple effective ways to augment HCV-specific T cell 
responses. HCV mutates rapidly and as such, fine specificity-based vaccines may have 
limited applicability. Our data suggest that the individual epitopes targeted may be less 
important than a strong overall CD8+ T cell response, and that there may be multiple 
ways to effectively produce a sterilizing immune response. 
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Table 6.1. Baseline clinical parameters 
Chronic HCV HCV Exposed, RNA HCV Tx responders HCVTx Neg non-res~onders 
Number (n) 18 5 17 5 
Age (yrs) 47±10 49±11 49±7.5 48±3 
Sex(%) 
M 77 20 53 80 
F 23 80 47 20 
HCV Genotype 
(%) 
1 40 0 59 60 
Non-1 5 0 6 0 
Unknown 55 100 35 40 
HCV Risk Factor 
(%) 
IVDU 50 40 52 20 
Transfusion 14 40 29 20 
Tattoo 5 0 0 20 
Endemic area 14 0 0 20 
Unknown 23 20 23 40 
Est. duration of 
infection (yrs) 
HCV 26±10 24±6 24±8.5 D 
-00 
.p. 
Table 6.1. (con't) 
HCV Treatment 
(%) 
IFN-a 
IFN-a. + Ribavirin 
PEG-IFNa. + Ribavirin 
HCV baseline 
viral load 
(IU/mL) 
Labs 
(Avg) 
AST (IU/L)2 
ALT (IU/L)3 
INR4 
Total bilirubin 
(~mol/L)5 
Chronic HCV HCV Exposed, RNA Neg 
NIA N/A 
Dl ND 
59 28 
105 22 
1 
11 10 
HCV Tx responders 
6 
53 
41 
779,111± 
1,332,464 
31 
31 
1.1 
11 
HCVTx 
non-responders 
0 
60 
40 
I ,913 ,333± 
2,413 ,344 
78 
81 
1.1 
16.5 
Albumin(g/L)6 40 38 41 31 
1 D, not determined 2 AST, aspartate aminotransferase; normal range 10-42 IU/L 3 ALT, alanine aminotransferase; normal 
range 10-41 IU/L 4INR, International normalized ratio normal range 0.9-1.1 5Total bilirubin normal range 0-16 ~mol/L 
6 Albumin normal range 38-50 g/L. Bold numbers are outside the normal range. -00 \.Jl 
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Table 6.2. Comparison of HCV-specific T cell response character in different groups. 
Responses from each of the groups are graded relative to the other 3 groups and 
summarized as a measure of the strength of the overall anti-HCV T cell response. 
Chronic HCV exposed Treated Treated 
Infection RNA negative Res~onders N onres~onders 
CDS+ T cell response 
NS3, NS4A core, NS3 , NS4B, core, NS3, None 
Specificit/ (++) NS5A, NS5B NS5A (0) 
(+++++) (+++) 
Relative Breadth1 ++5 ++++ +++ + 
Relative Magnitude3 ++ +++ ++++ + 
Relative Vigo/ +++ + ++++ ++ 
CD4+ T cell Res~onse + ++ + NT6 
Total' 10+/9+ 15+/13+ 15+/14+ ND8/4+ 
1Regions with greater than 50% of individuals responding are indicated. 2Breadth is the 
percentage of peptide pools to which an individual has greater than twice the number of 
background spots. 3Magnitude is the average cumulative number of IFN-y positive spots 
per pool. 4 Vigor is the average spot size per group. 5Relative response with respect to the 
four groups: + .is least and +++++ is maximum. ~T, not tested. 7Sum of the number of 
pluses per group. The first number is calculated with CDS+ and CD4+ T cell responses; 
the second number is CDS+ T cell responses alone. 8ND, not done. 
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Figure 6.1. HCV-specific CDS+ T cell response breadth. After overnight incubation 
of PBMC with one of 44 peptide pools, each containing 10 overlapping HCV 18-mers, 
IFN-y producing cells were visualized and enumerated by ELISPOT. Responses were 
considered positive if the number of spots in wells with HCV peptides was more than 
twice background. Bars represent the mean percentage of positive pools for individuals 
in each group (±SE). There were 18, 5, 16, and 5 individuals in the HCV chronic, 
spontaneous clearer, treated responder, treated non-responder groups respectively. 
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Figure 6.2. HCV region and pool-based specificity CDS+ T cell responses. (a) The 
percentage of individuals with positive responses to each HCV region is shown. Dark, 
fine hatched bars represent chronic infection (n= 18), white hatched bars for spontaneous 
clearers (n=5), dark horizontal hatch bars for treated responders (n= 16) and white left 
slanted bars for treated non-responders (n=5). The horizontal line indicates the threshold 
for a positive response. 
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Figure 6.2. (con't) (b) The percentage of individuals with positive HCV responses to 
each HCV pool is shown. An HCV region or pool was considered a significant target for 
a group if more than 50% of individuals in that group responded. The horizontal line 
indicates the threshold for a positive. response. 
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Figure 6.3. HCV-specific CDS+ T cell response magnitude. (a) Grey bars indicate the mean (± SE) number of IFN-y 
producing cells per million PBMC in positive peptide pools for each group. The Mann-Whitney U test was used to assess 
significant differences between groups. (b) Black bars indicate the mean (± SE) cumulative number ofiFN-y producing cells 
stimulated by all peptide pools in each group. The Mann-Whitney U test was used to test for differences between groups. 
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Figure 6.4. HCV-specific CDS+ T cell response vigor. (a) The amount of IFN-y 
produced per cel1 was assessed by measuring spot size in arbitrary units (termed vigor), 
and the mean±SE for each group is shown in grey bars. 
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Figure 6.4. (con't) (b) Response magnitude was plotted versus the vigor of the response 
in each group. Correlation was assessed by linear regression. 
(a) 
c 
0 
~ 
'-Q) 
~ 
0 
c. 
£ 
"3 
.!!1 
ro 
::J 
"0 
:~ 
"0 
c 
-::e. 
" 
(b) 
X 
Q) 
"0 
.s 
c: 
0 
~ 
:; 
E 
~ 
<( 
I 
a.. 
100 
- Chronic HCV Infection n=12 
c::::::J HCV exp. RNA neg n=2 
80 Bill HCV tx responders n=8 
60 
40 
20 
QL---_J~£L __ JU~L-~~~--~- n~,CL~--~-, ~~-------
1000 
800 
600 
400 
200 
0 
PHA C albicans HCV core HCV NS3 HCV NS4 
Antigen 
- Chronic HCV infection n=12 
c::::J HCV exp. RNA negative n=2 
60 
Bill HCV tx responders n=8 50 ~ 
"0 
c 
c 
0 
40 :a; 
:; 
E 
30 ~ 
(.) 
-= 
"(3 
Q) 
a. 
20 </) 
c: 
Q) 
C> 
~ 
10 <( 
r lA - -ifi-D-- ---~-~-- ---~--- ---
0 
PHA C. albicans HCV core HCV NS3 HCV NS4 
Antigen 
193 
Figure 6.5. CD4+ T cell responses. (a) The frequency of CD4+ T cell responses to 
mitogen (PHA), recall antigen (Candida albicans), and HCV antigens (core, NS3, NS4) 
was determined by proliferation assay for members of the chronic infection (n=12), 
spontaneous clearer (n=2) and treated responder (n=8} groups. (b) The average 
magnitude (±SE) of CD4+ T cell responses to mitogen (left hand axis), recall antigen and 
HCV antigen (right hand axis) is shown for each group. A stimulation index greater than 
3 (indicated by the horizontal dashed line) was considered positive. 
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CHAPTER 7 
SUMMARY AND DISCUSSION 
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Persistent infections are generally deleterious to the host, causing both immediate 
and long term pathology that cause increased morbidity and accelerated mortality. 
However bad it is for the infected person, persistent infection offers the opportunity to 
use an unsuccessful response to better understand the sensitivities or weak spots of the 
immune system in its unsuccessful interactions with various invaders. The list of 
weapons incorporated into the pathogen arsenal in order to frustrate stetilizing immunity 
continues to grow. Viruses have been patiicularly adept at evolving mechanisms to 
subve1i the immune response. In this work, we investigated whether HCV gene products 
induce IL-l 0, an immunomodulatory cytokine that facilitates chronic infection. We 
identified and phenotyped a novel cell population producing this immunomodulatory 
cytokine, not just in those infected with HCV but in all healthy controls tested. The 
production of IL-1 0 by this new cell type may have a role in immune system homeostasis 
through immune regulation, but may also contribute to viral persistence. More of these 
previously undescribed cells produce IL-l 0 when exposed to HCV proteins, an effect that 
is accentuated when HCV-na'ive cells from HIV-infected individuals are exposed to HCV 
proteins. We demonstrated more robust anti-HCV T cell responses with viral clearance, 
and distinguished features of anti-HCV T cell responses associated with spontaneous 
versus treatment-induced clearance. We also desctibed distinct HCV-specific T cell 
responses in HIV coinfection. Together, these findings emphasize the role of the immune 
system in HCV clearance, as well as in control of chronic infection and illustrate the 
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complex interactions between chronic pathogens in terms of their effects on the immune 
system. 
Our first objective was to identify cells that may be involved in modulating the 
immune response to HCV. While we anticipated that HCV proteins might induce some 
regulatory cytokines such as IL-l 0, we did not anticipate that the cells producing it would 
be a previously undescribed peripheral blood mononuclear leukocyte population. Surface 
antigens expressed on these cells are consistent with bone marrow origin, however, they 
do not conform to any previously defined lineage. One possibility is that they represent a 
precursor population that has not yet fully differentiated. This rare population was found 
in all individuals and produced IL-l 0 ex vivo, suggesting an as yet unidentified in vivo 
stimulus that maintains IL-l 0 gene expression at some level. Given the link between 
increased IL-l 0 and CD36 expression, several of the ubiquitous CD36 ligands such as 
apoptotic bodies or oxidized LDL are candidates for providing this stimulus. In the 
context of HCV infection, the potential role of apoptotic bodies in generation of the pro-
fibrogenic and tolerogenic cytokine IL-1 0 holds special interest. Intact HCV and HCV 
derived proteins have been implicated in induction of apoptotic cell death ( 431, 432), 
which may facilitate IL-l 0 production from our cell population. This could offer an 
additional mechanism for the hallmark fibrogenesis and viral persistence characte1istic of 
HCV infection. 
While we have concentrated on the role of this novel cell population in response 
to viral infection, it is possible that these cells also have a nonnal physiological function 
as homeostatic agents helping to preserve self-tolerance. These cell s may also offer the 
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opportunity to therapeutically modulate overzealous immune responses in autoimmunity 
by appropriate temporal and spatial direction of their IL-l 0 producfion towards specific 
target sites. Multiple sclerosis, for example, is an autoimmune disease treated in some 
instances with IFN-~, a type I interferon. Wang et al. demonstrated an IL-l 0 dependent 
decrease in IL-12 production in PBMC from IFN-~ treated multiple sclerosis patients 
compared to controls (433). This study suggests a role for IL-10 in disease amelioration, 
however, the usefulness of exogenous IL-1 0 administration has been hampered by limited 
bioavailability, variable serum concentration, and short in vivo half life (434). The cells 
we have identified may provide a physiological mechanism of IL-l 0 induction through 
the use of naturally occurring CD36 ligands that would attenuate autoimmune disease 
I 
while avoiding the limitations of external IL-l 0 administration. Further in vitro work on 
the manipulation of our cell population will be necessary to determine the distribution of 
this population, as well as the potential for IL-l 0 induction. 
The next steps in harnessing the potential of this population involve more 
extensive physical and functional characterization together with development of an in 
vitro culture system. Our current studies have been limited by the relatively low number 
of IL-1 o+ cells in peripheral blood. By devising a method to culture, expand and possibly 
transform them in vitro, it may be possible to develop a cell line appropriate for long tenn 
in vitro experiments. Access to human lymphoid tissue, perhaps from cadaveric organ 
donors or leukophoresis, would provide an excellent opportunity to isolate, sort and 
culture potentially large numbers of these cells. This would also be useful in allowing 
large scale microarray analysis to perform a more exhaustive phenotypic description of 
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the gene expression profile. This would faci litate comparison of the gene ' fingerprint ' of 
our cells with well established populations such as T cells, B cells, monocytes, NK cells, 
and stem cells in an effort to further delineate the cell lineage and ascertain their function. 
Exploration of small animal models such as the mouse for a comparable cell population 
will be another important next step. This would offer a readily manipulable system to 
study the effects of this population, as well as its frequency and distribution in lymphoid 
tissue and relative levels in murine models of autoimmunity, immunodeficiency and 
immunosuppression. Given that CD36 may play a large role, it would be particularly 
interesting to explore the immune function and response to infection of the already 
developed CD36 knockout mouse ( 435). 
As described in chapter 4, more mononuclear cells produce IL-l 0 in response to 
several HCV proteins in HCV-nai·ve individuals with HIV infection than in HCV-nai·ve 
controls. In contrast, IL-l 0 induction was not observed in the context of chronic HCV 
infection, and this lack of IL-l 0 may contribute to the hepatic immunopathology 
observed in persistent HCV infection. If there is ongoing antigenemia from chronic viral 
infection and replication, anti-HCV immune cells are activated and recruited to the liver. 
Here, cytokines may reduce viral load by eliminating infected hepatocytes, however, they 
also promote a profibrogenic environment that leads to liver fibrosis and eventually 
cirrhosis. The presence of IL-l 0 is anti-inflammatory and may attenuate the detrimental 
hepatic effects of inflammation. While the number of HCV monoinfected individuals in 
our comparison was small, the inter-individual results demonstrating little IL-l 0 
produced by PBMC in response to HCV proteins were very consistent. These results 
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suggest the establishment of persistent infection in the context of increased levels of 
irnrnunomodulatory cytokines, and subsequent attenuation of the IL-l 0 induction 
response that allows progressive disease in chronic infection. Our IL-l 0 results also 
correlate with the proliferation studies in HIV/HCV coinfected individuals, which implies 
that the HCV-induced IL-10 may be associated with a lack of CD4+ T cell proliferation. 
It will be necessary to extend these studies with more individuals, and determine how the 
structurally dissimilar HCV core NS3 and NS4 proteins generate a common effect on IL-
l 0 production. 
One of the main modulatory effects of IL-l 0 is indirect attenuation of T cell 
responses. Based on the results presented in chapter 3, we might expect that attenuated 
IL-l 0 production from the CD36 population in the setting of underlying HCV infection 
may allow anti-HCV T cell responses to develop. In fact, we observed a larger 
magnitude response in the HIV coinfected population than the chronically infected HCV 
individuals, but the breadth of the CD8+ T cell response remained limited. This suggests 
that while the IL-l 0 production seen in chronic HCV infection may play a role in limiting 
the magnitude of the T cell response, there are other factors that attenuate the breadth and 
specificity of the response that may not be IL-l 0 dependent. Mechanisms of impaired T 
cell function such as anergy and exhaustion are not likely to be directly dependent on IL-
l 0, however, the indirect effects of IL-l 0 on APC may play a role. Further phenotyping 
of both the responsive and non-responsive HCV -specific T cells for markers of effector 
function and differentiation will provide further insights into specific deficits in T cell 
function that limit sterilizing immunity in the context of chronic HCV infection. 
---------------------------- --------
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While studying HIV coinfection offered an opportunity to assess Immune 
responses in the setting of relative immunodeficiency, selecting individuals who clear 
HCV either spontaneously or after anti-viral therapy allowed comparison of T cell 
responses in the context of two different forms of successful HCV eradication. Not 
unexpectedly, we found more robust anti-HCV T cell responses in individuals who 
cleared the virus compared to those with chronic infection, underscoring the importance 
of the T cell response in viral clearance. However, there were substantial differences 
between the character of the CD8+ T cell responses generated in spontaneous viral 
clearance compared with treatment-associated viral clearance. Pharmacologic therapy 
provides anti-viral activity directly against HCV replication in addition to indirect effects 
through immune stimulation with IFN-alpha. This seems to produce a different type ofT 
cell response that is as efficacious in some instances as the immune response of 
spontaneous clearers. Further studies to ascertain the functionality of anti-HCV T cells 
will be important, and determination of individual epitopes will also provide insight into 
potential immunogen targets. HLA type was unavailable for these patients, and while 
they came from a relatively heterogeneous population, it will be impo1iant for further 
studies of epitope mapping to obtain this information. For similar reasons, having HCV 
genotypes would also be useful. 
We have shown that strong CD8+ T cell responses are important for viral 
clearance, and that the character of successful responses differs between various modes 
of clearance. We have also confirmed that HCV proteins induce IL-l 0 production, and 
identified a previously undescribed population of mononuclear cells that can be 
·---------------------------------------------------------------------------------
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manipulated by HCV proteins to produce more IL-l 0. This work provides insight into 
what constitutes a successful immune response to HCV, how the vims may cause worse 
disease in HIV coinfection, and provides a potential target for immune manipulation to 
ameliorate immunopathogenesis. Further studies to delineate how effector T cell 
maturation is affected by HCV and to elucidate the lineage of CD36+IL-l 0+ cells will 
provide exciting infonnation that impacts not just HCV infection, but immunology in 
general. 
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APPENDIX A 
Appendix A. HCV 18-mer peptide (NIH Research and Reference Reagent Program, 
Catalogue# 7620) pools. 441 peptides, overlapping by seven amino acids. Each pool 
consists of 1 0 adjacent peptides. 
Pool number HCV protein Amino Acid 
1-3 Core 1-192 
3-5 E1 192-384 
5-11 E2 384-747 
11-12 p7 747-810 
12-15 NS2 810-1027 
15-25 NS3 1027-1658 
24-26 NS4A 1658-1712 
25-29 NS4B 1712-1973 
29-36 NS5A 1973-2421 
36-44 NS5B 2422-3011 




